2024/10/12 更新

写真a

カミムラ ケンヤ
上村 顕也
KAMIMURA Kenya
所属
教育研究院 医歯学系 医学系列 教授
医歯学総合研究科 教授
職名
教授
▶ researchmapのプロフィールを表示
外部リンク

学位

  • 医学 ( 2007年3月   新潟大学 )

研究キーワード

  • 総合診療

  • ハイドロダイナミック遺伝子導入法

  • 血友病

  • 遺伝子治療

  • 凝固活性

  • Gastroenterology & Hepatology

  • 肝臓

  • Translational Research

  • Gene Therapy

  • 大動物

  • 血管造影手技

  • 臓器間ネットワーク

  • Hydrodynamic Gene Delivery

  • Non-viral Gene Delivery

  • 非ウイルスベクター•プラスミド

  • 遺伝子治療前臨床研究

  • 肝臓癌

  • 消化器癌

  • ゲノム編集

研究分野

  • ライフサイエンス / 消化器内科学

  • ライフサイエンス / 薬理学

  • ライフサイエンス / 腫瘍診断、治療学  / 遺伝子治療

経歴(researchmap)

  • 新潟大学大学院医歯学総合研究科   地域医療人材育成分野・医学部総合診療学講座   教授

    2023年11月 - 現在

      詳細を見る

  • 新潟大学医学部   医学科総合診療学講座   特任教授

    2020年12月 - 2023年10月

      詳細を見る

  • 新潟大学医歯学総合病院   消化器内科学   講師

    2019年4月 - 2020年11月

      詳細を見る

  • 新潟大学大学院医歯学総合研究科   消化器内科学分野   助教

    2015年8月 - 2019年3月

      詳細を見る

  • 新潟大学   Medical and Dental Hospital

    2010年1月 - 現在

      詳細を見る

  • University of Pittsburgh

    2007年 - 2010年

      詳細を見る

  • 新潟大学   Medical and Dental Hospital   その他

    1999年 - 2007年

      詳細を見る

▶ 全件表示

経歴

  • 新潟大学   医歯学総合研究科   教授

    2023年11月 - 現在

  • 新潟大学   教育研究院 医歯学系 医学系列   教授

    2023年11月 - 現在

  • 新潟大学   医歯学総合研究科   特任教授

    2020年12月 - 2023年10月

  • 新潟大学   医歯学総合病院 消化器内科   講師

    2018年4月 - 2020年11月

  • 新潟大学   医歯学総合研究科 分子細胞医学専攻 細胞機能   助教

    2015年8月 - 2018年3月

所属学協会

▶ 全件表示

委員歴

  • 日本遺伝子細胞治療学会 幹事  

    2022年 - 現在   

      詳細を見る

  • 日本肝臓学会 学会評議員  

    2022年 - 現在   

      詳細を見る

  • 新潟県地域医療対策協議会   『総合的な診療能力をもつ医師の養成・確保等に関する研究班』班員  

    2021年 - 現在   

      詳細を見る

    団体区分:自治体

    researchmap

  • 日本遺伝子細胞治療学会 評議員  

    2021年 - 現在   

      詳細を見る

  • 日本遺伝子細胞治療学会 教育・広報委員会 委員  

    2021年 - 現在   

      詳細を見る

  • 日本消化器病学会 学会評議員  

    2020年 - 現在   

      詳細を見る

  • 日本遺伝子細胞治療学会   若手ワーキンググループメンバー  

    2017年 - 現在   

      詳細を見る

  • 日本肝臓学会 東部肝評議員  

    2017年 - 現在   

      詳細を見る

  • 日本消化器内視鏡学会 甲信越支部評議員  

    2016年 - 現在   

      詳細を見る

  • 日本消化器病学会 甲信越支部評議員  

    2015年 - 現在   

      詳細を見る

  • 文部科学省科学技術・学術政策研究所科学技術動向研究センター   専門調査員  

    2014年 - 現在   

      詳細を見る

    団体区分:学協会

    researchmap

▶ 全件表示

 

論文

  • Maid gene dysfunction promotes hyperobesity via the reduction of adipose tissue inflammation in Mc4r gene-deficient mice. 国際誌

    Kyutaro Koyama, Akira Sakamaki, Shinichi Morita, Itsuo Nagayama, Marina Kudo, Yuto Tanaka, Naruhiro Kimura, Yoshihisa Arao, Hiroyuki Abe, Kenya Kamimura, Shuji Terai

    Scientific reports   14 ( 1 )   21126 - 21126   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The onset and progression mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are being studied. We developed and analyzed a new mouse model of obesity by combining maternal Id-like molecule (Maid) and melanocortin-4 receptor (Mc4r) gene deletions. Four mice, each at 12 and 28 weeks of age, were analyzed for each genotype: Maid gene knockout, Mc4r gene knockout, combined Mc4r and Maid gene knockout, and Mc4r gene knockout with a high-fat diet. Mice with a combined deficiency of Mc4r and Maid gene showed significantly more severe obesity compared to all other genotypes, but no liver fibrosis or a decline in metabolic status were observed. In visceral white adipose tissue, Maid and Mc4r gene knockout mice had fewer CD11c-positive cells and lower mRNA expression of both inflammatory and anti-inflammatory cytokines. Furthermore, Maid and Mc4r gene knockout mice showed lower expression of adipocytokines in visceral white adipose tissue and uncoupling protein-1 in scapular brown adipose tissue. The expression of adipocytokines and uncoupling protein-1 is regulated by sympathetic nerve signaling that contribute severe obesity in Maid and Mc4r gene knockout mice. These mechanisms contribute hyperobesity in Maid and Mc4r gene knockout mice.

    DOI: 10.1038/s41598-024-72217-1

    PubMed

    researchmap

  • PCPE-1, a brown adipose tissue-derived cytokine, promotes obesity-induced liver fibrosis. 国際誌

    Yung Ting Hsiao, Yohko Yoshida, Shujiro Okuda, Manabu Abe, Seiya Mizuno, Satoru Takahashi, Hironori Nakagami, Ryuichi Morishita, Kenya Kamimura, Shuji Terai, Tin May Aung, Ji Li, Takaaki Furihata, Jing Yuan Tang, Kenneth Walsh, Akihito Ishigami, Tohru Minamino, Ippei Shimizu

    The EMBO journal   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Metabolic dysfunction-associated steatohepatitis (MASH, previously termed non-alcoholic steatohepatitis (NASH)), is a major complication of obesity that promotes fatty liver disease. MASH is characterized by progressive tissue fibrosis and sterile liver inflammation that can lead to liver cirrhosis, cancer, and death. The molecular mechanisms of fibrosis in MASH and its systemic control remain poorly understood. Here, we identified the secreted-type pro-fibrotic protein, procollagen C-endopeptidase enhancer-1 (PCPE-1), as a brown adipose tissue (BAT)-derived adipokine that promotes liver fibrosis in a murine obesity-induced MASH model. BAT-specific or systemic PCPE-1 depletion in mice ameliorated liver fibrosis, whereas, PCPE-1 gain of function in BAT enhanced hepatic fibrosis. High-calorie diet-induced ER stress increased PCPE-1 production in BAT through the activation of IRE-1/JNK/c-Fos/c-Jun signaling. Circulating PCPE-1 levels are increased in the plasma of MASH patients, suggesting a therapeutic possibility. In sum, our results uncover PCPE-1 as a novel systemic control factor of liver fibrosis.

    DOI: 10.1038/s44318-024-00196-0

    PubMed

    researchmap

  • ダサチニブ及びケルセチンは老化細胞除去剤としてMASHメダカモデルにおいて老化細胞を減少させ病態改善に寄与する

    阿部 寛幸, 弥久保 俊太, 渡邉 雄介, 木村 成宏, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 上村 顕也, 寺井 崇二

    肝臓   65 ( Suppl.1 )   A514 - A514   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 顕性肝性脳症の発症予測における,呼気中水素・メタン分析によるSIBO診断の有用性の検討

    坂牧 僚, 横山 邦彦, 若林 拓哉, 阿部 寛幸, 土屋 淳紀, 上村 顕也, 寺井 崇二

    肝臓   65 ( Suppl.1 )   A410 - A410   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease. 査読 国際誌

    Itsuo Nagayama, Kenya Kamimura, Takashi Owaki, Masayoshi Ko, Takuro Nagoya, Yuto Tanaka, Marina Ohkoshi, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Shuji Terai

    Hepatology international   18 ( 1 )   155 - 167   2024年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Insulin-like growth factor-1 (IGF-1) is involved in the pathology of non-alcoholic fatty liver disease (NAFLD) and ameliorates fatty infiltration in the liver. It is activated by growth hormone (GH); however, the role of GH-IGF-1 axis in NAFLD developmental phase has not been well identified. Therefore, in this study, we focused on the effect of IGF-1 in NAFLD pathology and GH excretion activation from the pituitary gland by peripheral autonomic neural pathways relaying liver-brain-gut pathway and by central neuropeptides. METHODS: GH and IGF-1 levels were assessed in wild-type and melanocortin-4 receptor knockout mice upon the development of diet-induced NAFLD. The contribution of the peripheral autonomic nervous system connecting the liver-brain-gut axis was assessed by its blockade using capsaicin and that of the central nervous system was assessed by the expression of hypothalamic brain-derived neurotrophic factor (BDNF) and corticotropin-releasing factor (CRH), which activates GH release from the pituitary gland. RESULTS: In the NAFLD mouse models, the levels of GH and IGF-1 increased (p < .05). Further, hepatic fatty infiltration was suppressed even under peripheral autonomic nervous system blockade (p < .001), which inhibited gastric ghrelin expression. In mice with peripheral autonomic nervous blockade, hypothalamic BDNF and CRH were inhibited (p < .05), resulting in GH and IGF-1 excretion, whereas other neuropeptides of somatostatin and cortistatin showed no changes. These complementary effects were canceled in melanocortin-4 receptor knockout mice, which diminished BDNF and CRH release control. CONCLUSIONS: Our study demonstrates that the release of IGF-1 by the nervous system is a key factor in maintaining the pathological homeostasis of NAFLD, suggesting its therapeutic potential.

    DOI: 10.1007/s12072-023-10601-1

    PubMed

    researchmap

  • Development and validation of machine learning model for predicting treatment responders in patients with primary biliary cholangitis. 査読 国際誌

    Naruhiro Kimura, Kazuya Takahashi, Toru Setsu, Yusuke Horibata, Yusuke Kaneko, Haruka Miyazaki, Kohei Ogawa, Yuzo Kawata, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   54 ( 1 )   67 - 77   2024年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIMS: Ursodeoxycholic acid is the first-line treatment for primary biliary cholangitis, and treatment response is one of the factors predicting the outcome. To prescribe alternative therapies, clinicians might need additional information before deciphering the treatment response to ursodeoxycholic acid, contributing to a better patient prognosis. In this study, we developed and validated machine learning (ML) algorithms to predict treatment responses using pretreatment data. METHODS: This multicenter cohort study included collecting datasets from two data samples. Data 1 included 245 patients from 18 hospitals for ML development, and was divided into (i) training and (ii) development sets. Data 2 (iii: test set) included 51 patients from our hospital for validation. An extreme gradient boosted tree predicted the treatment response in the ML model. The area under the curve was used to evaluate the efficacy of the algorithm. RESULTS: Data 1 showed that patients complying with the Paris II treatment response had significantly lower serum alkaline phosphatase and total bilirubin levels than those who did not respond. Three factors, total bilirubin, total protein, and alanine aminotransferase levels were selected as essential variables for prediction. Data 2 showed that patients complying with the Paris II criteria had significantly high prothrombin time and low total bilirubin levels. The area under the curve of extreme gradient boosted tree was good for (ii) (0.811) and (iii) (0.856). CONCLUSIONS: We demonstrated the efficacy of ML in predicting the treatment response for patients with primary biliary cholangitis. Early identification of cases requiring additional treatment with our novel ML model may improve prognosis.

    DOI: 10.1111/hepr.13966

    PubMed

    researchmap

  • An updated review on the treatment for diversion colitis and pouchitis, with a focus on the utility of autologous fecal microbiota transplantation and its relationship with the intestinal microbiota.

    Kentaro Tominaga, Yuichi Kojima, Yuzo Kawata, Kazuya Takahashi, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Shuji Terai

    Bioscience of microbiota, food and health   43 ( 3 )   162 - 169   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Diversion colitis (DC) is characterized by mucosal inflammation in the defunctioned segment of the colon following a colostomy or ileostomy. The major causes of DC are an increase in the number of aerobic bacteria, a lack of short-chain fatty acids (SCFAs), and immune disorders in the diverted colon. However, its exact pathogenesis remains unknown. Various treatment strategies for DC have been explored, although none have been definitively established. Treatment approaches such as SCFAs, 5-aminosalicylic acid enemas, steroid enemas, and irrigation with fibers have been attempted, yielding various degrees of efficacies in mitigating mucosal inflammation. However, only individual case reports demonstrating the limited effect of the following therapies have been published: leukocytapheresis, dextrose (hypertonic glucose) spray, infliximab, an elemental diet, and coconut oil. The usefulness of probiotics for treating DC has recently been reported. Furthermore, fecal microbiota transplantation (FMT) has emerged as a promising treatment for DC. This review provides an update on the treatment strategies of DC, with a particular focus on FMT and its relationship with the intestinal microbiota. FMT may become the first choice of treatment for some patients in the future because of its low medical costs, ease of use, and minimal side effects. Furthermore, FMT can also be used for postoperative DC prophylaxis.

    DOI: 10.12938/bmfh.2024-014

    PubMed

    researchmap

  • MC4R、Maid両遺伝子欠損マウスを用いた慢性アルコール性肝障害モデルマウスの開発

    坂牧 僚, 酒井 規裕, 小川 和也, 木村 成宏, 荒生 祥尚, 阿部 寛幸, 上村 顕也, 寺井 崇二

    アルコールと医学生物学   42   44 - 46   2023年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:梵天書房  

    researchmap

  • Similarity of oncogenic protein expression in KRASG12D gene delivery-based rat pancreatic cancer model to that of human pancreatic cancer. 査読 国際誌

    Yuto Tanaka, Kenya Kamimura, Osamu Shibata, Kohei Ogawa, Chiyumi Oda, Hiroyuki Abe, Satoshi Ikarashi, Kazunao Hayashi, Takeshi Yokoo, Toshifumi Wakai, Shuji Terai

    Biochemical and biophysical research communications   673   29 - 35   2023年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The development of effective therapies and biomarkers for pancreatic cancer is an unmet clinical need. To address this, we have developed an easy-to-use pancreatic cancer rat animal model via pancreas-targeted hydrodynamic gene delivery of human pancreatic cancer-related genes. Our study aimed to determine the molecular similarity between the pancreatic tumor in the rat model and human pancreatic cancer. METHODS: KRASG12D gene-expressing plasmid was delivered to the pancreas of wild type rats via pancreas-targeted hydrodynamic gene delivery as previously reported. Tissue samples were collected at 5 weeks after the first gene delivery. The tumors developed in the rats were assessed for the expression of oncogenic proteins that are involved in human pancreatic cancer development. RESULTS: The development of a tumor mimicking pancreatic ductal adenocarcinoma was confirmed. The expression levels of Cyclin D1, c-Jun, IL-33, and Zip4 proteins in the tumor were immunohistochemically assessed and the correlation of the proteins was confirmed. The expression pattern showed similarity to that of surgically resected human pancreatic cancer tissues. CONCLUSIONS: Our study findings showing a similar pattern of oncogenic protein expression in novel KRASG12D gene-induced rat pancreatic cancer model and human pancreatic cancer will be useful for establishing novel tumor markers and therapeutic options for pancreatic cancer.

    DOI: 10.1016/j.bbrc.2023.06.057

    PubMed

    researchmap

  • 多職種の肝炎医療コーディネーターとの連携による,院内におけるC型肝炎患者の拾い上げと紹介率向上の効果

    荒生 祥尚, 酒井 規裕, 薛 徹, 渡邉 雄介, 木村 成宏, 阿部 寛幸, 坂牧 僚, 上村 博輝, 横尾 健, 土屋 淳紀, 上村 顕也, 寺井 崇二

    肝臓   64 ( Suppl.2 )   A634 - A634   2023年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs. 査読 国際誌

    Norihiro Sakai, Kenya Kamimura, Shuji Terai

    Pharmaceutics   15 ( 9 )   2023年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Conventional drug discovery involves significant steps, time, and expenses; therefore, novel methods for drug discovery remain unmet, particularly for patients with intractable diseases. For this purpose, the drug repurposing method has been recently used to search for new therapeutic agents. Repurposed drugs are mostly previously approved drugs, which were carefully tested for their efficacy for other diseases and had their safety for the human body confirmed following careful pre-clinical trials, clinical trials, and post-marketing surveillance. Therefore, using these approved drugs for other diseases that cannot be treated using conventional therapeutic methods could save time and economic costs for testing their clinical applicability. In this review, we have summarized the methods for identifying repurposable drugs focusing on immunotherapy.

    DOI: 10.3390/pharmaceutics15092190

    PubMed

    researchmap

  • Wilson's disease: practical information for general physicians. 査読 国際誌

    Kenya Kamimura

    Hepatobiliary surgery and nutrition   12 ( 4 )   598 - 600   2023年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語  

    DOI: 10.21037/hbsn-23-286

    PubMed

    researchmap

  • BCL11B expression in hepatocellular carcinoma relates to chemosensitivity and clinical prognosis. 査読 国際誌

    Hiroyuki Abe, Kenya Kamimura, Shujiro Okuda, Yu Watanabe, Jun Inoue, Yutaka Aoyagi, Toshifumi Wakai, Ryo Kominami, Shuji Terai

    Cancer medicine   12 ( 14 )   15650 - 15663   2023年7月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: B-cell lymphoma/leukemia 11B (BCL11B) is a subunit of SWI/SNF chromatin remodeling complexes and functions in cell cycle regulation and apoptosis upon DNA replication stress and damages via transcription. Many malignancies were reported to exhibit changes in BCL11B gene expression; however, no study has focused on the relationship between BCL11B and hepatocellular carcinoma, which potentially exhibits DNA replication stress and damages upon its oncogenesis. Thus, in this study, we examined the molecular characterization of BCL11B expression in hepatocellular carcinoma. METHODS AND RESULTS: The cumulative progression-free survival and overall survival were significantly longer in the clinical cases of BCL11B-negative hepatocellular carcinoma than BCL11B-positve cases. Microarray and real-time PCR analyses in hepatocellular carcinoma cell lines indicated a correlation between BCL11B and GATA6, a gene reported to be correlated with oncogenic activities and resistance to anthracycline, which is often used for hepatocellular carcinoma chemotherapy. Consequently, BCL11B-overexpressing cell lines exhibited resistance to anthracycline in cell growth assays and the resistance has been evidenced by the increased expression of BCL-xL in cell lines. The results were supported by the analyses of human HCC samples showing the correlation between BCL11B and GATA6 expressions. DISCUSSIONS AND CONCLUSION: Our results indicated that overexpression of BCL11B amplifies GATA6 expression in hepatocellular carcinoma in vitro and in vivo that leads to anti-apoptotic signal activation, and induces resistance to chemotherapy, which influenced the postoperative prognosis.

    DOI: 10.1002/cam4.6167

    PubMed

    researchmap

  • Liver lobe-specific hydrodynamic gene delivery to baboons: A preclinical trial for hemophilia gene therapy. 査読 国際誌

    Kenya Kamimura, Tsutomu Kanefuji, Takeshi Suda, Takeshi Yokoo, Guisheng Zhang, Yutaka Aoyagi, Dexi Liu

    Molecular therapy. Nucleic acids   32   903 - 913   2023年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hydrodynamics-based gene transfer has been successfully employed for in vivo gene delivery to the liver of small animals by tail vein injection and of large animals using a computer-assisted and image-guided protocol. In an effort to develop a hydrodynamic gene delivery procedure clinically applicable for gene therapy, we have evaluated the safety and effectiveness of a lobe-specific hydrodynamic delivery procedure for hepatic gene delivery in baboons. Reporter plasmid was used to assess the gene delivery efficiency of the lobe-specific hydrodynamic gene delivery, and plasmid-carrying human factor IX gene was used to examine the pattern of long-term gene expression. The results demonstrated liver lobe-specific gene delivery, therapeutic levels of human factor IX gene expression lasting for >100 days, and the efficacy of repeated hydrodynamic gene delivery into the same liver lobes. Other than a transient increase in blood concentration of liver enzymes right after the injection, no significant adverse events were observed in animals during the study period. The results obtained from this first non-human primate study support the clinical applicability of the procedure for lobe-specific hydrodynamic gene delivery to liver.

    DOI: 10.1016/j.omtn.2023.05.018

    PubMed

    researchmap

  • Machine learning prediction model for treatment responders in patients with primary biliary cholangitis. 査読 国際誌

    Naruhiro Kimura, Kazuya Takahashi, Toru Setsu, Shu Goto, Suguru Miida, Nobutaka Takeda, Yuichi Kojima, Yoshihisa Arao, Kazunao Hayashi, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   7 ( 6 )   431 - 438   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Treatment response to ursodeoxycholic acid may predict the prognosis of patients with primary biliary cholangitis (PBC). Recent studies have suggested the benefits of using machine learning (ML) to forecast complex medical predictions. We aimed to predict treatment response in patients with PBC using ML and pretreatment data. METHODS: We conducted a single-center retrospective study and collected data from 194 patients with PBC who were followed up for at least 12 months after treatment initiation. Patient data were analyzed with five ML models, namely random forest, extreme gradient boosting (XGB), decision tree, naïve Bayes, or logistic regression, to predict treatment response using the Paris II criteria. The established models were assessed using an out-of-sample validation. The area under the curve (AUC) was used to evaluate the efficacy of each algorithm. Overall survival and liver-related deaths were analyzed using Kaplan-Meier analysis. RESULTS: Compared to logistic regression (AUC = 0.595, P = 0.0219, 0.031 models), ML analyses showed significantly high AUC in the random forest (AUC = 0.84) and XGB (AUC = 0.83) models; however, the AUC was not significantly high for decision tree (AUC = 0.633) or naïve Bayes (AUC = 0.584) models. Kaplan-Meier analysis showed significantly improved prognoses in patients predicted to achieve the Paris II criteria by XGB (log-rank = 0.005 and 0.007). CONCLUSION: ML algorithms could improve treatment response prediction using pretreatment data, which could lead to better prognoses. In addition, the ML model using XGB could predict the prognosis of patients before treatment initiation.

    DOI: 10.1002/jgh3.12915

    PubMed

    researchmap

  • NASHメダカモデルにおける老化細胞除去剤としてのダサチニブ及びケルセチンの有用性に関する検証

    阿部 寛幸, 弥久保 俊太, 酒井 規裕, 木村 成宏, 坂牧 僚, 土屋 淳紀, 上村 顕也, 寺井 崇二

    肝臓   64 ( Suppl.1 )   A364 - A364   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances. 査読 国際誌

    Takeshi Suda, Takeshi Yokoo, Tsutomu Kanefuji, Kenya Kamimura, Guisheng Zhang, Dexi Liu

    Pharmaceutics   15 ( 4 )   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The principle of hydrodynamic delivery was initially used to develop a method for the delivery of plasmids into mouse hepatocytes through tail vein injection and has been expanded for use in the delivery of various biologically active materials to cells in various organs in a variety of animal species through systemic or local injection, resulting in significant advances in new applications and technological development. The development of regional hydrodynamic delivery directly supports successful gene delivery in large animals, including humans. This review summarizes the fundamentals of hydrodynamic delivery and the progress that has been made in its application. Recent progress in this field offers tantalizing prospects for the development of a new generation of technologies for broader application of hydrodynamic delivery.

    DOI: 10.3390/pharmaceutics15041111

    PubMed

    researchmap

  • 肥満モデルマウスを用いた、脂肪細胞の機能に着目した肥満制御メカニズムの解明

    坂牧 僚, 阿部 寛幸, 上村 顕也, 寺井 崇二

    新潟県医師会報   ( 876 )   12 - 13   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟県医師会  

    researchmap

  • 急性肝不全に対する治療 内科,外科の立場から 新潟県での急性肝不全診療ネットワークの構築とOn line HD導入への取り組み

    薛 徹, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌明, 寺井 崇二

    肝臓   64 ( 2 )   92 - 93   2023年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019. 査読 国際誌

    Hiroteru Kamimura, Toru Setsu, Naruhiro Kimura, Makoto Miyazawa, Shota Kaneko, Kenya Kamimura, Atsunori Tsuchiya, Yoshihiro Uesawa, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   53 ( 6 )   556 - 568   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: This study aimed to analyze the current trends of drug-induced liver-related adverse events in the Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases. METHODS: The characteristics of implicated drugs were investigated by analyzing big data on drug-induced liver-related adverse events over the past 20 years in FAERS, comparing drug rankings between the JADER and FAERS databases, and calculating rankings of drugs inducing liver-related adverse events using the Medical Dictionary for Regulatory Activities Terminology. RESULTS: In the 452,272 cases registered in FAERS from 1997 to 2019, warfarin, paracetamol, and adalimumab were the drugs most related to DILI. In the 38,919 cases registered in the JADER from 2004 to 2019, sorafenib, nivolumab, and herbal extracts were the drugs most related to DILI. No associations were found between the top 30 drugs in either of the two databases. Notably, the number of drug-induced liver-related adverse event reports and total adverse events has sharply increased in recent years. CONCLUSIONS: Although liver-related adverse events are largely caused by host immunity and other constitutional factors, differences in primary diseases, countries, and historical backgrounds lead to differences in the number of reports. Securing an appropriate database and a mechanism to collect real-time information on the frequency of adverse drug reactions is warranted. This article is protected by copyright. All rights reserved.

    DOI: 10.1111/hepr.13883

    PubMed

    researchmap

  • Navitoclax improves acute-on-chronic liver failure by eliminating senescent cells in mice. 査読 国際誌

    Yusuke Watanabe, Hiroyuki Abe, Naruhiro Kimura, Yoshihisa Arao, Natsuki Ishikawa, Maeda Yuichiro, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   53 ( 5 )   460 - 472   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Acute-on-chronic liver failure (ACLF), a disease with poor prognosis, is reportedly caused by cellular senescence due to mitochondrial dysfunction. In this study, we described and analyzed the underlying mechanism of a novel approach for ACLF using ABT263/navitoclax (Navi) that selectively eliminates senescent cells. METHODS: Irradiation-induced senescent hepatocytes were used for in vitro evaluation of the effects of Navi on ACLF (n = 6 for each group). Lipopolysaccharide- and carbon tetrachloride-induced ACLF mouse model was used for in vivo evaluation of the effects of Navi administration compared with the control using one-way or two-way analysis of variance, followed by Student's t-test or Kruskal-Wallis test. The effects on the senescence-associated secretory phenotype (n = 8 for each group) and mitochondrial functions, including adenosine triphosphate concentration and membrane potential (n = 8 for each group), were investigated using real-time polymerase chain reaction, immunohistochemistry, and enzyme analysis. RESULTS: Navi eliminated irradiation-induced senescent hepatocytes in vitro, leading to non-senescent hepatocyte proliferation. Navi eliminated senescent cells in the liver in vivo, resulting in downregulation of mRNA expression of senescence-associated secretory phenotype factors, a decrease of liver enzymes, and upregulated proliferation of non-senescent cells in the liver. Regarding mitochondrial functional assessment in the liver, adenosine triphosphate concentration and membrane potential were upregulated after Navi administration in vitro and in vivo. CONCLUSIONS: Navi may ameliorate ACLF damage by eliminating senescent cells in the liver, downregulating senescence-associated secretory phenotype factors, and upregulating mitochondrial functions. We believe that this novel approach using Navi will pave the way for ACLF treatment.

    DOI: 10.1111/hepr.13879

    PubMed

    researchmap

  • Basics, Epidemiology, Diagnosis, and Management of Liver Tumor. 査読 国際誌

    Hiroyuki Abe, Kenya Kamimura

    Journal of clinical medicine   12 ( 2 )   2023年1月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    Liver tumors include both benign (non-cancerous) and malignant (cancerous) varieties [...].

    DOI: 10.3390/jcm12020524

    PubMed

    researchmap

  • HBx and YAP expression could promote tumor development and progression in HBV-related hepatocellular carcinoma. 査読 国際誌

    Chiyumi Oda, Kenya Kamimura, Osamu Shibata, Shinichi Morita, Yuto Tanaka, Toru Setsu, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Kofuji, Toshifumi Wakai, Hiroshi Nishina, Shuji Terai

    Biochemistry and biophysics reports   32   101352 - 101352   2022年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) accounts for 10%-20% of the total HCC numbers. Its clinical features include the occurrence in the younger generation, large tumors, and poor prognosis. The contribution of hepatitis B virus X (HBx) protein in hepatocytes during activation of various oncogenic pathways has been reported. We aimed to assess the possible association between HBx and Yes-associated protein (YAP) expression in the liver tissue and the clinical features of HBV-related HCC. Methods: The relationship between HBx and YAP expression was examined in vivo using HCC tumor and peritumor tissues (n = 55). The clinical information including tumor size, marker, and the prognosis was assessed with protein expressions. The in vitro gene expression analyses were conducted using HBx- and YAP-overexpressing HCC cell lines. Results: Among 19 cases of HBV-related, 17 cases of hepatitis C virus (HCV)-related, and 19 cases of nonviral-related HCC, the HBV-related tumor showed the largest size. The HBx-stained area in the tumor and peritumor tissue showed a significant correlation with tumor size and serum α-fetoprotein level. YAP expression was higher in HBV-related tumor tissue than in the peritumor tissue and HCV-related tumor. Additionally, HBx and YAP protein expressions are correlated and both expressions in the tumor contributed to the poor prognosis. An in vitro study demonstrated that HBx and YAP overexpression in the hepatocytes activate the various oncogenic signaling pathways. Conclusions: Our study demonstrated that YAP expression in the liver of HBV-infected patients might be the key factor in HBV-related HCC development and control of tumor-related features.

    DOI: 10.1016/j.bbrep.2022.101352

    PubMed

    researchmap

  • 糖鎖欠損トランスフェリン値はγ-GTP値と相補的にアルコール性肝硬変の予後不良に関連する

    坂牧 僚, 小山 究太郎, 酒井 規裕, 阿部 寛幸, 上村 顕也, 寺井 崇二

    アルコールと医学生物学   41   71 - 73   2022年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:梵天書房  

    アルコール性肝硬変症例67例(男性86.6%:年齢中央値65歳)を対象に、糖鎖欠損トランスフェリン(CDT)値とγ-GTP値と予後の関連について後方視的に検討した。経過観察期間は3年とした。Cox回帰分析の結果、%CDT値は単変量で有意な予後不良因子であったが多変量では抽出されず、γ-GTP高値が独立した予後不良因子であることが分かった。対象を%CDT値およびγ-GTP値ともに正常値であった12例(1群)、一方が高値であった34例(2群)、両方とも高値であった21例(3群)に分けて予後比較した。その結果、3年生存率は1群が100.0%で有意に予後良好であった。以上より、%CDTかγ-GTPの一方が高値であると予後不良に関連することが示された。

    researchmap

  • Letrozole ameliorates liver fibrosis through the inhibition of the CTGF pathway and 17β-hydroxysteroid dehydrogenase 13 expression. 査読

    Norihiro Sakai, Kenya Kamimura, Hirotaka Miyamoto, Masayoshi Ko, Takuro Nagoya, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Hiroyuki Soki, Ayako Tokunaga, Tatsuo Inamine, Mikiro Nakashima, Hatsune Enomoto, Kazuki Kousaka, Hidehisa Tachiki, Kaname Ohyama, Shuji Terai

    Journal of gastroenterology   58 ( 1 )   53 - 68   2022年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: To establish a treatment option for liver fibrosis, the possibility of the drug repurposing theory was investigated, with a focus on the off-target effects of active pharmaceutical ingredients. METHODS: First, several active pharmaceutical ingredients were screened for their effects on the gene expression in the hepatocytes using chimeric mice with humanized hepatocytes. As per the gene expression-based screening assay for 36 medications, we assessed the mechanism of the antifibrotic effect of letrozole, a third-generation aromatase inhibitor, in mouse models of liver fibrosis induced by carbon tetrachloride (CCl4) and a methionine choline-deficient (MCD) diet. We assessed liver histology, serum biochemical markers, and fibrosis-related gene and protein expressions in the hepatocytes. RESULTS: A gene expression-based screening assay revealed that letrozole had a modifying effect on fibrosis-related gene expression in the hepatocytes, including YAP, CTGF, TGF-β, and CYP26A1. Letrozole was administered to mouse models of CCl4- and MCD-induced liver fibrosis and it ameliorated the liver fibrosis. The mechanisms involved the inhibition of the Yap-Ctgf profibrotic pathway following a decrease in retinoic acid levels in the hepatocytes caused by suppression of the hepatic retinol dehydrogenase, Hsd17b13 and activation of the retinoic acid hydrogenase, Cyp26a1. CONCLUSIONS: Letrozole slowed the progression of liver fibrosis by inhibiting the Yap-Ctgf pathway. The mechanisms involved the modification of the Hsd17b13 and Cyp26a1 expressions led to the suppression of retinoic acid in the hepatocytes, which contributed to the activation of Yap-Ctgf pathway. Because of its off-target effect, letrozole could be repurposed for the treatment of liver fibrosis. The third-generation aromatase inhibitor letrozole ameliorated liver fibrosis by suppressing the Yap-Ctgf pathway by partially modifying the Hsd17b13 and Cyp26a1 expressions, which reduced the retinoic acid level in the hepatocytes. The gene expression analysis using chimeric mice with humanized liver revealed that the mechanisms are letrozole specific and, therefore, may be repurposed for the treatment of liver fibrosis.

    DOI: 10.1007/s00535-022-01929-w

    PubMed

    researchmap

  • アテゾリズマブ+ベバシズマブ併用療法の非奏効例におけるLate line移行時期についての検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A582 - A582   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性肝疾患におけるTGFβ3の発現と肝予備能との関連性についての検討

    阿部 寛幸, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A597 - A597   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • アテゾリズマブ+ベバシズマブ併用療法の非奏効例におけるLate line移行時期についての検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A582 - A582   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性肝疾患におけるTGFβ3の発現と肝予備能との関連性についての検討

    阿部 寛幸, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.2 )   A597 - A597   2022年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302. 査読 国際誌

    Masafumi Ikeda, Yasuaki Arai, Yoshitaka Inaba, Toshihiro Tanaka, Shunsuke Sugawara, Yoshihisa Kodama, Takeshi Aramaki, Hiroshi Anai, Shinichi Morita, Yoshinori Tsukahara, Hiroshi Seki, Mikio Sato, Kenya Kamimura, Kimei Azama, Masakatsu Tsurusaki, Eiji Sugihara, Masaya Miyazaki, Tatsushi Kobayashi, Miyuki Sone

    Liver cancer   11 ( 5 )   440 - 450   2022年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Introduction: With the advent of effective systemic therapy, transarterial chemoembolization (TACE) is established as a highly effective locoregional treatment modality for carefully selected patients with hepatocellular carcinoma (HCC). This randomized controlled trial was conducted to clarify whether selective TACE with drug-eluting beads (DEB-TACE) loaded with epirubicin or selective conventional TACE (cTACE) with epirubicin-ethiodized oil might be more effective for obtaining complete response(CR) in patients with HCC. Methods: Between March 2016 and May 2019, Child-Pugh class A or B patients with unresectable HCC who were scheduled to receive selective TACE were randomly assigned at a 1:1 ratio to the DEB-TACE arm or the cTACE arm. The primary endpoint was the CR rate at 3 months, as evaluated according to the modified Response Evaluation Criteria in Solid Tumors by an independent review committee, and the secondary endpoints were the CR rate at 1 month and incidences of adverse events. Results: A total of 200 patients (DEB-TACE, 99 patients; cTACE, 101 patients) were enrolled in the study. The CR rates at 3 months and 1 month were significantly higher in the cTACE arm (75.2%, 84.2%) as compared with the DEB-TACE arm (27.6%, 35.7%). However, the frequencies of adverse events of any grade, including pyrexia (DEB-TACE vs. cTACE, 19.4% vs. 45.5%, p = 0.0001), fatigue (5.1% vs. 15.8%, p = 0.0194), malaise (11.1% vs. 25.7%, p = 0.0103), appetite loss (12.1% vs. 28.7%, p = 0.0048), abdominal pain (12.1% vs. 23.8%, p = 0.0423), increased serum bilirubin (22.2% vs. 48.5%, p = 0.0002), hypoalbuminemia (43.4% vs. 60.3%, p = 0.0154), increased serum aspartate aminotransferase (35.7% vs. 81.2%, p < 0.0001), and increased serum alanine aminotransferase (35.7% vs. 77.2%, p < 0.0001), were also significantly higher in the cTACE arm than in the DEB-TACE arm. Conclusions: Selective cTACE appeared to have higher CR rates for local tumor control as compared to selective DEB-TACE for HCC. However, the frequency of postembolization syndrome was also significantly higher in the cTACE group than in the DEB-TACE group. Thus, to achieve CR, cTACE may be selected over DEB-TACE in patients who can be expected to tolerate postembolization syndrome.

    DOI: 10.1159/000525500

    PubMed

    researchmap

  • Effects of a selective PPARα modulator, sodium-glucose cotransporter 2 inhibitor, and statin on the myocardial morphology of medaka nonalcoholic fatty liver disease model. 査読 国際誌

    Marina Ohkoshi-Yamada, Kenya Kamimura, Atsushi Kimura, Yuto Tanaka, Itsuo Nagayama, Shunta Yakubo, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

    Biochemical and biophysical research communications   625   116 - 121   2022年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic dysregulation and is linked with various cardiovascular complications, which often lead to poor prognostic outcomes. To develop a standard therapy for NAFLD and to urgently address its complications, the current study aimed to investigate the mechanisms of NAFLD-related heart disease and the therapeutic effects of drugs targeting various metabolic pathways. METHODS: To explore the mechanism of NAFLD-related heart disease, a medaka model of high-fat diet-induced NAFLD was utilized. The gross structural, histological, and inflammatory changes in the myocardium were evaluated in a time-dependent manner. In addition, the therapeutic effects of medicines used for NAFLD treatment including, selective peroxisome proliferator-activated receptor α modulator (SPPARMα, pemafibrate), sodium-glucose cotransporter 2 (SGLT2) inhibitor (tofogliflozin), and statin (pitavastatin), and their combinations on heart pathology were evaluated. To determine the mechanisms underlying the therapeutic effects, the expression of genes related to liver inflammation was assessed via whole transcriptome sequencing analysis. RESULTS: The fish with NAFLD-related heart injury presented with cardiomyocyte hypertrophy, which led to cardiac hypertrophy. This morphological change was caused by the infiltration of inflammatory cells, including macrophages and CD4- and CD8-positive lymphocytes, in the cardiac wall and the expression of transforming growth factor beta 1 in the cardiomyocytes. Further, the livers of the fish had upregulated expressions of senescence-associated secretory phenotype-related genes. Treatment with pemafibrate, tofogliflozin, and pitavastatin reduced these changes and, consequently, cardiomyopathy. CONCLUSION: Our results demonstrated that NAFLD-related heart disease was attributed to the senescence-associated secretory phenotype-induced inflammatory activity in the cardiac wall, which resulted in myocardial hypertrophy. Moreover, the effects of SPPARMα, SGLT2 inhibitor, and statin on NAFLD-related heart disease were evident in the medaka NAFLD model.

    DOI: 10.1016/j.bbrc.2022.07.117

    PubMed

    researchmap

  • Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis. 査読 国際誌

    Naruhiro Kimura, Toru Setsu, Yoshihisa Arao, Norihiro Sakai, Yusuke Watanabe, Hiroyuki Abe, Hiroteru Kamimura, Akira Sakamaki, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Akihiko Osaki, Kentarou Igarashi, Nobuo Waguri, Masahiko Yanagi, Toru Takahashi, Soichi Sugitani, Yuka Kobayashi, Masaaki Takamura, Akira Yoshikawa, Toru Ishikawa, Toshiaki Yoshida, Toshiaki Watanabe, Hitoshi Bannai, Tomoyuki Kubota, Kazuhiro Funakoshi, Hiroto Wakabayashi, So Kurita, Norio Ogata, Masashi Watanabe, Yuhsaku Mita, Shigeki Mori, Motoya Sugiyama, Toru Miyajima, Sumio Takahashi, Shuichi Sato, Kisei Ishizuka, Hironobu Ohta, Yutaka Aoyagi, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   6 ( 8 )   577 - 586   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background and Aim: Symptoms of primary biliary cholangitis (PBC) frequently impair one's quality of life (QOL). Nonetheless, with improved treatment, the prognosis of PBC also improves. QOL plays an important role in patients with PBC. In this study, we aimed to reevaluate the transition of new symptom development in PBC and its predictive factors. Methods: This retrospective multicenter study enrolled 382 patients with PBC for symptom analysis. The impact of a newly developed symptom on PBC prognosis was investigated by Kaplan-Meier analysis with propensity score matching and logistic progression analysis. Results: The cumulative risk of developing a new symptom after 10 and 20 years of follow-up was 7.6 and 28.2%, and specifically that of pruritus, which was the most common symptom, was 6.7 and 23.3%, respectively. In Cox hazard risk analysis, serum Alb level (hazard ratio [HR], 1.097; 95% confidence interval [CI], 1.033-1.165; P = 0.002), the serum D-Bil level (HR, 6.262; 95% CI, 2.522-15.553, P < 0.001), and Paris II criteria (HR, 0.435; 95% CI, 0.183-1.036; P = 0.037) were significant independent predictors of a new symptom. Kaplan-Meier analysis showed that the overall survival and liver-related death were not significant between patients with and without a new symptom. Conclusion: The cumulative risk of new symptom development is roughly 30% 20 years after diagnosis and could be predicted by factors including serum albumin levels, serum D-Bil level, and Paris II criteria.

    DOI: 10.1002/jgh3.12789

    PubMed

    researchmap

  • 肝性腹水が腹部コンパートメント症候群を介して腎機能へ与える影響の検討

    上村 博輝, 酒井 規裕, 小島 雄一, 川田 雄三, 渡邊 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 2 )   199 - 203   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    大量の肝性腹水が腹腔内圧の上昇をもたらし、腹部コンパートメント症候群を発症している状況を腹水前後の膀胱内圧測定、腎静脈流速測定を中心に検討した。対象症例は穿刺前後の膀胱内圧測定、腎静脈の流速測定等が可能であった腹水合併肝硬変8例。穿刺前後の膀胱内圧、尿潜血反応、腎機能、腎静脈流速等を経時的に観察した。末期肝硬変患者が肝腎症候群へ移行する過程で腹水による腹腔内圧の上昇が腎うっ血を併発させ、レニン-アンギオテンシン-アルドステロン系の亢進に関係する可能性が示唆された。(著者抄録)

    researchmap

  • 【肝性脳症の病態と治療】肝性脳症と腸内細菌 病態と治療

    坂牧 僚, 上村 顕也, 横山 邦彦, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 薛 徹, 阿部 寛幸, 上村 博輝, 横尾 健, 土屋 淳紀, 寺井 崇二

    消化器・肝臓内科   12 ( 1 )   68 - 72   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 肝性腹水が腹部コンパートメント症候群を介して腎機能へ与える影響の検討

    上村 博輝, 酒井 規裕, 小島 雄一, 川田 雄三, 渡邊 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 横尾 健, 坂牧 僚, 土屋 淳紀, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   28 ( 2 )   199 - 203   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    大量の肝性腹水が腹腔内圧の上昇をもたらし、腹部コンパートメント症候群を発症している状況を腹水前後の膀胱内圧測定、腎静脈流速測定を中心に検討した。対象症例は穿刺前後の膀胱内圧測定、腎静脈の流速測定等が可能であった腹水合併肝硬変8例。穿刺前後の膀胱内圧、尿潜血反応、腎機能、腎静脈流速等を経時的に観察した。末期肝硬変患者が肝腎症候群へ移行する過程で腹水による腹腔内圧の上昇が腎うっ血を併発させ、レニン-アンギオテンシン-アルドステロン系の亢進に関係する可能性が示唆された。(著者抄録)

    researchmap

  • The liver-gut peripheral neural axis and nonalcoholic fatty liver disease pathologies via hepatic serotonin receptor 2A. 査読 国際誌

    Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Shuji Terai

    Disease models & mechanisms   15 ( 7 )   2022年6月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Serotonin (5-HT) is one of the key bioamines of nonalcoholic fatty liver disease (NAFLD). Its mechanism via autonomic neural signal pathways remains unexplained; hence, we evaluated the involvement of 5-HT and related-signaling pathways via autonomic nerves in NAFLD. Diet-induced NAFLD animal models were developed using wild-type and melanocortin 4 receptor knockout (MC4RKO) mice, and the effects of autonomic neural axis on NAFLD physiology, 5-HT and its receptors (Htrs), and lipid metabolism-related genes were assessed applying hepatic nerve blockade. Hepatic neural blockade retarded the progression of NAFLD by reducing 5-HT in the small intestine, hepatic Htr2a, and hepatic lipogenic genes expression, and HTR2A antagonist reproduced these effects. The effects were milder in MC4RKO, and brain 5-HT and Htr2c expression did not correlate with peripheral neural blockade. Our study demonstrates that the autonomic liver-gut neural axis is involved in the etiology of diet-induced NAFLD and that 5-HT and HTR2A are key factors, implying that the modulation of the axis and use of HTR2A antagonists are potentially novel therapeutic strategies for NAFLD treatment.

    DOI: 10.1242/dmm.049612

    PubMed

    researchmap

  • Involvement of DNA Damage Response via the Ccndbp1-Atm-Chk2 Pathway in Mice with Dextran-Sodium-Sulfate-Induced Colitis. 査読 国際誌

    Ryoko Horigome, Kenya Kamimura, Yusuke Niwa, Kohei Ogawa, Ken-Ichi Mizuno, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Tomoyuki Sugano, Akira Sakamaki, Hiroteru Kamimura, Masaaki Takamura, Shuji Terai

    Journal of clinical medicine   11 ( 13 )   2022年6月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The dextran sodium sulfate (DSS)-induced colitis mouse model has been widely utilized for human colitis research. While its mechanism involves a response to double-strand deoxyribonucleic acid (DNA) damage, ataxia telangiectasia mutated (Atm)-checkpoint kinase 2 (Chk2) pathway activation related to such response remains unreported. Recently, we reported that cyclin D1-binding protein 1 (Ccndbp1) activates the pathway reflecting DNA damage in its knockout mice. Thus, this study aimed to examine the contribution of Ccndbp1 and the Atm-Chk2 pathway in DSS-induced colitis. We assessed the effect of DSS-induced colitis on colon length, disease activity index, and histological score and on the Atm-Chk2 pathway and the subsequent apoptosis in Ccndbp1-knockout mice. DSS-induced colitis showed distal colon-dominant Atm and Chk2 phosphorylation, increase in TdT-mediated dUTP-biotin nick end labeling and cleaved caspase 3-positive cells, and histological score increase, causing disease activity index elevation and colon length shortening. These changes were significantly ameliorated in Ccndbp1-knockout mice. In conclusion, Ccndbp1 contributed to Atm-Chk2 pathway activation in the DSS-induced colitis mouse model, causing inflammation and apoptosis of mucosal cells in the colon.

    DOI: 10.3390/jcm11133674

    PubMed

    researchmap

  • Daisaikoto improves fatty liver and obesity in melanocortin-4 receptor gene-deficient mice via the activation of brown adipose tissue. 査読 国際誌

    Shinichi Morita, Akira Sakamaki, Kyutaro Koyama, Osamu Shibata, Takashi Owaki, Chiyumi Oda, Atsushi Kimura, Taiki Nakaya, Katsuya Ohbuchi, Miwa Nahata, Naoki Fujitsuka, Norihiro Sakai, Hiroyuki Abe, Kenya Kamimura, Shuji Terai

    Scientific reports   12 ( 1 )   10105 - 10105   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Melanocortin 4 receptor gene-knockout (MC4R-KO) mice are known to develop obesity with a high-fat diet. Meanwhile, daisaikoto, one of Kampo medicines, is a drug that is expected to have therapeutic effects on obesity. Here, we report the efficacy of daisaikoto in MC4R-KO mice. Eight-week-old MC4R-KO male mice (n = 12) were divided into three groups as follows: the SD group, which is fed with a standard diet; the HFD group, fed a high-fat diet; and the DSK group, fed with a high-fat diet containing 10% of daisaikoto. After the four-week observation period, mice in each group were sacrificed and samples were collected. The body weights at 12 weeks were significantly higher in the HFD group than in the other groups, indicating that daisaikoto significantly reduced body weight gain and fat deposition of the liver. The metabolome analysis indicated that degradation of triglycerides and fatty acid oxidation in the liver were enhanced by daisaikoto administration. In MC4R-KO mice, the cytoplasm and uncoupling protein 1 expression of brown adipose tissue was decreased; however, it was reversed in the DSK group. In conclusion, daisaikoto has potentially improved fatty liver and obesity, making it a useful therapeutic agent for obesity and fatty liver.

    DOI: 10.1038/s41598-022-14371-y

    PubMed

    researchmap

  • Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene delivery method. 査読 国際誌

    Osamu Shibata, Kenya Kamimura, Yuto Tanaka, Kohei Ogawa, Takashi Owaki, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Hiroyuki Abe, Satoshi Ikarashi, Kazunao Hayashi, Takeshi Yokoo, Shuji Terai

    Molecular therapy. Nucleic acids   28   342 - 352   2022年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This research developed an easy-to-use, reproducible pancreatic cancer animal model utilizing pancreas-targeted hydrodynamic gene delivery to deliver human pancreatic cancer-related genes to the pancreas of wild-type rats. KRAS G12D -induced pancreatic intraepithelial neoplasia lesions showed malignant transformation in the main pancreatic duct at 4 weeks and developed acinar-to-ductal metaplasia, which led to pancreatic ductal adenocarcinoma within 5 weeks, and the gene combination of KRAS G12D and YAP enhanced these effects. The repeat hydrodynamic gene delivery of KRAS G12D  + YAP combination at 4 weeks showed acinar-to-ductal metaplasia in all rats and pancreatic ductal adenocarcinoma in 80% of rats 1 week later. Metastatic tumors in the liver, lymph nodes, and subcutaneous lesions and nervous invasion were confirmed. KRAS G12D and YAP combined transfer contributes to the E- to N-cadherin switch in pancreatic ductal adenocarcinoma cells and to tumor metastases. This pancreatic cancer model will speed up pancreatic cancer research for novel treatments and biomarkers for early diagnosis.

    DOI: 10.1016/j.omtn.2022.03.019

    PubMed

    researchmap

  • Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature. 査読

    Natsuki Ishikawa, Kenya Kamimura, Saori Endo, Soichi Ishii, Kazuya Ogawa, Norihiro Sakai, Hiroyuki Abe, Masayoshi Ko, Osamu Shibata, Youhei Koseki, Junji Yokoyama, Akira Sakamaki, Shuji Terai

    Internal medicine (Tokyo, Japan)   2022年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Regarding the prognosis of cases with advanced-stage hepatocellular carcinoma (HCC), a recent clinical study showed that the immune checkpoint inhibitors atezolizumab plus bevacizumab have superior efficacy to sorafenib. However, only a few reports have focused on their effects on extrahepatic metastases. We herein report a case of HCC in a 59-year-old man with intrahepatic lesions treated successfully by hepatic arterial chemoembolization, radiotherapy, and sorafenib; the extrahepatic lesion in the adrenal gland was treated by atezolizumab plus bevacizumab. The patient showed a tumor-free condition for one year. We have summarized the clinical course and reviewed the literature to underscore the efficacy of atezolizumab plus bevacizumab for treating extrahepatic lesions of HCC.

    DOI: 10.2169/internalmedicine.9341-22

    PubMed

    researchmap

  • Relative Dose Intensityに基づく高齢者レンバチニブ投与における全生存期間の検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A302 - A302   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Intestinal duplication diagnosed preoperatively with double-balloon enteroscopy: an extremely rare case report and literature review. 査読

    Yusuke Niwa, Kentaro Tominaga, Yuzo Kawata, Takamasa Kobayashi, Takeshi Mizuwasa, Kazuya Takahashi, Hiroki Sato, Junji Kohisa, Satoshi Abe, Kenya Kamimura, Junji Yokoyama, Hirokazu Kawai, Hideaki Sugino, Hajime Umezu, Yumiko Hirai, Masato Nakano, Yoshifumi Shimada, Hitoshi Kameyama, Toshifumi Wakai, Shuji Terai

    Clinical journal of gastroenterology   15 ( 2 )   381 - 387   2022年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gastrointestinal duplications are congenital malformations that are usually observed in pediatric patients. Diagnosis in adulthood is quite rare, and preoperative diagnosis of gastrointestinal duplication is difficult, particularly in the small intestine. We encountered an extremely rare adult case of duplication of the jejunum, which showed a stomach-like form diagnosed using double-balloon enteroscopy (DBE). The patient was an 18-year-old male who had been experiencing upper abdominal pain and vomiting repeatedly without any triggers for 3 years. Various examinations were performed, but no cause of symptoms was found. DBE revealed a narrow opening of the lumen at the upper jejunum, and the lumen was covered with mucosal folds similar to those of the stomach. Enteroclysis via DBE showed a tubular structure on the mesenteric side of the jejunum. We diagnosed a jejunal tubular duplication with ectopic gastric mucosa and underwent partial small bowel resection. The patient's abdominal symptoms resolved. From this, DBE can be a useful tool for diagnosing intestinal duplication in adults. We believe that this case and literature review will facilitate the accurate and prompt diagnosis of small intestinal duplication.

    DOI: 10.1007/s12328-022-01596-7

    PubMed

    researchmap

  • 肝疾患の小児・成人移行期医療の課題-全人的ケアの確立を目指して 成人外来へ受診する可能性をもつ小児脂肪肝の特徴

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A169 - A169   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Effects of a novel selective PPARα modulator, statin, sodium-glucose cotransporter 2 inhibitor, and combinatorial therapy on the liver and vasculature of medaka nonalcoholic steatohepatitis model. 査読 国際誌

    Atsushi Kimura, Kenya Kamimura, Marina Ohkoshi-Yamada, Yoko Shinagawa-Kobayashi, Ryo Goto, Takashi Owaki, Chiyumi Oda, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

    Biochemical and biophysical research communications   596   76 - 82   2022年3月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is a disease entity with an increasing incidence, with involvement of several metabolic pathways. Various organs, including the liver, kidneys, and the vasculature, are damaged in NASH, indicating the urgent need to develop a standard therapy. Therefore, this study was conducted to investigate the effects of drugs targeting various metabolic pathways and their combinations on a high-fat diet (HFD)-induced NASH medaka model. METHODS: To investigate the effects of drugs on vascular structures, the NASH animal model was developed using the fli::GFP transgenic medaka fed with HFD at 20 mg/fish daily. The physiological changes, histological changes in the liver, vascular structures in the fin, and serum biochemical markers were evaluated in a time-dependent manner after treatment with selective peroxisome proliferator-activated receptor α modulator (pemafibrate), statin (pitavastatin), sodium-glucose cotransporter 2 inhibitor (tofogliflozin), and their combinations. Furthermore, to determine the mechanisms underlying the effects, whole transcriptome sequencing was conducted using medaka liver samples. RESULTS: Histological analyses revealed significant suppression of fat accumulation and fibrotic changes in the liver after treatment with drugs and their combinations. The expression levels of steatosis- and fibrosis-related genes were modified by the treatments. Moreover, the HFD-induced vascular damages in the fin exhibited milder changes after treatment with the drugs. CONCLUSION: The effects of treating various metabolic pathways on the medaka body, liver, and vascular structures of the NASH medaka model were evidenced. Moreover, to our knowledge, this study is the first to report whole genome sequence and gene expression evaluation of medaka livers, which could be helpful in clarifying the molecular mechanisms of drugs.

    DOI: 10.1016/j.bbrc.2022.01.086

    PubMed

    researchmap

  • Cyclin D1 Binding Protein 1 Responds to DNA Damage through the ATM-CHK2 Pathway. 査読 国際誌

    Yusuke Niwa, Kenya Kamimura, Kohei Ogawa, Chiyumi Oda, Yuto Tanaka, Ryoko Horigome, Masato Ohtsuka, Hiromi Miura, Koichi Fujisawa, Naoki Yamamoto, Taro Takami, Shujiro Okuda, Masayoshi Ko, Takashi Owaki, Atsushi Kimura, Osamu Shibata, Shinichi Morita, Norihiro Sakai, Hiroyuki Abe, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Shuji Terai

    Journal of clinical medicine   11 ( 3 )   2022年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cyclin D1 binding protein 1 (CCNDBP1) is considered a tumor suppressor, and when expressed in tumor cells, CCNDBP1 can contribute to the viability of cancer cells by rescuing these cells from chemotherapy-induced DNA damage. Therefore, this study focused on investigating the function of CCNDBP1, which is directly related to the survival of cancer cells by escaping DNA damage and chemoresistance. Hepatocellular carcinoma (HCC) cells and tissues obtained from Ccndbp1 knockout mice were used for the in vitro and in vivo examination of the molecular mechanisms of CCNDBP1 associated with the recovery of cells from DNA damage. Subsequently, gene and protein expression changes associated with the upregulation, downregulation, and irradiation of CCNDBP1 were assessed. The overexpression of CCNDBP1 in HCC cells stimulated cell growth and showed resistance to X-ray-induced DNA damage. Gene expression analysis of CCNDBP1-overexpressed cells and Ccndbp1 knockout mice revealed that Ccndbp1 activated the Atm-Chk2 pathway through the inhibition of Ezh2 expression, accounting for resistance to DNA damage. Our study demonstrated that by inhibiting EZH2, CCNDBP1 contributed to the activation of the ATM-CHK2 pathway to alleviate DNA damage, leading to chemoresistance.

    DOI: 10.3390/jcm11030851

    PubMed

    researchmap

  • Use of a Deep Learning Approach for the Sensitive Prediction of Hepatitis B Surface Antigen Levels in Inactive Carrier Patients. 査読 国際誌

    Hiroteru Kamimura, Hirofumi Nonaka, Masaya Mori, Taichi Kobayashi, Toru Setsu, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Journal of clinical medicine   11 ( 2 )   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Deep learning is a subset of machine learning that can be employed to accurately predict biological transitions. Eliminating hepatitis B surface antigens (HBsAgs) is the final therapeutic endpoint for chronic hepatitis B. Reliable predictors of the disappearance or reduction in HBsAg levels have not been established. Accurate predictions are vital to successful treatment, and corresponding efforts are ongoing worldwide. Therefore, this study aimed to identify an optimal deep learning model to predict the changes in HBsAg levels in daily clinical practice for inactive carrier patients. We identified patients whose HBsAg levels were evaluated over 10 years. The results of routine liver biochemical function tests, including serum HBsAg levels for 1, 2, 5, and 10 years, and biometric information were obtained. Data of 90 patients were included for adaptive training. The predictive models were built based on algorithms set up by SONY Neural Network Console, and their accuracy was compared using statistical analysis. Multiple regression analysis revealed a mean absolute percentage error of 58%, and deep learning revealed a mean absolute percentage error of 15%; thus, deep learning is an accurate predictive discriminant tool. This study demonstrated the potential of deep learning algorithms to predict clinical outcomes.

    DOI: 10.3390/jcm11020387

    PubMed

    researchmap

  • Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. 査読 国際誌

    Kunihiko Yokoyama, Akira Sakamaki, Kazuya Takahashi, Takumi Naruse, Chihiro Sato, Yuzo Kawata, Kentaro Tominaga, Hiroyuki Abe, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    PloS one   17 ( 2 )   e0264459   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Overt hepatic encephalopathy (HE) is one of the complications of liver cirrhosis (LC), which negatively affects the prognosis and quality of life of patients. Small intestinal bacterial overgrowth (SIBO) is significantly associated with LC and its complications, including HE. We investigated the relationship between SIBO and LC, and the difference between hydrogen-producing and methane-producing SIBO (H-SIBO and M-SIBO, respectively). This is a prospective cohort study of 107 cases. Breath measurements of hydrogen and methane concentrations were performed for the diagnosis of SIBO. The study cohort included 81 males with a median age of 70 (40-86) years, and SIBO was detected in 31 cases (29.0%). There were no significant differences between the SIBO positive and SIBO negative groups. Reclassification into H-SIBO (16 cases) and others (91 cases) was performed, and the Child-Pugh score was only derived in the multivariate logistic analysis (P = 0.028, odds ratio 1.39, 95% confidence interval 1.04-1.85). Furthermore, H-SIBO was significantly associated with covert HE in chi-square test (50.0% vs. 24.2%, P = 0.034). In addition, we evaluated the therapeutic response on SIBO of rifaximin in eight covert HE patients. 20% patients with M-SIBO and 67% patients with H-SIBO showed an improvement of the breath test. In conclusion, H-SIBO, but not M-SIBO, is significantly associated with liver function, and rifaximin might be more effective for covert HE with H-SIBO. Therefore, the diagnosis of SIBO, including the classification as H-SIBO and M-SIBO, might help to determine the choice of treatment for HE.

    DOI: 10.1371/journal.pone.0264459

    PubMed

    researchmap

  • Longitudinal increase in albumin-bilirubin score is associated with non-malignancy-related mortality and quality of life in patients with liver cirrhosis. 査読 国際誌

    Akira Sakamaki, Masaaki Takamura, Norihiro Sakai, Yusuke Watanabe, Yoshihisa Arao, Naruhiro Kimura, Toru Setsu, Hiroyuki Abe, Takeshi Yokoo, Hiroteru Kamimura, Shunsuke Tsubata, Nobuo Waguri, Toru Ishikawa, Hirokazu Kawai, Soichi Sugitani, Tomomi Sato, Kazuhiro Funakoshi, Masashi Watanabe, Kentarou Igarashi, Kenya Kamimura, Atsunori Tsuchiya, Yutaka Aoyagi, Shuji Terai

    PloS one   17 ( 2 )   e0263464   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Due to the developments in the treatment for hepatitis, it is possible to prevent the progression of liver fibrosis and improve patients' prognosis even if it has already led to liver cirrhosis (LC). Consequently, a two-step study was conducted. To begin with, a retrospective study was conducted to identify the potential predictors of non-malignancy-related mortality from LC. Then, we prospectively analyzed the validity of these parameters as well as their association with patients' quality of life. In the retrospective study, 89 cases were included, and the multivariate Cox regression analysis indicated that age (P = 0.012), model for end-stage liver disease (MELD) score (P = 0.012), and annual rate of change of the albumin-bilirubin (ALBI) score (P < 0.001) were significantly associated with LC prognosis. In the prospective study, 70 patients were included, and the patients were divided into cirrhosis progression and non-progression groups. The univariate logistic regression analysis indicated the serum procollagen type III N-terminal peptide level (P = 0.040) and MELD score (P = 0.010) were significantly associated with the annual rate of change of the ALBI score. Furthermore, the mean Chronic Liver Disease Questionnaire score worsened from 5.3 to 4.9 in the cirrhosis progression group (P = 0.034). In conclusion, a longitudinal increase in the ALBI score is closely associated with non-malignancy-related mortality and quality of life.

    DOI: 10.1371/journal.pone.0263464

    PubMed

    researchmap

  • Rapid progression of colonic mucinous adenocarcinoma with immunosuppressive condition: A case report and review of literature. 査読 国際誌

    Youhei Koseki, Kenya Kamimura, Yuto Tanaka, Marina Ohkoshi-Yamada, Qiliang Zhou, Yoshifumi Matsumoto, Takeshi Mizusawa, Hiroki Sato, Akira Sakamaki, Hajime Umezu, Junji Yokoyama, Shuji Terai

    World journal of clinical cases   9 ( 30 )   9182 - 9191   2021年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    BACKGROUND: Colorectal mucinous adenocarcinoma is a rare subtype of colorectal cancer and is characterized by an abundance of mucin in the tumor. In addition, the colorectal mucinous adenocarcinoma often demonstrates poor differentiation in the histology of tumor cells and poor prognosis compared with those with adenocarcinoma. Here, we present the case of a young woman with colonic mucinous adenocarcinoma showing significantly rapid progression within four months of immunosuppressant therapy for Henoch-Schönlein purpura. CASE SUMMARY: Here we report a rare case of ascending colon mucinous adenocarcinoma with lymph node and liver metastases which developed and progressed rapidly within four months during the treatment of Henoch-Schönlein purpura using corticosteroids. The systemic screening examinations showed no tumors before the immunosuppressant therapy. Fortunately, the patient was successfully treated with chemotherapy. CONCLUSION: While no direct evidence that the immunosuppressants accelerated the tumor development, the case presenta tion and review of the literature demonstrated that surveillance for malignancies before and during treatment with immunosuppressive agents is essential.

    DOI: 10.12998/wjcc.v9.i30.9182

    PubMed

    researchmap

  • Rare complication of hepatocellular carcinoma in Wilson's disease. 査読 国際誌

    Marina Ohkoshi-Yamada, Kenya Kamimura, Hiroteru Kamimura, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   5 ( 10 )   1220 - 1222   2021年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    The complication of hepatocellular carcinoma (HCC) in Wilson's disease is rare. Wilson's disease treatment using D-penicillamine (DPA) is useful to prevent HCC occurrence; however, it also causes iron accumulation and synergistic radical formation in the liver, which may enhance carcinogenesis. Reported herein is a case of HCC in Wilson's disease treated with DPA for 36 years. The tumor was surgically resected and histologically diagnosed with moderately differentiated HCC surrounded by cirrhotic tissue with fatty infiltration. Rhodanine staining revealed a slight positively stained area in both tumor and surrounding tissues. Information obtained from this case and literature review highlight the feature of HCC in Wilson's disease.

    DOI: 10.1002/jgh3.12648

    PubMed

    researchmap

  • Advances in the Treatment of Gastrointestinal Bleeding: Safety and Efficiency of Transnasal Endoscopy. 査読 国際誌

    Hiroyuki Abe, Kenya Kamimura, Yoshihisa Arao, Junji Kohisa, Shuji Terai

    Medicines (Basel, Switzerland)   8 ( 9 )   2021年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    Acute upper gastrointestinal bleeding (UGIB) is a common disorder and a gastroenterological emergency. With the development of new techniques and devices, the survivability after gastrointestinal bleeding is improving. However, at the same time, we are facing the difficulty of severely complicated cases with various diseases. For example, while endoscopic examination with a normal diameter endoscope is essential for the diagnosis and treatment of UGIB, there are several cases in which it cannot be used. In these cases, transnasal endoscopy (TNE) may be a viable treatment option. This report reviews current hemostatic devices for endoscopic treatment and the safety and efficiency of using TNE in complicated cases. The latter will be demonstrated in a case report where TNE was employed in a patient with severe esophageal stenosis. This review summarizes the advances made in the devices used and will provide further ideas for the physician in terms of combining these devices and TNE.

    DOI: 10.3390/medicines8090053

    PubMed

    researchmap

  • The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan. 査読 国際誌

    Akira Sakamaki, Kenya Kamimura, Takeshi Yokoo, Akihiko Osaki, Seiichi Yoshikawa, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Nobuo Waguri, Manabu Takeuchi, Kazuhiro Funakoshi, Shuji Terai

    Medicine   100 ( 32 )   e26902   2021年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    ABSTRACT: Gastrointestinal bleeding, hepatic encephalopathy (HE), and hepatocarcinogenesis are associated with the prognosis of patients with liver cirrhosis (LC). Proton pump inhibitors (PPIs) have been used to prevent bleeding, however the effects of PPIs on overall survival have not yet been elucidated. Therefore, this multicenter retrospective study aimed to assess the effect of PPI on the prognosis and HE occurrence of the patients with liver cirrhosis in Japan.A total of 456 patients diagnosed with LC at the 4 institutes during the study period (2010-2014) were assessed. PPI-treated and non-treated patients were compared using propensity score matching analysis. Primary and secondary endpoints of the study were set as the occurrence of HE and overall survival, respectively.A comparison of all cases showed a significantly poorer hepatic reserve function in the PPI-treated patients. The propensity-score matching analysis was performed and 120 PPI-treated patients were 1:1 matched with non-treated patients. The analysis revealed a higher incidence of HE in the PPI-treated than in the non-treated patients (P = .032; hazard ratio [HR], 2.162; 95% confidence interval [CI], 1.066-4.176), but the prognosis of PPI-treated patients was no worse than that of non-treated patients (P = .676; HR, 1.101; 95% CI, 0.702-1.726).This retrospective study showed that PPI administration for the patients with liver cirrhosis may partly be related to the increased incidence of HE but not worsen the patient prognosis.

    DOI: 10.1097/MD.0000000000026902

    PubMed

    researchmap

  • The promise of radiotherapy for hepatocellular carcinoma. 査読 国際誌

    Kenya Kamimura, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   51 ( 8 )   837 - 838   2021年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語  

    DOI: 10.1111/hepr.13687

    PubMed

    researchmap

  • Novel reporter mouse models useful for evaluating in vivo gene editing and for optimization of methods of delivering genome editing tools. 査読 国際誌

    Hiromi Miura, Jurai Imafuku, Aki Kurosaki, Masahiro Sato, Yongjie Ma, Guisheng Zhang, Akiko Mizutani, Kenya Kamimura, Channabasavaiah B Gurumurthy, Dexi Liu, Masato Ohtsuka

    Molecular therapy. Nucleic acids   24   325 - 336   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The clustered regularly interspersed palindromic repeats (CRISPR) system is a powerful genome-editing tool to modify genomes, virtually in any species. The CRISPR tool has now been utilized in many areas of medical research, including gene therapy. Although several proof-of-concept studies show the feasibility of in vivo gene therapy applications for correcting disease-causing mutations, and new and improved tools are constantly being developed, there are not many choices of suitable reporter models to evaluate genome editor tools and their delivery methods. Here, we developed and validated reporter mouse models containing a single copy of disrupted EGFP (ΔEGFP) via frameshift mutations. We tested several delivery methods for validation of the reporters, and we demonstrated their utility to assess both non-homologous end-joining (NHEJ) and via homology-directed repair (HDR) processes in embryos and in somatic tissues. With the use of the reporters, we also show that hydrodynamic delivery of ribonucleoprotein (RNP) with Streptococcus pyogenes (Sp)Cas9 protein mixed with synthetic guide RNA (gRNA) elicits better genome-editing efficiencies than the plasmid vector-based system in mouse liver. The reporters can also be used for assessing HDR efficiencies of the Acidaminococcus sp. (As)Cas12a nuclease. The results suggest that the ΔEGFP mouse models serve as valuable tools for evaluation of in vivo genome editing.

    DOI: 10.1016/j.omtn.2021.03.003

    PubMed

    researchmap

  • Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. 査読 国際誌

    Naruhiro Kimura, Masaaki Takamura, Nobutaka Takeda, Yusuke Watanabe, Yoshihisa Arao, Masahumi Takatsuna, Suguru Takeuchi, Hiroyuki Abe, Toru Setsu, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    Hepatology international   15 ( 2 )   437 - 443   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Biochemical response to treatment in patients with primary biliary cholangitis (PBC) reflects prognosis. However, the best predictive criteria to detect biochemical response remain undetermined. In addition, because these criteria need > 6 months until definition, parameters that can estimate its results before initiating treatment are needed. METHODS: We conducted a single-center retrospective study on 196 patients with PBC, followed up for at least 12 months after initiating treatment. RESULTS: Kaplan-Meier analysis showed that Paris II (p = 0.002) and Rotterdam criteria (p = 0.001) could estimate the overall survival of PBC patients, whereas Paris II (p = 0.001), Rotterdam (p = 0.001), and Rochester criteria (p= 0.025) could estimate liver-related deaths. Cox hazard analysis revealed Paris II and Rotterdam criteria as significantly independent predictors of overall survival (hazard ratio (HR) 3.948, 95% CI 1.293-12.054, p = 0.016 and HR 6.040, 95% CI 1.969-18.527, p = 0.002, respectively) and liver-related deaths (HR 10.461, 95% CI 1.231-88.936, p = 0.032 and HR 10.824, 95% CI 1.252-93.572, p = 0.032, respectively). The results of Paris II criteria could be estimated by serum prothrombin time (Odds ratio (OR) 1.052, 95% CI 1.008-1.098, p = 0.021) and alanine transaminase level (OR 0.954, 95% CI 0.919-0.991, p = 0.014) whereas, those of Rotterdam criteria could be estimated by serum albumin level (OR 3.649, 95% CI 1.098-12.128, p = 0.035) at the time of diagnosis. CONCLUSIONS: This study highlights the best prediction criteria and pre-treatment parameters that facilitate the prognosis of PBC patients.

    DOI: 10.1007/s12072-021-10163-0

    PubMed

    researchmap

  • Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver. 査読 国際誌

    Masayoshi Ko, Kenya Kamimura, Takashi Owaki, Takuro Nagoya, Norihiro Sakai, Itsuo Nagayama, Yusuke Niwa, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Ryosuke Inoue, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Shuji Terai

    Disease models & mechanisms   14 ( 3 )   2021年3月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The etiology of non-alcoholic fatty liver disease (NAFLD) consists of various factors, including neural signal pathways. However, the molecular mechanisms of the autonomic neural signals influencing NAFLD progression have not been elucidated. Therefore, we examined the involvement of the gut-liver neural axis in NAFLD development and tested the therapeutic effect of modulation of this axis in this study. To test the contribution of the gut-liver neural axis, we examined NAFLD progression with respect to body weight, hepatic steatosis, fibrosis, intestinal tight junction, microbiota and short-chain fatty acids in NAFLD models of choline-deficient defined L-amino-acid and high-fat diet-fed mice with or without blockades of autonomic nerves from the liver. Blockade of the neural signal from the liver to the gut in these NAFLD mice models ameliorated the progression of liver weight, hepatic steatosis and fibrosis by modulating serotonin expression in the small intestine. It was related to the severity of the liver pathology, the tight junction protein expression, microbiota diversity and short-chain fatty acids. These effects were reproduced by administrating serotonin antagonist, which ameliorated the NAFLD progression in the NAFLD mice models. Our study demonstrated that the gut-liver neural axis is involved in the etiologies of NAFLD progression and that serotonin expression through this signaling network is the key factor of this axis. Therefore, modulation of the gut-liver neural axis and serotonin antagonist ameliorates fatty and fibrotic changes in non-alcoholic fatty liver, and can be a potential therapeutic target of NAFLD.This article has an associated First Person interview with the first author of the paper.

    DOI: 10.1242/dmm.048922

    PubMed

    researchmap

  • Successful treatment of positive-sense RNA virus coinfection with autoimmune hepatitis using double filtration plasmapheresis. 査読 国際誌

    Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    BMJ case reports   14 ( 3 )   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Double filtration plasmapheresis (DFPP) is an apheretic technique that selectively removes high molecular weight substances using a plasma component filter. DFPP has been used to treat positive-sense RNA virus infections, mainly chronic hepatitis C virus (HCV) infection, because of its ability to directly eliminate viral particles from blood plasma from 2008 to about 2015, before direct-acting antiviral agents was marketed. This effect has been termed virus removal and eradication by DFPP. HCV is a positive-sense RNA virus similar to West Nile virus, dengue virus and the SARS and Middle East respiratory syndrome coronaviruses. SARS-CoV-2 is classified same viral species. These viruses are all classified in Family Flaviviridae which are family of single-stranded plus-stranded RNA viruses. Viral particles are 40-60 nm in diameter, enveloped and spherical in shape. We present a rare case of HCV removal where an RNA virus infection that copresented with virus-associated autoimmune hepatitis was eliminated using DFPP. Our results indicate that DFPP may facilitate prompt viraemia reduction and may have novel treatment applications for SARS-CoV-2, that is, use of therapeutic plasma exchange for fulminant COVID-19.

    DOI: 10.1136/bcr-2020-236984

    PubMed

    researchmap

  • Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers. 国際誌

    Kenya Kamimura, Takeshi Suda, Yasuo Fukuhara, Shujiro Okuda, Yu Watanabe, Takeshi Yokoo, Akihiko Osaki, Nobuo Waguri, Toru Ishikawa, Toshihiro Sato, Yutaka Aoyagi, Masaaki Takamura, Toshifumi Wakai, Shuji Terai

    Scientific reports   11 ( 1 )   6255 - 6255   2021年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cisplatin (CDDP) is one of the chemotherapeutic drugs being used to treat various cancers. Although effective in many cases, as high doses of CDDP cause cytotoxic effects that may worsen patients' condition, therefore, a marker of sensitivity to CDDP is necessary to enhance the safety and efficiency of CDDP administration. This study focused on adipose most abundant 2 (APM2) to examine its potential as a marker of CDDP sensitivity. The relationship of APM2 expression with the mechanisms of CDDP resistance was examined in vitro and in vivo using hepatocellular carcinoma (HCC) cells, tissues and serum of HCC patients (n = 71) treated initially with intrahepatic arterial infusion of CDDP followed by surgical resection. The predictability of serum APM2 for CDDP sensitivity was assessed in additional 54 HCC patients and 14 gastric cancer (GC) patients. APM2 expression in CDDP-resistant HCC was significantly higher both in serum and the tissue. Bioinformatic analyses and histological analyses demonstrated upregulation of ERCC6L (DNA excision repair protein ERCC6-like) by APM2, which accounts for the degree of APM2 expression. The serum APM2 level and chemosensitivity for CDDP were assessed and cut-off value of serum APM2 for predicting the sensitivity to CDDP was determined to be 18.7 µg/mL. The value was assessed in HCC (n = 54) and GC (n = 14) patients for its predictability of CDDP sensitivity, resulted in predictive value of 77.3% and 100%, respectively. Our study demonstrated that APM2 expression is related to CDDP sensitivity and serum APM2 can be an effective biomarker of HCC and GC for determining the sensitivity to CDDP.Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028487).

    DOI: 10.1038/s41598-021-85498-7

    PubMed

    researchmap

  • Relationship between detection of hepatitis B virus in saliva and periodontal disease in hepatitis B virus carriers in Japan. 査読 国際誌

    Hiroteru Kamimura, Jun Watanabe, Tomoyuki Sugano, Junji Kohisa, Hiroyuki Abe, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Shogo Okoshi, Yoshinari Tanabe, Ritsuo Takagi, Hirofumi Nonaka, Shuji Terai

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy   27 ( 3 )   492 - 496   2021年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    INTRODUCTION: Although hepatitis B virus infection is well-described, the additional risk posed by oral bleeding in individuals with chronic hepatitis B virus infection has not been determined. This study aimed to determine the quantity of hepatitis B virus in the saliva of carriers in Japan, as a means of understanding the potential risk for horizontal transmission. METHODS: Saliva samples from 48 confirmed hepatitis B virus carriers were included in the analysis. Hepatitis B virus concentrations and the presence of occult blood as periodontal disease were evaluated in each sample. RESULTS: Hepatitis B surface antigen was identified in 46 of the 48 samples (98%), with hepatitis B virus DNA identified in 19 of the 48 saliva samples (40%). Occult blood was detected in 32 (67%) samples with the prevalence increasing as a function of age (r = 0.413; P = 0.003). There was a significantly positive correlation between hepatitis B virus DNA levels in the serum and saliva specimens (r = 0.895; P < 0.001). CONCLUSIONS: Occult blood in saliva was detected in most participants. The detection of hepatitis B virus DNA correlated positively with hepatitis B virus in the serum and occult blood in the saliva. Therefore, improved care of periodontal disease among older people is important for preventing horizontal transmission of hepatitis B virus.

    DOI: 10.1016/j.jiac.2020.10.028

    PubMed

    researchmap

  • Multiple Tumor-Like Fatty Changes in the Liver Disappeared After Hepatitis C Virus Eradication With Direct-Acting Antiviral Treatment. 査読 国際誌

    Norihiro Sakai, Kenya Kamimura, Shuji Terai

    The American journal of gastroenterology   116 ( 2 )   237 - 237   2021年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.14309/ajg.0000000000000703

    PubMed

    researchmap

  • 【肝硬変診療ガイドラインの改正をめぐって】肝腎症候群

    坂牧 僚, 薛 徹, 阿部 寛幸, 上村 顕也, 高村 昌昭, 寺井 崇二

    消化器・肝臓内科   9 ( 2 )   155 - 159   2021年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • Acute on chronicの新展開 当科における我が国の新診断基準でのAcute On Chronic Liver Failure症例の検討

    野尻 俊介, 土屋 淳紀, 阿部 聡司, 坂牧 僚, 上村 博輝, 上村 顕也, 高村 昌昭, 寺井 崇二

    肝臓   62 ( 2 )   107 - 107   2021年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge. 査読 国際誌

    Hiroteru Kamimura, Takeki Sato, Kazuki Natsui, Takamasa Kobayashi, Tomoaki Yoshida, Kenya Kamimura, Atsunori Tsuchiya, Toshiko Murayama, Junji Yokoyama, Hirokazu Kawai, Masaaki Takamura, Shuji Terai

    International journal of molecular sciences   22 ( 3 )   2021年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass and strength that occurs with aging or in association with various diseases. The condition is prevalent worldwide and occurs more frequently in patients with chronic diseases owing to the intrinsic relationship of muscles with glucose, lipid, and protein metabolism. Liver cirrhosis is characterized by the progression of necro-inflammatory liver diseases, which leads to fibrosis, portal hypertension, and a catabolic state, which causes loss of muscle tissue. Sarcopenia is of significant concern in the state of liver cirrhosis because sarcopenia has been associated with higher mortality, increased hospital admissions, worse post-liver transplant outcomes, decreased quality of life, and increased risk for other complications associated with cirrhosis. Therefore, sarcopenia is also an important feature of liver cirrhosis, representing a negative prognostic factor and influencing mortality. An increased understanding of sarcopenia could lead to the development of novel therapeutic approaches that could help improve the cognitive impairment of cirrhotic patients; therefore, we present a review of the mechanisms and diagnosis of sarcopenia in liver disease and existing therapeutic approaches.

    DOI: 10.3390/ijms22031425

    PubMed

    researchmap

  • Effect of Lenvatinib on a Hepatocellular Carcinoma with Fibroblast Growth Factor Receptor 4 Expression: A Case Report and Review of the Literature. 査読

    Osamu Shibata, Kenya Kamimura, Masayoshi Ko, Norihiro Sakai, Hiroyuki Abe, Shinichi Morita, Takeshi Mizusawa, Hiroki Sato, Akira Sakamaki, Shuji Terai

    Internal medicine (Tokyo, Japan)   60 ( 11 )   1709 - 1715   2020年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Basic and clinical research have shown that the expression of molecules involved in the hepatocellular carcinoma cell signaling pathway is related to the sensitivity to molecular-targeted agents. We herein report a case of HCC that was effectively treated with lenvatinib after a poor response to sorafenib. The tumor showed a high expression of fibroblast growth factor receptor 4, which is reportedly related to the sensitivity to lenvatinib in vitro. The information obtained from this case and from our literature review highlights the importance of assessing the expression of the molecules involved in tumors for effective precision medicine.

    DOI: 10.2169/internalmedicine.6580-20

    PubMed

    researchmap

  • Daily Monitoring of Serum Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein Is Useful for Predicting Therapeutic Effect of Tolvaptan in Cirrhotic Ascites. 査読

    Masaaki Takamura, Akira Sakamaki, Yoshihisa Arao, Toru Setsu, Hiroteru Kamimura, Takeshi Yokoo, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

    The Tohoku journal of experimental medicine   252 ( 4 )   287 - 296   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Wisteria floribunda agglutinin (WFA) is a lectin that binds to the sugar chain of Mac-2 binding protein (M2BP), and WFA-positive M2BP (WFA+-M2BP) has been reported as a useful marker for assessing liver fibrosis in chronic liver disease. Tolvaptan (TLV), a selective vasopressin V2 receptor antagonist, is used for cirrhotic ascites in Japan, but good predictors of treatment efficacy remain to be established. Our aim was to investigate whether WFA+-M2BP monitoring before and after TLV administration can predict treatment efficacy in patients with cirrhotic ascites. Twenty patients (10 men), with a median age of 72 years, were enrolled. Cirrhosis was caused by hepatitis B virus (n = 3), hepatitis C virus (n = 4), alcohol (n = 8), and others (n = 5). Responders were defined as having a body weight loss of ≥ 1.5 kg/week after TLV administration. Serum WFA+-M2BP levels were measured at baseline and days 1, 3, and 7 after TLV treatment. Twelve patients (60%) were responders. Baseline WFA+-M2BP levels were correlated with serum albumin levels (r = -0.544, P = 0.013). The baseline furosemide dose was lower and platelet count was higher in responders than in non-responders (P < 0.05). The ratio of WFA+-M2BP levels on day 1 after TLV administration to baseline was lower in responders than in non-responders (P < 0.05). The decrease in the ratio discriminated responders from non-responders (AUC = 0.844, P < 0.05). In conclusion, monitoring serum WFA+-M2BP is helpful for predicting the efficacy of TLV treatment in patients with cirrhotic ascites.

    DOI: 10.1620/tjem.252.287

    PubMed

    researchmap

  • Monitoring chronological change by liver-to-spleen attenuation ratio for secondary hepatic steatosis for a short term. 査読

    Hiroteru Kamimura, Kunihiko Yokoyama, Shunsuke Nojiri, Yuko Komoro, Toshiko Murayama, Yu Koyama, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    Clinical journal of gastroenterology   13 ( 6 )   1219 - 1224   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Parenteral nutrition-associated liver disease (PNALD) causes hepatic steatosis and moderate liver enzyme elevation due to lack of enteral nutrition and deficiency of some nutrients. However, the period for recovery from PNALD after a nutritional intervention is unknown with no report. Herein, we report a case of a 44-year-old Japanese woman with severe fatty infiltration of the liver due to malnutrition. Our nutritional support team administered appropriate total parenteral, especially fat and carnitine, nutrition to improve her malnutrition. Chronological changes in liver-to-spleen attenuation ratio were also considered because of her disease state. Computed tomography demonstrated improved attenuation of the liver, and the liver enzymes level normalized after 5 weeks from appropriate nutrition. Understanding the nutritional condition of a patient may help in elucidating an appropriate treatment strategy.

    DOI: 10.1007/s12328-020-01165-w

    PubMed

    researchmap

  • Usefulness of ultrasonography to assess the response to steroidal therapy for the rare case of type 2b immunoglobulin G4-related sclerosing cholangitis without pancreatitis: A case report. 査読 国際誌

    Yuto Tanaka, Kenya Kamimura, Ryota Nakamura, Marina Ohkoshi-Yamada, Yohei Koseki, Takeshi Mizusawa, Satoshi Ikarashi, Kazunao Hayashi, Hiroki Sato, Akira Sakamaki, Junji Yokoyama, Shuji Terai

    World journal of clinical cases   8 ( 22 )   5821 - 5830   2020年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    BACKGROUND: A type 2b immunoglobulin G4 (IgG4)-related sclerosing cholangitis (SC) without autoimmune pancreatitis is a rare condition with IgG4-SC. While the variety of the imaging modalities have tested its usefulness in diagnosing the IgG4-SC, however, the usage of ultrasonography for the assessment of the response to steroidal therapy on the changes of bile duct wall thickness have not been reported in the condition. Therefore, the information of our recent case and reported cases have been summarized. CASE SUMMARY: We report the case of an 82-year-old Japanese man diagnosed with isolated IgG4-related SC based on the increase of serum IgG4, narrowing of the bile duct, its wall thickness, no complication of autoimmune pancreatitis, and IgG4 positive inflammatory cell infiltration to the wall with the fibrotic changes. The cholangiogram revealed type 2b according to the classification. Corticosteroid treatment showed a favorable effect, with the smooth decrease in serum IgG4 and the improvement of the bile duct wall thickness. CONCLUSION: As isolated type 2b, IgG4-SC is rare, the images, histological findings, and clinical course of our case will be helpful for physicians to diagnose and treat the new cases appropriately.

    DOI: 10.12998/wjcc.v8.i22.5821

    PubMed

    researchmap

  • Esophageal High-Resolution Manometry for Diagnosing the Severity of the Chronic Intestinal Pseudo-Obstruction: A Case Series. 査読 国際誌

    Hiroki Sato, Kenya Kamimura, Hideaki Matsui, Takashi Owaki, Shinichi Morita, Yuto Tanaka, Natsuki Ishikawa, Yoshifumi Shimada, Junji Yokoyama, Toshifumi Wakai, Shuji Terai

    Digestive diseases and sciences   66 ( 11 )   3960 - 3967   2020年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Chronic intestinal pseudo-obstruction (CIPO) is a severe and refractory intestinal motility disorder. However, due to its rarity and difficult histological investigation, its pathophysiology has not been characterized. AIM: Therefore, in this study, we aimed to determine the role of esophageal high-resolution manometry (HRM) in CIPO and the histological and clinical characteristics of the disease. METHODS: Patients with CIPO were analyzed for clinical characteristics; histological findings; and clinical courses after therapeutic intervention. In addition, HRM was performed to determine the esophageal involvement. RESULTS: Eleven patients were diagnosed with CIPO, and five required the long period of parenteral nutrition showing impaired esophageal motility including achalasia and absent contractility diagnosed with HRM. The four of these five cases showed acute onset of the CIPO following the triggering events of pregnancy, appendicitis, and surgery. In contrast, other six patients with normal or Jackhammer esophagus on HRM had moderate severity of CIPO with gradual onset. The histological analyses revealed that the loss of the intestinal neural ganglion cells and layers by inflammation, destruction, and atrophy are related to the severity of the clinical course of the disease and esophageal HRM findings of achalasia and absent contractility. CONCLUSIONS: HRM may be useful to diagnose the severity of the clinical course and to determine the therapeutic options for CIPO.

    DOI: 10.1007/s10620-020-06701-9

    PubMed

    researchmap

  • Efficacy and Safety of the Radiotherapy for Liver Cancer: Assessment of Local Controllability and its Role in Multidisciplinary Therapy. 査読 国際誌

    Marina Ohkoshi-Yamada, Kenya Kamimura, Osamu Shibata, Shinichi Morita, Motoki Kaidu, Toshimichi Nakano, Katsuya Maruyama, Atsushi Ota, Hirotake Saito, Nobuko Yamana, Tomoya Oshikane, Yukiyo Goto, Natsumi Yoshimura, Satoshi Tanabe, Hisashi Nakano, Madoka Sakai, Yuto Tanaka, Yohei Koseki, Yoshihisa Arao, Hiroyuki Abe, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Hidefumi Aoyama, Shuji Terai

    Cancers   12 ( 10 )   2020年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This study investigated the efficacy and safety of radiotherapy as part of multidisciplinary therapy for advanced hepatocellular carcinoma (HCC). Clinical data of 49 HCC patients treated with radiotherapy were assessed retrospectively. The efficacy of radiotherapy was assessed by progression-free survival, disease control rate, and overall survival. Safety was assessed by symptoms and hematological assay, and changes in hepatic reserve function were determined by Child-Pugh score and albumin-bilirubin (ALBI) score. Forty patients underwent curative radiotherapy, and nine patients with portal vein tumor thrombus (PVTT) underwent palliative radiotherapy as part of multidisciplinary therapy. Local disease control for curative therapy was 80.0% and stereotactic body radiotherapy was 86.7% which was greater than that of conventional radiotherapy (60.0%). Patients with PVTT had a median observation period of 651 days and 75% three-year survival when treated with multitherapy, including radiotherapy for palliative intent, transcatheter arterial chemoembolization, and administration of molecular targeted agents. No adverse events higher than grade 3 and no changes in the Child-Pugh score and ALBI score were seen. Radiotherapy is safe and effective for HCC treatment and can be a part of multidisciplinary therapy.

    DOI: 10.3390/cancers12102955

    PubMed

    researchmap

  • 【肝硬変のトータルマネジメント】肝腎症候群に対する治療 海外での動向

    坂牧 僚, 薛 徹, 阿部 寛幸, 上村 顕也, 高村 昌昭, 寺井 崇二

    肝臓クリニカルアップデート   6 ( 2 )   205 - 211   2020年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    肝腎症候群は肝硬変や末期肝疾患患者に発症した可逆的な腎機能障害である。薬物治療の基本は、アルブミン製剤投与下に血管収縮薬を投与することであり、欧米ではテルリプレシンが最も一般的に使用されている。また、経頸静脈的肝内門脈大循環短絡術や血液透析も考慮されるが、肝移植が根治的な治療として位置付けられている。治療方針の決定においては、個々の症例の状況を慎重に検討のうえ、最新のガイドラインなどを参考にしつつ行う必要がある。(著者抄録)

    researchmap

  • Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis. 査読

    Akira Sakamaki, Kunihiko Yokoyama, Fusako Yamazaki, Hiroteru Kamimura, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    Internal medicine (Tokyo, Japan)   59 ( 15 )   1849 - 1853   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 66-year-old Japanese man was admitted to our hospital with grade 2 hepatic encephalopathy (HE). Abdominal computed tomography and laboratory examinations revealed decompensated liver cirrhosis. Intravenous administration of branched-chain amino acids immediately ameliorated the HE, and lactulose was initiated. However, a breath test revealed small intestinal bacterial overgrowth (SIBO); therefore, rifaximin was additionally initiated. The breath test was repeated after discharge, when no evidence of SIBO or overt HE was identified. This case suggested that a breath test is effective for the identification of SIBO and that the administration of a poorly absorbed antibiotic should be considered in SIBO-positive HE patients taking lactulose.

    DOI: 10.2169/internalmedicine.4593-20

    PubMed

    researchmap

  • Effect of methionine/choline-deficient diet and high-fat diet-induced steatohepatitis on mitochondrial homeostasis in mice. 査読 国際誌

    Yoshihisa Arao, Hirokazu Kawai, Kenya Kamimura, Takamasa Kobayashi, Oki Nakano, Manabu Hayatsu, Tatsuo Ushiki, Shuji Terai

    Biochemical and biophysical research communications   527 ( 2 )   365 - 371   2020年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Considering the increase in cases of non-alcoholic steatohepatitis (NASH), the use of appropriate animal model of NASH is essential to understand the underlying pathogenesis mechanism. To date, several mice models have been used; however, significant differences in the etiologies and food administered affected the results, with inconsistent conclusions. Therefore, it is necessary to understand these models and their differences to be able to choose appropriate models. Inspired by the fact that mitochondrial (mt)DNA content is changed in non-alcoholic fatty liver disease in humans, we investigated the mtDNA copy number in the NASH mice models induced by high-fat diet (HFD) and methionine/choline-deficient diet (MCD) to understand the differences between these models. Megamitochondria were observed in both MCD and HFD groups. However, the MCD group showed significant decrease in liver mtDNA content compared with that in the HFD group. These changes were associated with significant upregulation of mitochondrial biogenesis- and degradation-related genes in MCD model than in HFD model. Thus, stability of mtDNA is associated with the differences between MCD and HFD-induced NASH models often used in studies; these findings could help in choosing appropriate models for studies on NASH.

    DOI: 10.1016/j.bbrc.2020.03.180

    PubMed

    researchmap

  • Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status. 査読 国際誌

    Kentaro Tominaga, Kenya Kamimura, Hiroki Sato, Masayoshi Ko, Yuzo Kawata, Takeshi Mizusawa, Junji Yokoyama, Shuji Terai

    World journal of clinical cases   8 ( 11 )   2092 - 2101   2020年6月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pyoderma gangrenosum (PG) is a neutrophilic dermatosis clinically characterized by the presence of painful skin ulcerations with erythematous. As it is frequently associated with inflammatory bowel diseases, including ulcerative colitis, gastroenterologists should be familiar with the disease including therapeutic options. Therefore, we have conducted a review focusing on the cytapheresis for PG in cases of inflammatory bowel diseases. A literature search was conducted to extract studies published in the last 20 years, with information on demographics, clinical symptoms, treatment, and the clinical course from a total of 22 cases reported and our recent case. In most patients, cytapheresis was associated with improvement or resolution of PG after failure of conventional therapeutic options such as corticosteroids, antibiotics, immunosuppressive agents and immunoglobulin. Based on the information summarized, cytapheresis is helpful in the majority of patients with PG refractory to medical treatment associated with inflammatory bowel diseases and could be further studied in a multicenter, randomized trial.

    DOI: 10.12998/wjcc.v8.i11.2092

    PubMed

    researchmap

  • Ghrelin-insulin-like growth factor-1 axis is activated via autonomic neural circuits in the non-alcoholic fatty liver disease. 査読 国際誌

    Takuro Nagoya, Kenya Kamimura, Ryosuke Inoue, Masayoshi Ko, Takashi Owaki, Yusuke Niwa, Norihiro Sakai, Toru Setsu, Akira Sakamaki, Takeshi Yokoo, Hiroteru Kamimura, Yuka Nakamura, Masaki Ueno, Shuji Terai

    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society   32 ( 5 )   e13799   2020年5月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The correlation of the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) with non-alcoholic fatty liver disease (NAFLD) has been reported in epidemiological studies. However, the mechanisms of molecular and inter-organ systems that render these factors to influence on NAFLD have not been elucidated. In this study, we examined the induction of ghrelin which is the GH-releasing hormone and IGF-1, and involvement of autonomic neural circuits, in the pathogenesis of NAFLD. METHODS: The expression of gastric and hypothalamic ghrelin, neural activation in the brain, and serum IGF-1 were examined in NAFLD models of choline-deficient defined l-amino-acid diet-fed, melanocortin 4 receptor knockout mice, and partial hepatectomy mice with or without the blockades of autonomic nerves to test the contribution of neural circuits connecting the brain, liver, and stomach. KEY RESULTS: The fatty changes in the liver increased the expression of gastric ghrelin through the autonomic pathways which sends the neural signals to the arcuate nucleus in the hypothalamus through the afferent vagal nerve which reached the pituitary gland to release GH and then stimulate the IGF-1 release from the liver. In addition, high levels of ghrelin expression in the arcuate nucleus were correlated with NAFLD progression regardless of the circuits. CONCLUSIONS: Our study demonstrated that the fatty liver stimulates the autonomic nervous signal circuits which suppress the progression of the disease by activating the gastric ghrelin expression, the neural signal transduction in the brain, and the release of IGF-1 from the liver.

    DOI: 10.1111/nmo.13799

    PubMed

    researchmap

  • Change in body composition in patients with achalasia before and after peroral endoscopic myotomy. 査読 国際誌

    Takeshi Mizusawa, Hiroki Sato, Kenya Kamimura, Satoru Hashimoto, Ken-Ichi Mizuno, Hiroteru Kamimura, Satoshi Ikarashi, Kazunao Hayashi, Masaaki Takamura, Junji Yokoyama, Shuji Terai

    Journal of gastroenterology and hepatology   35 ( 4 )   601 - 608   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Patients with achalasia experience weight loss because of dysphagia caused by impaired relaxation of the lower esophageal sphincter. This study aimed to use dual bioelectrical impedance analysis (BIA) to determine the change in bodyweight and body composition in patients with achalasia before and after peroral endoscopic myotomy (POEM). METHODS: Patients with achalasia who underwent POEM from 2013 to 2018 (n = 72) were retrospectively analyzed for change in bodyweight before and after 3 months. Additionally, change in body composition was prospectively investigated in the final 10 of 72 patients using non-radiation dual BIA. RESULTS: Twenty patients (27.8%) were underweight (body mass index < 18.5) before undergoing POEM. No clinical parameters were identified to be associated with the underweight condition before POEM and be predictive of an increase in bodyweight after POEM. Low visceral fat volume observed on dual BIA correlated closely with the result obtained using computed tomography (Pearson correlation coefficient: r = 0.850, P < 0.01). Patients with achalasia had a statistically significant increase in visceral (P < 0.01) and subcutaneous fat volumes (P < 0.01) after POEM. Skeletal muscle mass index slightly increased (P = 0.02), although the value after POEM was still low. No blood biomarkers were indicators for low bodyweight or low visceral fat volume. CONCLUSIONS: Dual BIA is an effective non-invasive tool to evaluate the change in body composition of underweight patients with achalasia. Skeletal muscle volume was not enough after POEM, although a rapid increase in the intra-abdominal fat volume was observed. Additional studies are warranted to understand the pathological implications.

    DOI: 10.1111/jgh.14847

    PubMed

    researchmap

  • Huge liver tumor in young man. 査読 国際誌

    Osamu Shibata, Kenya Kamimura, Rie Azumi, Kei Shibuya, Shintaro Shiba, Tatsuya Ohno, Shuji Terai

    JGH open : an open access journal of gastroenterology and hepatology   4 ( 2 )   301 - 302   2020年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    Intrahepatic cholangiocarcinoma is the second leading primary hepatic tumors, accounting for 5% of all hepatic tumors. The curability depends on the operability; however, the difficulty of early diagnosis and late clinical presentation account for the poor prognosis. Therefore, development of a novel therapeutic option and a method to determine the viability of the primary tumor, which hinder the assessment of the impact of other therapies, including chemotherapy and radiotherapy are needed. Although FDG-PET has been used to detect distant metastases of ICC, which are present in 20% of patients at the initial diagnosis, little is known about the efficacy of FDG-PET of the primary lesion of ICC. Here, we present the case of a 31-year-old male diagnosed with unresectable ICC and successfully treated with carbon-ion radiation, and present the usefulness of fluorodeoxyglucose-positron emission tomography in the determination of the viability of the tumor.

    DOI: 10.1002/jgh3.12234

    PubMed

    researchmap

  • Prostaglandin E2 and its receptor EP2 trigger signaling that contributes to YAP-mediated cell competition. 査読 国際誌

    Erika Ishihara, Yuya Nagaoka, Toshiaki Okuno, Satoshi Kofuji, Mari Ishigami-Yuasa, Hiroyuki Kagechika, Kenya Kamimura, Shuji Terai, Takehiko Yokomizo, Yukihiko Sugimoto, Yasuyuki Fujita, Akira Suzuki, Hiroshi Nishina

    Genes to cells : devoted to molecular & cellular mechanisms   25 ( 3 )   197 - 214   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Cell competition is a biological process by which unfit cells are eliminated from "cell society." We previously showed that cultured mammalian epithelial Madin-Darby canine kidney (MDCK) cells expressing constitutively active YAP were eliminated by apical extrusion when surrounded by "normal" MDCK cells. However, the molecular mechanism underlying the elimination of active YAP-expressing cells was unknown. Here, we used high-throughput chemical compound screening to identify cyclooxygenase-2 (COX-2) as a key molecule triggering cell competition. Our work shows that COX-2-mediated PGE2 secretion engages its receptor EP2 on abnormal and nearby normal cells. This engagement of EP2 triggers downstream signaling via an adenylyl cyclase-cyclic AMP-PKA pathway that, in the presence of active YAP, induces E-cadherin internalization leading to apical extrusion. Thus, COX-2-induced PGE2 appears a warning signal to both abnormal and surrounding normal cells to drive cell competition.

    DOI: 10.1111/gtc.12750

    PubMed

    researchmap

  • Effect of Diphtheria Toxin-Based Gene Therapy for Hepatocellular Carcinoma. 査読 国際誌

    Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Norihiro Sakai, Takuro Nagoya, Yuji Kobayashi, Masato Ohtsuka, Hiromi Miura, Akira Sakamaki, Hiroteru Kamimura, Norio Miyamura, Hiroshi Nishina, Shuji Terai

    Cancers   12 ( 2 )   2020年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatocellular carcinoma (HCC) is a major global malignancy, responsible for >90% of primary liver cancers. Currently available therapeutic options have poor performances due to the highly heterogeneous nature of the tumor cells; recurrence is highly probable, and some patients develop resistances to the therapies. Accordingly, the development of a novel therapy is essential. We assessed gene therapy for HCC using a diphtheria toxin fragment A (DTA) gene-expressing plasmid, utilizing a non-viral hydrodynamics-based procedure. The antitumor effect of DTA expression in HCC cell lines (and alpha-fetoprotein (AFP) promoter selectivity) is assessed in vitro by examining HCC cell growth. Moreover, the effect and safety of the AFP promoter-selective DTA expression was examined in vivo using an HCC mice model established by the hydrodynamic gene delivery of the yes-associated protein (YAP)-expressing plasmid. The protein synthesis in DTA transfected cells is inhibited by the disappearance of tdTomato and GFP expression co-transfected upon the delivery of the DTA plasmid; the HCC cell growth is inhibited by the expression of DTA in HCC cells in an AFP promoter-selective manner. A significant inhibition of HCC occurrence and the suppression of the tumor marker of AFP and des-gamma-carboxy prothrombin can be seen in mice groups treated with hydrodynamic gene delivery of DTA, both 0 and 2 months after the YAP gene delivery. These results suggest that DTA gene therapy is effective for HCC.

    DOI: 10.3390/cancers12020472

    PubMed

    researchmap

  • 【難治性腹水の対策】肝腎症候群

    薛 徹, 荒生 祥尚, 上村 博輝, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    消化器・肝臓内科   7 ( 2 )   169 - 174   2020年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • Rare Brain Metastasis From a Pancreatobiliary Subtype of Intraductal Papillary Mucinous Neoplasm. 査読 国際誌

    Yoshihisa Arao, Kenya Kamimura, Masatoshi Ikemi, Kazunao Hayashi, Masayuki Takaki, Shunsaku Takahashi, Satoshi Seino, Hiroyuki Abe, Shintaro Tsuboguchi, Yutaka Otsu, Kazuhiro Sanpei, Junji Kohisa, Shuhei Kondo, Yusuke Tani, Junko Ito, Yasuko Toyoshima, Akiyoshi Kakita, Yoichi Ajioka, Shuji Terai

    Pancreas   49 ( 1 )   e8-e11 - e11   2020年1月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    DOI: 10.1097/MPA.0000000000001450

    PubMed

    researchmap

  • Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis. 査読 国際誌

    Akira Sakamaki, Kunihiko Yokoyama, Kyutaro Koyama, Shinichi Morita, Hiroyuki Abe, Kenya Kamimura, Masaaki Takamura, Shuji Terai

    PloS one   15 ( 11 )   e0242582   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In alcoholic liver cirrhosis (LC) patients, obesity has become a problem that progresses into liver dysfunction. Herein, we investigated the relationship between the prognosis of steatohepatitis and body weight, along with fat accumulation in patients with alcoholic LC. We conducted a single-center retrospective study, enrolled 104 alcoholic LC patients without hepatocellular carcinoma (HCC) based on histological and clinical evidence, and investigated factors related to poor prognosis using multivariate Cox regression and cluster analyses. Cox regression analysis revealed three independent relevant factors: subcutaneous adipose tissue (SAT) index (median 34.8 cm2/m2, P = 0.009, hazard ratio [HR] 1.017, 95% confidence interval [CI] 1.004-1.030), total bilirubin level (median 1.7 mg/dL, P = 0.003, HR 1.129, 95% CI 1.042-1.223), and prothrombin time value (median 64%, P = 0.007, HR 0.967, 95% CI 0.943-0.991). In the cluster analysis, we categorized the patients into three groups: no adipose tissue accumulation (NAT group), SAT prior accumulation (SAT group), and visceral adipose tissue prior accumulation (VAT group). The results of the three groups revealed that the SAT group displayed a significantly poor prognosis of the Kaplan-Meier curve (67.1 vs 21.2 vs 65.3, P<0.001) of a 5-year survival rate. Propensity score matching analysis of the SAT and VAT groups was performed to adjust the patient's background, but no significant differences were found between them; however, the prognosis was poorer (21.2 vs 66.3, P<0.001), and hemostatic factors were still at a lower level in the SAT group. These findings suggest that SAT accumulation type of obesity is a poor prognostic factor in alcoholic LC patients without HCC, and the hemorrhagic tendency might worsen the poor prognosis in such cases.

    DOI: 10.1371/journal.pone.0242582

    PubMed

    researchmap

  • Pulmonary tumor thrombotic microangiopathy of hepatocellular carcinoma: A case report and review of literature. 査読 国際誌

    Shinichi Morita, Kenya Kamimura, Hiroyuki Abe, Yukari Watanabe-Mori, Chiyumi Oda, Takamasa Kobayashi, Yoshihisa Arao, Yusuke Tani, Riuko Ohashi, Yoichi Ajioka, Shuji Terai

    World journal of gastroenterology   25 ( 48 )   6949 - 6958   2019年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare condition in patients with hepatocellular carcinoma (HCC); to date, few cases have been reported. While hepatic dysfunction has been focused on the later stages of HCC, the management of symptoms in PTTM is important for supportive care of the cases. For the better understanding of PTTM in HCC, the information of our recent case and reported cases have been summarized. CASE SUMMARY: A patient with HCC exhibited acute and severe respiratory failure. Radiography and computed tomography of the chest revealed the multiple metastatic tumors and a frosted glass-like shadow with no evidence of infectious pneumonia. We diagnosed his condition as acute respiratory distress syndrome caused by the lung metastases and involvement of the pulmonary vessels by tumor thrombus. Administration of prednisolone to alleviate the diffuse alveolar damages including edematous changes of alveolar wall caused by the tumor cell infiltration and ischemia showed mild improvement in his symptoms and imaging findings. An autopsy showed the typical pattern of PTTM in the lung with multiple metastases. CONCLUSION: PTTM is caused by tumor thrombi in the arteries and thickening of the pulmonary arterial endothelium leading to the symptoms of dyspnea in terminal staged patients. Therefore, supportive management of symptoms is necessary in the cases with PTTM and hence we believe that the information presented here is of great significance for the diagnosis and management of symptoms of PTTM with HCC.

    DOI: 10.3748/wjg.v25.i48.6949

    PubMed

    researchmap

  • Rare Mesenteric Arterial Diseases: Fibromuscular Dysplasia and Segmental Arterial Mediolysis and Literature Review. 査読

    Masayoshi Ko, Kenya Kamimura, Akira Sakamaki, Yusuke Niwa, Kentaro Tominaga, Kenichi Mizuno, Shuji Terai

    Internal medicine (Tokyo, Japan)   58 ( 23 )   3393 - 3400   2019年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Fibromuscular dysplasia (FMD) and segmental arterial mediolysis (SAM) are noninflammatory, nonatherosclerotic arterial diseases that cause aneurysm, occlusion, and thromboses. These diseases are rarely seen in mesenteric arterial lesions; however, as they can be lethal if appropriate management is not provided, the accumulation of clinical information from cases is essential. We herein report the cases of a 57-year-old man diagnosed with FMD and a 63-year-old man diagnosed with SAM. We conclude that an early diagnosis with imaging modalities and clinical information followed by the appropriate treatment improves the prognosis of these arterial diseases.

    DOI: 10.2169/internalmedicine.3094-19

    PubMed

    researchmap

  • Efficacy of gelatin hydrogels incorporating triamcinolone acetonide for prevention of fibrosis in a mouse model. 査読 国際誌

    Nao Nakajima, Satoru Hashimoto, Hiroki Sato, Kazuya Takahashi, Takuro Nagoya, Kenya Kamimura, Atsunori Tsuchiya, Junji Yokoyama, Yuichi Sato, Hanako Wakatsuki, Masayuki Miyata, Yusuke Akashi, Ryusuke Tanaka, Ken Matsuda, Yasuhiko Tabata, Shuji Terai

    Regenerative therapy   11   41 - 46   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Introduction: Triamcinolone acetonide (TA), a steroid, is often used clinically to prevent dysfunctions associated with fibrosis. The objective of this study was to examine whether TA can be suspended in a gelatin sheet for tissue engineering using a mouse skin wound model. Methods: TA was suspended in biodegradable gelatin and freeze-dried in a sheet form. The sheet was analyzed for homogeneity and controlled release of TA by high-performance liquid chromatography. We made two skin wounds on the dorsal side of mice. Gelatin sheets with TA (TA sheet) and without TA (control sheet) were attached to each skin wound. To determine the efficacy of the prepared TA sheet on the skin wounds, TA-sheet versus TA-injection experiments were conducted. Hematoxylin and eosin staining was performed to assess the grade of epithelialization and alpha smooth muscle actin (α-SMA) immunohistochemical staining was conducted to evaluate myofibroblast infiltration. Results: In the TA-release test in vitro, 7.7 ± 2.3% of TA was released from the sheet by 24 h. After replacing the initial phosphate-buffered saline (PBS) with collagenase PBS, the amount of released TA increased over time. The wound area/original skin wound area after 15 days with the TA sheet was significantly larger than that with the control sheet (26.9 ± 5.5% vs 10.7 ± 2.6%, p = 0.023). The α-SMA positive area/whole area with the TA sheet was significantly lower than that with the control sheet (4.65 ± 0.66% vs 7.24 ± 0.7%, p = 0.023). Furthermore, the α-SMA positive area/whole area with the TA sheet was significantly lower than that with TA injection (5.32 ± 0.45% vs 7.93 ± 0.75%, p = 0.013). Conclusions: We developed a TA sheet and confirmed both the homogeneity of the suspended TA and controlled-release of the TA in the presence of collagenase in vitro. The TA sheet caused less myofibroblast infiltration into the tissue than the control sheet or TA injection did.

    DOI: 10.1016/j.reth.2019.04.001

    PubMed

    researchmap

  • Inhibition of sodium-glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis-related kidney disease. 査読 国際誌

    Takuro Nagoya, Kenya Kamimura, Ryo Goto, Yoko Shinagawa-Kobayashi, Yusuke Niwa, Atsushi Kimura, Norihiro Sakai, Masayoshi Ko, Hiroshi Nishina, Shuji Terai

    FEBS open bio   9 ( 12 )   2016 - 2024   2019年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The effect of sodium-glucose cotransporter 2 inhibitor (SGLT2I) on nonalcoholic steatohepatitis (NASH) has been reported, but there are few studies on its effect on NASH-related renal injury. In this study, we examined the effect of SGLT2I using a novel medaka fish model of NASH-related kidney disease, which was developed by feeding the d-rR/Tokyo strain a high-fat diet. SGLT2I was administered by dissolving it in water of the feeding tank. SGLT2I ameliorates macrophage accumulation and oxidative stress and maintained mitochondrial function in the kidney. The results demonstrate the effect of SGLT2I on NASH-related renal injury and the usefulness of this novel animal model for research into NASH-related complications.

    DOI: 10.1002/2211-5463.12734

    PubMed

    researchmap

  • Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. 査読 国際誌

    Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Shuji Terai

    Cancers   11 ( 12 )   2019年11月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The liver is a key organ for metabolism, protein synthesis, detoxification, and endocrine function, and among liver diseases, including hepatitis, cirrhosis, malignant tumors, and congenital disease, liver cancer is one of the leading causes of cancer-related deaths worldwide. Conventional therapeutic options such as embolization and chemotherapy are not effective against advanced-stage liver cancer; therefore, continuous efforts focus on the development of novel therapeutic options, including molecular targeted agents and gene therapy. In this review, we will summarize the progress toward the development of gene therapies for liver cancer, with an emphasis on recent clinical trials and preclinical studies.

    DOI: 10.3390/cancers11121865

    PubMed

    researchmap

  • Methotrexate-related lymphoproliferative disorders in the liver: Case presentation and mini-review. 査読 国際誌

    Takeshi Mizusawa, Kenya Kamimura, Hiroki Sato, Takeshi Suda, Hiroyuki Fukunari, Go Hasegawa, Osamu Shibata, Shinichi Morita, Akira Sakamaki, Junji Yokoyama, Yu Saito, Yoshihisa Hori, Yuduru Maruyama, Fumitoshi Yoshimine, Takahiro Hoshi, Shinichi Morita, Tsutomu Kanefuji, Masaaki Kobayashi, Shuji Terai

    World journal of clinical cases   7 ( 21 )   3553 - 3561   2019年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    BACKGROUND: Immunosuppression is effective in treating a number of diseases, but adverse effects such as bone marrow suppression, infection, and oncogenesis are of concern. Methotrexate is a key immunosuppressant used to treat rheumatoid arthritis. Although it is effective for many patients, various side effects have been reported, one of the most serious being methotrexate-related lymphoproliferative disorder. While this may occur in various organs, liver involvement is rare. Information on these liver lesions, including clinical characteristics, course, and imaging studies, has not been summarized to date. CASE SUMMARY: We present a case of 70-year-old woman presented with a 2-wk history of fever and abdominal pain. She had had rheumatoid arthritis for 5 years and was being treated with medication including methotrexate. Contrast-enhanced computed tomography revealed multiple low density tumors in the liver and the histological analyses showed significant proliferation of lymphocytes in masses that were positive on immunohistochemical staining for CD3, CD4, CD8, and CD79a but negative for CD20 and CD56. Staining for Epstein-Barr virus-encoded RNA was negative. And based on these findings, the liver tumors were diagnosed as Methotrexate-related lymphoproliferative disorders. A time-dependent disappearance of the liver tumors after stopping methotrexate supported the diagnoses. CONCLUSION: The information obtained from our case and a review of 9 additional cases reported thus far assist physicians who may face the challenge of diagnosing and managing this disorder.

    DOI: 10.12998/wjcc.v7.i21.3553

    PubMed

    researchmap

  • Efficacy and safety of ribavirin therapy for chronic hepatitis E after kidney transplantation. 査読 国際誌

    Tomoaki Yoshida, Masaaki Takamura, Ryo Goto, Suguru Takeuchi, Atsunori Tsuchiya, Kenya Kamimura, Masayuki Tasaki, Yuki Nakagawa, Kazuhide Saito, Yoshihiko Tomita, Shuji Terai

    Hepatology research : the official journal of the Japan Society of Hepatology   49 ( 10 )   1244 - 1248   2019年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatitis E virus (HEV) infection has been recognized as an acute condition. However, recent reports have shown that immunocompromised patients, such as those receiving solid-organ transplantation, can develop chronic hepatitis with HEV infection. We report two cases of chronic hepatitis E after kidney transplantation (KT) who were successfully treated with ribavirin monotherapy. Several years after KT, both patients had sustained elevations in the levels of liver enzymes for a period of more than 6 months. Both patients had HEV infection, genotype 3a. Histological studies showed infiltration of inflammatory cells without fibrosis. Treatment included ribavirin monotherapy at a dosage of 600 mg daily for 3 months. One month after therapy initiation, HEV-RNA turned to negative, and remained negative at 24 weeks after ribavirin therapy without severe complications. Although the treatment of chronic hepatitis E is not fully established, ribavirin therapy can be a safe and effective treatment for chronic hepatitis E.

    DOI: 10.1111/hepr.13363

    PubMed

    researchmap

  • Colorectal neuroendocrine carcinoma: A case report and review of the literature. 査読 国際誌

    Tomoaki Yoshida, Kenya Kamimura, Kazunori Hosaka, Koji Doumori, Hiromitsu Oka, Akito Sato, Yasuo Fukuhara, Shoji Watanabe, Tomomi Sato, Akira Yoshikawa, Takashi Tomidokoro, Shuji Terai

    World journal of clinical cases   7 ( 14 )   1865 - 1875   2019年7月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Colorectal neuroendocrine carcinoma (NEC) is a rare tumor that demonstrates aggressive growth pattern with ingrowth into the tract, metastasis to the other organs, and invasion to the surrounding organs; these clinical characteristics result in poor prognosis. Surgical resection appears as an effective approach; however, because it is difficult to accurately diagnose NEC during the early stage and owing to its aggressive growth pattern, development of a reliable standard chemotherapy regimen and management strategies are essential. CASE SUMMARY: Here, we report the case of patient with NEC showing an aggressive growth pattern that resulted in the rupture of the tumor to the outside the colon after stenting of the internal colonic stenosis. In addition, the tumor invaded into the duodenum, thereby causing duodenal stenosis that required an additional stent in the duodenum. This aggressive growth pattern is one of the main features of the NEC that is different from adenocarcinoma. To clarify the clinical characteristics, we reviewed 60 recently reported cases, including data on tumor location, size, treatment, and prognosis. CONCLUSION: We consider that the information presented here is of great significance for the diagnosis, treatment, and management of symptoms of the patients with NEC.

    DOI: 10.12998/wjcc.v7.i14.1865

    PubMed

    researchmap

  • A case report of psychiatric symptoms following direct-acting antiviral and ribavirin combination therapy for chronic hepatitis C in a patient with innate anxiety. 査読 国際誌

    Akira Sakamaki, Kenya Kamimura, Naoki Fukui, Haruka Watanabe, Norihiro Sakai, Kentaro Tominaga, Kenichi Mizuno, Masaaki Takamura, Hirokazu Kawai, Takuro Sugai, Satoshi Yamagiwa, Toshiyuki Someya, Shuji Terai

    BMC gastroenterology   19 ( 1 )   85 - 85   2019年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Direct-acting antivirals (DAAs) result in a highly sustained virological response rate and better patient tolerance. However, this therapeutic approach may, on rare occasions, give rise to psychiatric symptoms. We describe a case requiring discontinuation of DAA and ribavirin combination therapy due to psychiatric symptoms in a patient with congenital anxious personality traits. The information summarized here will be helpful to physicians treating chronic hepatitis C virus (HCV) infection in patients with underlying psychiatric problems. CASE PRESENTATION: A 57-year-old Japanese woman diagnosed with chronic HCV infection was prescribed DAA and ribavirin combination therapy. She had a history of mild innate anxiety and development of psychiatric symptoms due to interferon (IFN) therapy 8 years prior, which subsided with discontinuation of the therapy. Similar psychiatric symptoms such as enervation, palpitations, an episode of hyperventilation, and consciousness disturbances with myotonia were observed after the administration of the antiviral agents. No abnormal findings related to her symptoms were observed on laboratory or imaging results. Psychiatrists diagnosed the patient as having a somatization disorder induced by the antiviral agents on the basis of innate anxiety. After the discontinuation of therapy, her symptoms gradually improved. CONCLUSIONS: Although DAAs were not causative factors for psychiatric symptoms in phase 3 studies, a post-marketing study reported psychiatric symptoms such as depression in patients with underlying psychiatric problems. Our case suggests psychiatric symptoms might worsen after DAA and ribavirin administration in patients with underlying psychiatric disorders, and therefore, close monitoring is necessary for these patients, especially if they have a history of psychiatric symptoms after IFN.

    DOI: 10.1186/s12876-019-1013-1

    PubMed

    researchmap

  • Rational arrangement of measuring shear wave speed in the liver. 査読 国際誌

    Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Itsuo Nagayama, Takahiro Hoshi, Satoshi Abe, Shinichi Morita, Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Kazuyoshi Yagi, Shuji Terai

    World journal of gastroenterology   25 ( 20 )   2503 - 2513   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Shear wave speed has been widely applied to quantify a degree of liver fibrosis. However, there is no standardized procedure, which makes it difficult to utilize the speed universally. AIM: To provide procedural standardization of shear wave speed measurement. METHODS: Point shear wave elastography (pSWE) was measured in 781 patients, and two-dimensional shear wave elastography (2dSWE) was measured on the same day in 18 cases. Regions-of-interest were placed at 12 sites, and the median and robust coefficient-of-variation (CVR) were calculated. A residual sum-of-square (Σdi2) was computed for bootstrap values of 1000 iterations in 18 cases with each assumption of 1 to 12 measurements. The proportion of the Σdi2 (%Σdi2) was calculated as the ratio of Σdi2 to pSWE after converting it based on the correlation between pSWE and 2dSWE. RESULTS: The CVR showed a significantly broader distribution in the left lobe (P < 0.0001), and the smallest CVR in the right anterior segment that covered 95% cases was 40.4%. pSWE was significantly higher in the left lobe than in the right lobe (1.63 ± 0.78 m/s vs 1.61 ± 0.78 m/s, P = 0.0004), and the difference between the lobes became further discrete when the subjects were limited to the cases with a CVR less than 40.4% in any segment (1.76 ± 0.80 m/s vs 1.70 ± 0.82 m/s, P < 0.0001). The highest values of the CVR in every 0.1 m/s interval were plotted in convex upward along pSWE and peaked at 1.93 m/s. pSWE and 2dSWE were significantly correlated (P < 0.0001, r = 0.95). In 216000 resamples from 18 cases, the %Σdi2 of 12 sites was 8.0% and gradually increased as the acquisition sites decreased to reach a significant difference with a %Σdi2 of 7 sites (P = 0.027). CONCLUSION: These data suggest that shear wave speed should be measured at 8 or more sites of spreading in both lobes.

    DOI: 10.3748/wjg.v25.i20.2503

    PubMed

    researchmap

  • A Rare Duodenal Carcinosarcoma: A Case Report and Literature Review. 査読

    Yoshihisa Arao, Kenya Kamimura, Masatoshi Ikemi, Masayuki Takaki, Shunsaku Takahashi, Satoshi Seino, Hiroyuki Abe, Junji Kohisa, Takashi Kato, Yoichi Ajioka, Shuji Terai

    Internal medicine (Tokyo, Japan)   58 ( 9 )   1273 - 1278   2019年5月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Carcinosarcoma is a biphasic malignant tumor comprising both carcinomatous and sarcomatous components; its occurrence in the duodenum is very rare. We herein report the case of a 96-year-old woman with duodenal carcinosarcoma showing rapid growth within the past year. The tumor was found to be bulging into the lumen and predominantly comprised sarcomatoid components with focal positive staining for cytokeratin. Therefore, the tumor was diagnosed as duodenal carcinosarcoma. The clinical information of the present case and our literature review of the 12 cases reported to date will help physicians diagnose and treat this rare tumor.

    DOI: 10.2169/internalmedicine.2094-18

    PubMed

    researchmap

  • Multiple Endocrine Neoplasia Type 1-Related Acute Pancreatitis. 査読

    Takahashi S, Kamimura K, Abe H, Watanabe Y, Hayashi K, Mizuno K, Yamamoto T, Takeuchi M, Natsui M, Terai S

    Pancreas   48 ( 5 )   e35 - e38   2019年5月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    DOI: 10.1097/MPA.0000000000001267

    Web of Science

    PubMed

    researchmap

  • Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. 査読 国際誌

    Kenya Kamimura, Akira Sakamaki, Hiroteru Kamimura, Toru Setsu, Takeshi Yokoo, Masaaki Takamura, Shuji Terai

    World journal of gastroenterology   25 ( 15 )   1817 - 1827   2019年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aging of the organ function causes sensitivity to the disease progression and need careful consideration for the medical treatment. With the increase of aging population, the opportunity to provide medical treatment for people in very old age is rapidly increasing therefore, the understanding of the various physiological changes of cellular function, size and function of organs are essential for the decision of therapeutic options. Among the various chronic conditions seen in elderly people, we have focused on liver cirrhosis, since despite specific therapeutic options for many of liver diseases including direct acting antivirals for hepatitis C virus, nucleoside analogs for hepatitis B, and corticosteroids for autoimmune hepatitis, there is currently no standard therapy to treat liver cirrhosis, which is the final stage of these liver diseases. Therefore, management of the various symptoms of liver cirrhosis is essential, and aging-related parameters must be considered in the decision making for therapeutic strategies and dosage of the available medicine. In this mini-review, we have summarized the therapeutic options to manage various symptoms of liver cirrhosis, carefully considering the physiological changes of various organs associated with aging.

    DOI: 10.3748/wjg.v25.i15.1817

    PubMed

    researchmap

  • Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH). 査読 国際誌

    Goto R, Kamimura K, Shinagawa-Kobayashi Y, Sakai N, Nagoya T, Niwa Y, Ko M, Ogawa K, Inoue R, Yokoo T, Sakamaki A, Kamimura H, Abe S, Nishina H, Terai S

    FEBS open bio   9 ( 4 )   643 - 652   2019年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/2211-5463.12598

    PubMed

    researchmap

  • Esophageal Stenosis by Prostate Cancer Metastasis. 査読

    Kamimura K, Shinagawa-Kobayashi Y, Mizuno K, Terai S

    The American journal of gastroenterology   114 ( 4 )   685 - 687   2019年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者  

    DOI: 10.14309/ajg.0000000000000185

    PubMed

    researchmap

  • 肝性脳症治療の変遷 肝臓と消化管―腸・肝・脳相関をベースに―各種肝疾患における腸内細菌叢の変化

    上村顕也, 坂牧僚, 薛徹, 横尾健, 上村博輝, 阿部聡司, 高村昌昭, 寺井崇二

    肝胆膵   78 ( 3 )   441‐446   2019年3月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis. 査読 国際誌

    Ogawa K, Kamimura K, Terai S

    Hepatology (Baltimore, Md.)   69 ( 2 )   914 - 916   2019年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/hep.30189

    PubMed

    researchmap

  • Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine. 査読 国際誌

    Sakai N, Kamimura K, Shinagawa-Kobayashi Y, Nagoya T, Niwa Y, Ko M, Setsu T, Sakamaki A, Yokoo T, Abe S, Kamimura H, Sugitani S, Yanagi M, Terai S

    Cancer management and research   11   4437 - 4448   2019年

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2147/CMAR.S201424

    PubMed

    researchmap

  • Identification of molecular transition of hepatocellular carcinoma: a novel method to predict the initiation of metastasis. 査読

    Kamimura K

    Stem cell investigation   6   5   2019年

     詳細を見る

    担当区分:筆頭著者, 責任著者  

    DOI: 10.21037/sci.2019.02.02

    PubMed

    researchmap

  • Gene Therapy for Pancreatic Diseases: Current Status. 査読

    Kamimura K, Yokoo T, Terai S

    International journal of molecular sciences   19 ( 11 )   2018年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者  

    DOI: 10.3390/ijms19113415

    PubMed

    researchmap

  • 超高齢者における肝硬変診療 査読

    上村顕也, 坂牧僚, 木村成広, 薛徹, 上村博輝, 横尾健, 阿部聡司, 寺井崇二

    消化器・肝臓内科   4 ( 4 )   344 - 347   2018年10月

     詳細を見る

  • Usefulness of Capsule Endoscopy and Double-balloon Enteroscopy for the Diagnosis of Multiple Carcinoid Tumors in the Small Intestine: Case Reports and a Literature Review. 査読

    Tominaga K, Kamimura K, Yokoyama J, Terai S

    Internal medicine (Tokyo, Japan)   58 ( 5 )   655 - 659   2018年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    DOI: 10.2169/internalmedicine.1700-18

    Web of Science

    PubMed

    researchmap

  • Diagnosis and management of fibromuscular dysplasia and segmental arterial mediolysis in gastroenterology field: A mini-review. 査読 国際誌

    Ko M, Kamimura K, Ogawa K, Tominaga K, Sakamaki A, Kamimura H, Abe S, Mizuno K, Terai S

    World journal of gastroenterology   24 ( 32 )   3637 - 3649   2018年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3748/wjg.v24.i32.3637

    PubMed

    researchmap

  • Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. 査読 国際誌

    Takamasa Kobayashi, Hirokazu Kawai, Oki Nakano, Satoshi Abe, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    BMC cancer   18 ( 1 )   756 - 756   2018年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The impact of sarcopenia on the prognosis of patients with hepatocellular carcinoma (HCC) who receive transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization and transcatheter arterial infusion chemotherapy, remains unclear. We investigated the prognostic value of skeletal muscle loss (SML) stratified by cutoffs for sarcopenia and rate of change in skeletal muscle mass over 6 months. METHODS: We retrospectively evaluated 102 patients with HCC treated with transcatheter intra-arterial therapies between 2005 and 2015. Computed tomography images of the third lumbar vertebra (L3) were analyzed to obtain the skeletal muscle area normalized for the height squared, defined as the skeletal muscle index at L3 (L3 SMI), before and 6 months after treatment. Low or high SMI was defined using cutoff values of 42 cm2/m2 in men and 38 cm2/m2 in women. The rate of change in skeletal muscle mass (ΔL3 SMI) over 6 months was calculated. Overall survival (OS) was compared in groups classified by baseline L3 SMI and ΔL3 SMI; prognostic significance was assessed with univariate and multivariate analyses, using Cox proportional hazards models. RESULTS: OS did not differ significantly between groups with low (n = 31) and high (n = 71) SMI at baseline (P = 0.172), but OS was significantly poorer in patients with SML (n = 41), defined as ΔL3 SMI < - 4.6% over 6 months than in those without SML (n = 61, P = 0.018). On multivariate analysis, SML (hazard ratio [HR], 1.675; 95% confidence interval [CI], 1.031-2.721; P = 0.037), serum alpha-fetoprotein ≥20 ng/mL (HR, 2.550; 95% CI, 1.440-4.515; P = 0.001), and maximum tumor diameter ≥ 30 mm (HR, 1.925; 95% CI, 1.166-3.179; P = 0.010) were independent predictors of poor OS. Baseline L3 SMI was not significantly associated with OS (HR, 1.405; 95% CI, 0.861-2.293; P = 0.174). CONCLUSIONS: ΔL3 SMI was an independent prognostic factor in patients with HCC treated with transcatheter intra-arterial therapies. Further study is required to reveal whether prevention of skeletal muscle depletion might be a new therapeutic strategy to contribute to improved clinical outcomes in patients with HCC.

    DOI: 10.1186/s12885-018-4673-2

    PubMed

    researchmap

  • Renal Impairment in Chronic Hepatitis B: A Review. 査読 国際誌

    Hiroteru Kamimura, Toru Setsu, Naruhiro Kimura, Takeshi Yokoo, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    Diseases (Basel, Switzerland)   6 ( 2 )   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The liver plays a key role in the metabolism of proteins. Liver dysfunction affects many organs because it communicates with the spleen and all digestive organs through the portal vein. Additionally, the kidney is an organ that is closely related to the liver and is involved in liver diseases. Glomerulonephritis is an important extrahepatic manifestation of chronic hepatitis B virus (HBV) infection. Nucleos(t)ide analog (NA) therapy effectively suppresses HBV replication by inhibiting HBV polymerase, thus decreasing the levels of serum HBV-DNA and delaying the progression of cirrhosis. Although NA therapy is recommended for all patients with chronic HBV infection, regardless of the level of renal dysfunction, there is limited information on NA use in patients with chronic kidney disease. In addition, in patients with end-stage liver cirrhosis, hepatorenal syndrome can be fatal. Hence, we should take into account the stage of impaired renal function in patients with cirrhosis. The aims of this article are to review the epidemiology, clinical presentation, treatment, and prevention of HBV-associated nephropathy.

    DOI: 10.3390/diseases6020052

    PubMed

    researchmap

  • Diversion colitis and pouchitis: A mini-review 査読

    Kentaro Tominaga, Kenya Kamimura, Kazuya Takahashi, Junji Yokoyama, Satoshi Yamagiwa, Shuji Terai

    World Journal of Gastroenterology   24 ( 16 )   1734 - 1747   2018年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:Baishideng Publishing Group Co., Limited  

    Diversion colitis is characterized by inflammation of the mucosa in the defunctioned segment of the colon after colostomy or ileostomy. Similar to diversion colitis, diversion pouchitis is an inflammatory disorder occurring in the ileal pouch, resulting from the exclusion of the fecal stream and a subsequent lack of nutrients from luminal bacteria. Although the vast majority of patients with surgically-diverted gastrointestinal tracts remain asymptomatic, it has been reported that diversion colitis and pouchitis might occur in almost all patients with diversion. Surgical closure of the stoma, with reestablishment of gut continuity, is the only curative intervention available for patients with diversion disease. Pharmacologic treatments using short-chain fatty acids, mesalamine, or corticosteroids are reportedly effective for those who are not candidates for surgical reestablishment
    however, there are no established assessment criteria for determining the severity of diversion colitis, and no management strategies to date. Therefore, in this mini-review, we summarize and review various recently-reported treatments for diversion disease. We are hopeful that the information summarized here will assist physicians who treat patients with diversion colitis and pouchitis, leading to better case management.

    DOI: 10.3748/wjg.v24.i16.1734

    Scopus

    PubMed

    researchmap

  • Endoscopic ultrasound-guided transmural drainage for subphrenic abscess: Report of two cases and a literature review 査読

    Shinichi Morita, Kenya Kamimura, Takeshi Suda, Chiyumi Oda, Takahiro Hoshi, Tsutomu Kanefuji, Kazuyoshi Yagi, Shuji Terai

    BMC Gastroenterology   18 ( 1 )   55   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BioMed Central Ltd.  

    Background: An intra-abdominal abscess can sometimes become serious and difficult to treat. The current standard treatment strategy for intra-abdominal abscess is percutaneous imaging-guided drainage. However, in cases of subphrenic abscess, it is important to avoid passing the drainage route through the thoracic cavity, as this can lead to respiratory complications. The spread of intervention techniques involving endoscopic ultrasonography (EUS) has made it possible to perform drainage via the transmural route. Case presentation: We describe two cases of subphrenic abscess that occurred after intra-abdominal surgery. Both were treated successfully by EUS-guided transmural drainage (EUS-TD) without severe complications. Our experience of these cases and a review of the literature suggest that the drainage catheters should be placed both internally and externally together into the abscess cavity. In previous cases there were no adverse events except for one case of mediastinitis and pneumothorax resulting from transesophageal drainage. Therefore, we consider that the transesophageal route should be avoided if possible. Conclusions: Although further studies are necessary, our present two cases and a literature review suggest that EUS-TD is feasible and effective for subphrenic abscess, and not inferior to other treatments. We anticipate that this report will be of help to physicians when considering the drainage procedure for this condition. As there have been no comparative studies to date, a prospective study involving a large number of patients will be necessary to determine the therapeutic options for such cases.

    DOI: 10.1186/s12876-018-0782-2

    Scopus

    PubMed

    researchmap

  • Autonomic nervous system network and liver regeneration 査読

    Kenya Kamimura, Ryosuke Inoue, Takuro Nagoya, Norihiro Sakai, Ryo Goto, Masayoshi Ko, Yusuke Niwa, Shuji Terai

    World Journal of Gastroenterology   24 ( 15 )   1616 - 1621   2018年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   出版者・発行元:Baishideng Publishing Group Co., Limited  

    To date, various signal transducers, cytokines, growth factors, and hormones have been reported to play an important role in homeostasis of various organs. Various cells and organs are involved in the hepatic regeneration process, which proceeds as a result of the coordination of many factors. While these factors are well known to be involved in the liver regeneration after the liver injury, however, as the details of such mechanisms have not been sufficiently elucidated, the practical applicability of hepatic regeneration based on the action of these and cytokines growth factors is still unclear. In terms of the involvement of the autonomic nervous system in hepatic regeneration, cell proliferation resulting from direct signal transduction to the liver has also been reported and recent studies focusing on the inter-organ communication via neural network opened a novel aspect of this field for therapeutic applicability. Therefore, the appropriate understanding of the relationship between autonomic neural network and liver regeneration through various organs including brain, afferent nerve, efferent nerve, etc . is essential. This mini-review explains the principle of neural system involved in the inter-organ communication and its contribution on the liver regeneration upon the liver injury reviewing recent progress in this field.

    DOI: 10.3748/wjg.v24.i15.1616

    Scopus

    PubMed

    researchmap

  • A case of Behçet's disease with various gastrointestinal findings. 査読

    Tominaga K, Kamimura K, Takahashi K, Yokoyama J, Terai S

    Clinical journal of gastroenterology   11 ( 5 )   1 - 5   2018年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12328-018-0860-6

    Scopus

    PubMed

    researchmap

  • Bleeding from a Small-Intestinal Ulcer Associated with Chronic Hepatitis C. 査読 国際誌

    Hiroteru Kamimura, Satoshi Yamagiwa, Iwasaki Tomohiro, Wataru Higuchi, Norio Ogata, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Hirokazu Kawai, Shuji Terai

    The American journal of case reports   19   234 - 237   2018年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND Hepatitis C virus infection is probably the most common chronic viral infection and affects an estimated 180 million people worldwide. Extrahepatic manifestations are well recognized among patients with chronic HCV infection. CASE REPORT We report a case of melena occurring in a 69-year-old Japanese man who had been diagnosed with CHC and who was treated with antiviral therapy. CONCLUSIONS Finally, he was diagnosed with multiple small intestine ulcers in a short time. We herein report the case of HCV with rapidly developing small intestine ulcers.

    PubMed

    researchmap

  • Effect of a neural relay on liver regeneration in mice: activation of serotonin release from the gastrointestinal tract 査読

    Ryosuke Inoue, Kenya Kamimura, Takuro Nagoya, Norihiro Sakai, Takeshi Yokoo, Ryo Goto, Kohei Ogawa, Yoko Shinagawa-Kobayashi, Yukari Watanabe-Mori, Akira Sakamaki, Satoshi Abe, Hiroteru Kamimura, Norio Miyamura, Hiroshi Nishina, Shuji Terai

    FEBS Open Bio   8 ( 3 )   449 - 460   2018年3月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley Blackwell  

    The development of therapeutic options to promote hepatic regeneration following severe liver injury is essential. While humoral factors have been reported as mechanisms of liver regeneration, the contributions of interorgan communication to liver regeneration have not been reported. In this study, we examined the effect of a neural relay on liver regeneration via activation of serotonin release from the gastrointestinal (GI) tract. Our results demonstrated that the afferent visceral nerve from the liver activates the efferent vagus nerve from the brain, leading to activation of serotonin release from the GI tract and contributing to liver regeneration. While it is difficult to apply these results directly to human health, we believe that this study may represent a step toward developing essential therapeutics to promote liver regeneration.

    DOI: 10.1002/2211-5463.12382

    Scopus

    PubMed

    researchmap

  • Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model 査読

    Yoko Shinagawa-Kobayashi, Kenya Kamimura, Ryo Goto, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Norihiro Sakai, Takuro Nagoya, Akira Sakamaki, Satoshi Abe, Soichi Sugitani, Masahiko Yanagi, Koichi Fujisawa, Yoshizu Nozawa, Naoto Koyama, Hiroshi Nishina, Makoto Furutani-Seiki, Isao Sakaida, Shuji Terai

    Biochemical and Biophysical Research Communications   496 ( 2 )   556 - 561   2018年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier B.V.  

    Background Sorafenib (SFN) is an anti-angiogenic chemotherapeutic that prolongs survival of patients with hepatocellular carcinoma (HCC)
    its side effects, including vascular damages such as hand-foot syndrome (HFS), are a major cause of therapy discontinuation. We previously reported that maintenance of peripheral blood flow by intake of dried bonito broth (DBB) significantly prevented HFS and prolonged the administration period. The amino acids contained in DBB probably contribute to its effects, but the mechanism has not been clarified. We hypothesized that histidine, the largest component among the amino acids contained in DBB, has effects on SFN-induced vascular damage, and evaluated this possibility using a novel medaka fish model. Methods The fli::GFP transgenic medaka fish model has a fluorescently visible systemic vasculature. We fed the fish with SFN with and without histidine to compare blood flow and vascular structure among the differently fed models. The vascular cross-sectional area of each fish was measured to determine vascular diameter changes. Results Our results demonstrated that SFN-fed medaka developed a narrower vascular diameter. In addition, this narrowing was counteracted by addition of histidine to the medaka diet. We observed no positive effect of histidine on regeneration of cut vessels or on cell growth of endothelial cells and HCC cell lines. Conclusion We proved the efficacy of the medaka model to assess vascular changes after administration of specific chemicals. And our results suggest that SFN causes vascular damage by narrowing peripheral vessel diameter, and that histidine effectively counteracts these changes to maintain blood flow.

    DOI: 10.1016/j.bbrc.2018.01.057

    Scopus

    PubMed

    researchmap

  • The factors influencing long-term outcomes of stenting for malignant colorectal obstruction in elderly group in community medicine 査読

    Michitaka Imai, Kenya Kamimura, Yoshifumi Takahashi, Toshihiro Sato, Osamu Isokawa, Masaki Maruyama, Takamasa Kobayashi, Kazunao Hayashi, Shuji Terai

    International Journal of Colorectal Disease   33 ( 2 )   189 - 197   2018年2月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Verlag  

    Purpose: Malignant bowel obstruction is a complication of colorectal carcinoma or metastasis from other carcinoma, and it causes significant damage on the condition of elderly patients
    however, the self-expandable metallic stents (SEMSs) have been effectively used either for palliation or for bridging to the surgical procedure for this condition. The aim of this study was to investigate the factors influencing long-term outcomes of old-aged patients with SEMS for large bowel obstruction to develop the strategy for those patients in the community medicine. Methods: We performed a retrospective review of 42 patients with a median age of 83.0 years (range, 65–99 years), who underwent SEMS placement for malignant colorectal obstruction between 2006 and 2015 in our hospital. Univariate and multivariate logistic regressions were performed on data from the patients to assess the factors affecting 6-month survival without stent dysfunction. Results: The study population comprised 24 females (57.1%) and 18 males (42.9%). Of these, 38 patients (90.5%) received SEMS as palliation, whereas 4 patients (9.5%) underwent subsequent surgery. SEMSs were successfully inserted in 97.6% of patients. The median duration of follow-up was 205.0 days (range, 20–1377 days). On multivariate analysis, shorter stents (&lt
    10 cm) yielded better outcomes than longer stents (≥ 10 cm) (P = 0.041), and the Cox proportional hazard model also indicated that shorter stents (P = 0.036) predicted longer event-free survival. Conclusions: Elderly patients with malignant bowel obstruction receiving shorter stents had longer event-free survival after stenting with better general condition.

    DOI: 10.1007/s00384-017-2946-x

    Scopus

    PubMed

    researchmap

  • 臨床応用可能な肝臓選択的核酸医薬送達法の確立 招待 査読

    上村顕也, 横尾健, 寺井崇二

    BIO Clinica   33 ( 1 )   34 - 38   2018年1月

     詳細を見る

  • Effective prevention of sorafenib-induced hand-foot syndrome by dried-bonito broth. 査読 国際誌

    Kenya Kamimura, Yoko Shinagawa-Kobayashi, Ryo Goto, Kohei Ogawa, Takeshi Yokoo, Akira Sakamaki, Satoshi Abe, Hiroteru Kamimura, Takeshi Suda, Hiroshi Baba, Takayuki Tanaka, Yoshizu Nozawa, Naoto Koyama, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Yutaka Aoyagi, Shuji Terai

    Cancer management and research   10   805 - 813   2018年

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Sorafenib (SOR) is a molecular medicine that prolongs the survival of patients with hepatocellular carcinoma (HCC). Therefore, the management of side effects is essential for the longer period of continuous medication. Among the various side effects, hand-foot syndrome (HFS) is the most common, occurring in 30%-50% of patients, and often results in discontinuation of the SOR medication. However, its mechanism has not been clarified, and no effective prevention method has been reported for the symptoms. Therefore, this study aimed to analyze its mechanism and to develop an effective prevention regimen for the symptoms. Materials and methods: To assess the mechanism of SOR-induced HFS, the peripheral blood flow in the hand and foot was carefully monitored by Doppler ultrasound, thermography, and laser speckle flowgraphy in the cases treated with SOR and its contribution was assessed. Then, the effect of dried-bonito broth (DBB), which was reported to improve peripheral blood flow, on the prevention of the symptom was examined by monitoring its occurrence and the peripheral blood flow. Results: A total of 25 patients were enrolled in this study. In all, eight patients developed HFS, and all cases showed a significant decrease in the peripheral blood flow. DBB contributed to an increase in the flow (p = 0.009) and significantly decreased occurrence of HFS (p = 0.005) than control. Multivariable analysis showed that the ingestion of DBB is a significant independent contributor to HFS-free survival period (p = 0.035). Conclusion: The mechanism of SOR-induced HFS involves a decrease in the peripheral blood flow, and the ingestion of DBB effectively prevents the development of the syndrome by maintaining the flow.

    DOI: 10.2147/CMAR.S159370

    PubMed

    researchmap

  • Prognostic value of subcutaneous adipose tissue volume in hepatocellular carcinoma treated with transcatheter intra-arterial therapy. 査読 国際誌

    Takamasa Kobayashi, Hirokazu Kawai, Oki Nakano, Satoshi Abe, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    Cancer management and research   10   2231 - 2239   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Prognosis of patients with hepatocellular carcinoma (HCC) who undergo transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization and transcatheter arterial infusion chemotherapy, is affected by many clinical factors including liver function and tumor progression. However, the effect of body composition such as skeletal muscle and visceral and subcutaneous adipose tissues (VAT and SAT, respectively) on the prognosis of these patients remains unclear. We investigated the prognostic value of body composition in HCC patients treated with transcatheter intra-arterial therapies. Patients and methods: This study retrospectively evaluated 100 HCC patients treated with transcatheter intra-arterial therapies between 2005 and 2015. Areas of skeletal muscle, VAT, and SAT were measured on computed tomography images at third lumbar vertebra level and normalized by the height squared to calculate the skeletal muscle index, VAT index, and SAT index (SATI). The visceral to subcutaneous adipose tissue area ratio was also calculated. Overall survival (OS) was compared between high- and low-index groups for each body composition. Furthermore, prognostic significance was assessed by univariate and multivariate analyses using Cox proportional hazards models. Results: Among the body composition indexes, only SATI could significantly differentiate OS (p=0.012). Multivariate analysis showed that SATI (low- vs. high-SATI: HR, 2.065; 95% CI, 1.187-3.593; p=0.010), serum albumin (<3.5 vs. ≥3.5 g/dL; HR, 2.007; 95% CI, 1.037-3.886; p=0.039), serum alpha-fetoprotein (<20 vs. ≥20 ng/mL; HR, 0.311; 95% CI, 0.179-0.540; p<0.001), and Modified Response Evaluation Criteria in Solid Tumors assessment (complete response+partial response+stable disease vs. progressive disease; HR, 0.392; 95% CI, 0.221-0.696; p=0.001) were indicated as independent prognostic factors for OS. Conclusion: High SAT volume is associated with better survival outcomes in HCC patients treated with transcatheter intra-arterial therapies. Elucidation of the mechanisms regulating SAT volume may offer a new therapeutic strategy for these patients.

    DOI: 10.2147/CMAR.S167417

    PubMed

    researchmap

  • 遺伝子治療の現況と新規遺伝子治療法開発に向けた基礎及び臨床研究 招待

    上村 顕也

    新潟県医師会報 学術「綜説」   ( 813号 )   2 - 8   2017年12月

     詳細を見る

  • Efficacy and Safety of Pancreas-Targeted Hydrodynamic Gene Delivery in Rats 査読

    Kohei Ogawa, Kenya Kamimura, Yuji Kobayashi, Hiroyuki Abe, Takeshi Yokoo, Norihiro Sakai, Takuro Nagoya, Akira Sakamaki, Satoshi Abe, Kazunao Hayashi, Satoshi Ikarashi, Junji Kohisa, Masanori Tsuchida, Yutaka Aoyagi, Guisheng Zhang, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY-NUCLEIC ACIDS   9   80 - 88   2017年12月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CELL PRESS  

    Development of an effective, safe, and convenient method for gene delivery to the pancreas is a critical step toward gene therapy for pancreatic diseases. Therefore, we tested the possibility of applying the principle of hydrodynamic gene delivery for successful gene transfer to pancreas using rats as a model. The established procedure involves the insertion of a catheter into the superior mesenteric vein with temporary blood flow occlusion at the portal vein and hydrodynamic injection of DNA solution. We demonstrated that our procedure achieved efficient pancreas-specific gene expression that was 2,000-fold higher than that seen in the pancreas after the systemic hydrodynamic gene delivery. In addition, the level of gene expression achieved in the pancreas by the pancreas-specific gene delivery was comparable to the level in the liver achieved by a liver-specific hydrodynamic gene delivery. The optimal level of reporter gene expression in the pancreas requires an injection volume equivalent to 2.0% body weight with flow rate of 1 mL/s and plasmid DNA concentration at 5 mu g/mL. With the exception of transient expansion of intercellular spaces and elevation of serum amylase levels, which recovered within 3 days, no permanent tissue damage was observed. These results suggest that pancreas-targeted hydrodynamic gene delivery is an effective and safe method for gene delivery to the pancreas and clinically applicable.

    DOI: 10.1016/j.omtn.2017.08.009

    Web of Science

    PubMed

    researchmap

  • Effect of Helicobacter pylori eradication on elder cases: Observational study in community-based medicine 査読

    Masaki Maruyama, Kenya Kamimura, Ayako Hoshiyama, Koki Hoshiyama, Mari Hoshiyama, Yoshihiro Hoshiyama, Shuji Terai

    WORLD JOURNAL OF CLINICAL CASES   5 ( 12 )   412 - 418   2017年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    AIM
    To examine the effect of Helicobacter pylori (H. pylon) eradication therapy on the extra-gastrointestinal factors in elderly patients by a before-after observational study in community medicine.
    METHODS
    Medical records (1 May 2013-31 January 2014) of 130 patients who underwent H. pylori eradication therapy with 2-year after-eradication observation in our institute were reviewed. Data on sex; age; body weight; body mass index (BMI); mean corpuscular volume (MCV); total protein; low-density lipoprotein cholesterol, triglyceride, haemoglobin A1c and haemoglobin levels and gastric hyperplastic polyps (GHPs) at eradication was extracted. Two-year after-eradication change in data was analysed by paired-sample t-test; relationship between GHPs and subclinical iron deficiency anaemia (IDA) improvement was evaluated.
    RESULTS
    The mean patient age (median, interquartile range) at eradication was 69.6 (71.5, 64-77) years. Paired-sample t-tests showed that body weight, BMI and MCV increased by 0.52 kg (P = 0.018), 0.25 kg/m(2) (P = 0.006) and 0.83 fL (P &lt; 0.001), respectively. The nonparametric Mann Whitney test showed no significant difference in the change rate of MCV after eradication between the groups with and without GHPs (P = 0.892).
    CONCLUSION
    H. pylori eradication therapy prevented weight loss and subclinical IDA in elderly individuals. GHPs were not associated with subclinical IDA.

    DOI: 10.12998/wjcc.v5.i12.412

    Web of Science

    PubMed

    researchmap

  • Endoscopic ultrasound-guided fine-needle aspiration for diagnosing a rare extraluminal duodenal gastrointestinal tumor. 査読 国際誌

    Hayashi K, Kamimura K, Hosaka K, Ikarashi S, Kohisa J, Takahashi K, Tominaga K, Mizuno K, Hashimoto S, Yokoyama J, Yamagiwa S, Takizawa K, Wakai T, Umezu H, Terai S

    World journal of gastrointestinal endoscopy   9 ( 12 )   583 - 589   2017年12月

     詳細を見る

    担当区分:責任著者   記述言語:英語  

    DOI: 10.4253/wjge.v9.i12.583

    PubMed

    researchmap

  • 臓器間ネットワークからみた肝胆膵の恒常性とその破綻 臓器間ネットワークの破綻による疾患 自律神経線維が肝再生に与えるインパクト

    上村顕也, 井上良介, 名古屋拓郎, 酒井規裕, 寺井崇二

    肝胆膵   75 ( 5 )   967‐972   2017年11月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 【臓器間ネットワークからみた肝胆膵の恒常性とその破綻】 臓器間ネットワークの破綻による疾患 自律神経線維が肝再生に与えるインパクト

    上村 顕也, 井上 良介, 名古屋 拓郎, 酒井 規裕, 寺井 崇二

    肝・胆・膵   75 ( 5 )   967 - 972   2017年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • Intraductal Papillary Neoplasm of the Bile Duct: A Rare Liver Tumor Complicated by Malignancy 査読

    Kentaro Tominaga, Kenya Kamimura, Akira Sakamaki, Shuji Terai

    HEPATOLOGY   66 ( 5 )   1695 - 1697   2017年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:WILEY  

    DOI: 10.1002/hep.29266

    Web of Science

    PubMed

    researchmap

  • A Case of Hepatorenal Syndrome and Abdominal Compartment Syndrome with High Renal Congestion. 査読 国際誌

    Hiroteru Kamimura, Takayuki Watanabe, Tomoyuki Sugano, Nao Nakajima, Junji Yokoyama, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Takashi Kato, Gen Watanabe, Satoshi Yamagiwa, Shuji Terai

    The American journal of case reports   18   1000 - 1004   2017年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND Hepatorenal syndrome (HRS) is a reversible renal impairment that occurs in patients with acute liver failure and advanced liver cirrhosis. HRS is due to a renal vasoconstriction that results from extreme vasodilatation. It is therefore a functional disorder, not associated with structural kidney damage. On the other hand, end-stage liver diseases are often complicated by massive ascites. Massive ascites may cause abdominal compartment syndrome (ACS), which includes impairment of renal blood flow, but there are no reports indicating that kidney lesions caused by ACS may pathologically contribute to end-stage liver diseases. CASE REPORT A 40-year-old man with acute liver failure was admitted to our hospital. He was diagnosed with type 1 HRS and showed ACS at the same time. He died 30 days after admission. There were signs of congestion in the kidneys upon dissection and advanced erythroid fullness in the renal tubules. CONCLUSIONS We report an autopsy case with HRS and ACS diagnosed with a clinical and histopathological consideration of liver and kidney. Further clinical studies are needed to improve management of renal failure in patients with acute liver failure and advanced liver cirrhosis.

    PubMed

    researchmap

  • Trousseau症候群を合併した胆管細胞癌の2例

    品川 陽子, 上村 顕也, 酒井 規裕, 熊木 大輔, 小川 光平, 安住 里英, 冨永 顕太郎, 坂牧 僚, 五十嵐 聡, 林 和直, 山本 幹, 水野 研一, 山際 訓, 寺井 崇二

    肝臓   58 ( 9 )   528 - 535   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    Trousseau症候群は、Trousseauによって1865年に報告された、悪性腫瘍に合併する血栓症である。その脳卒中症状は、重篤な神経症状を呈し、直接的に生命予後に関与しうる傍悪性腫瘍症候群の一つとして認識されている。今回、胆管細胞癌に脳卒中症状を呈するTrousseau症候群を合併し死亡した2例を経験したので報告する。症例1は90歳、男性、症例2は58歳、女性でいずれの症例も生活習慣病の危険因子を有し、40mm前後の肝腫瘍で初診、各種画像検査、胆汁細胞診、組織診にて胆管細胞癌の診断となった。経過中、腫瘍の急激な増大、胆道出血を合併し、本症候群を発症しやすい状況であった。担癌患者では、病態が急速に進行する場合、凝固線溶系の異常値などに留意し、抗凝固療法の開始を含む対応が本症候群の発症を予防し、原病に対する治療介入の機会を増やしうる方法論であると考え、報告する。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2017&ichushi_jid=J00263&link_issn=&doc_id=20171003140007&doc_link_id=130006106557&url=http%3A%2F%2Fci.nii.ac.jp%2Fnaid%2F130006106557&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  • A Huge Abdominal Tumor Abdominal Abscess 査読

    Norihiro Sakai, Kenya Kamimura, Shuji Terai

    GASTROENTEROLOGY   153 ( 3 )   E5 - E6   2017年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:W B SAUNDERS CO-ELSEVIER INC  

    DOI: 10.1053/j.gastro.2017.01.037

    Web of Science

    PubMed

    researchmap

  • Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient 査読

    Akira Sakamaki, Takayuki Watanabe, Satoshi Abe, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    Clinical Journal of Gastroenterology   10 ( 3 )   261 - 264   2017年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Tokyo  

    A 56-year-old Japanese man with liver cirrhosis (LC) due to hepatitis C virus was admitted to our hospital for radiofrequency ablation of residual tumor following lusutrombopag administration. Laboratory tests revealed thrombocytopenia and leukopenia. The patient’s LC was managed, and he was classified as Child–Pugh A. After admission, lusutrombopag was administered for 7 days. The platelet count increased to over 50,000/mm3 after 7–14 days and returned to previous levels 50 days after administration. Leukocyte and erythrocyte counts also increased in response to the treatment and stayed elevated for over 120 days. Lusutrombopag acts selectively on human thrombopoietin (TPO) receptors and activates signaling pathways that promote the proliferation and differentiation of bone marrow progenitor cells into megakaryocytes, consequently increasing the blood platelet count. However, the patient treated with lusutrombopag in our case study showed increased blood leukocyte and erythrocyte counts as well. Given that TPO receptors are reportedly expressed in not only megakaryocyte progenitor cells but also hematopoietic progenitors, lusutrombopag may potentially improve pancytopenia caused by LC and can be used for the recovery of blood counts before other treatments.

    DOI: 10.1007/s12328-017-0735-2

    Scopus

    PubMed

    researchmap

  • Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: Patient-reported outcome based analyses 査読

    Kenya Kamimura, Takeshi Yokoo, Hiroteru Kamimura, Akira Sakamaki, Satoshi Abe, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    PLOS ONE   12 ( 6 )   e0178991   2017年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Background and aim
    Among various symptoms accompanied with chronic liver disease, pruritus affects the quality of life of patients, causing physical and mental stress, and worsens hepatic function. Recently, kappa-opioid receptor agonist, nalfurafine hydrochloride was approved to treat central pruritus in patients with liver disease in Japan. This study aimed to assess the long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients.
    Methods
    A patient-reported outcome using questionnaire-based methods was used for 41 liver disease patients with or without pruritus symptoms. Nalfurafine hydrochloride (2.5 mu g/day) was orally administered to 18 patients suffering from pruritus symptoms and whose current treatment was not effective. The same questionnaires and visual analogue scales (VAS) were repeatedly followed up for the patients for the entire follow-up period, and biochemical analyses were performed to evaluate the safety of the treatment.
    Results
    Pruritus completely disappeared in seven of 18 cases, and VAS scores showed a decreasing trend over time from the start of nalfurafine hydrochloride administration in all patients who received the medication. Among 11 patients who were followed up for more than 12 weeks, nine patients showed continuous improvement of symptoms, and this progress was still apparent at &gt;= 20 weeks after starting administration (p &lt; 0.0001). The medication was discontinued in four patients because of progression of primary disease, high cost, oral dryness, and anemia. No significant toxicity was observed on the serum biochemical analyses.
    Conclusions
    Nalfurafine hydrochloride contributed to long-term suppression of pruritus without significant safety problems.

    DOI: 10.1371/journal.pone.0178991

    Web of Science

    PubMed

    researchmap

  • Spontaneous regression of hepatocellular carcinoma: A mini-review 査読

    Akira Sakamaki, Kenya Kamimura, Satoshi Abe, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    WORLD JOURNAL OF GASTROENTEROLOGY   23 ( 21 )   3797 - 3804   2017年6月

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    Spontaneous tumor regression is an extremely rare phenomenon in the oncology field. However, there are several case reports resulted in the regression of hepatocellular carcinoma (HCC) and the accumulation of clinical information and analyses of the mechanism can contribute to the development of a novel therapy. For this purpose, we have carefully reviewed 23 cases of spontaneously regressed HCC published in recent 5 years and our case. The information regarding the tumor size, tumor marker, treatments, etc., have been summarized. The mechanism of spontaneous regression has been discussed to date and presumed to be due to many factors, including hypoxia and immunological reactions. In this careful review of the 24 cases based on the clinical information, hypoxia, systemic inflammation, and both upon spontaneous regression were seen in 3, 8, and 4 cases, respectively among the 15 cases for which the information regarding the proposed mechanisms are available. Recent development of immunotherapeutic approaches in oncology shows promising results, therefore, accumulation of additional cases and analysis of mechanisms underlying the spontaneous regression of HCC are essential and could lead to the development of a new generation of immunotherapies including antibodies directed against immune reactions.

    DOI: 10.3748/wjg.v23.i21.3797

    Web of Science

    PubMed

    researchmap

  • Effect of double platinum agents, combination of miriplatintransarterial oily chemoembolization and cisplatinhepatic arterial infusion chemotherapy, in patients with hepatocellular carcinoma: Report of two cases 査読

    Kohei Ogawa, Kenya Kamimura, Yukari Watanabe, Yosuke Motai, Daisuke Kumaki, Ryoya Seki, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Takeshi Suda, Satoshi Yamagiwa, Shuji Terai

    WORLD JOURNAL OF CLINICAL CASES   5 ( 6 )   238 - 246   2017年6月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    Hepatocellular carcinoma (HCC) is one of the most common cancers and the third highest cause of cancerassociated mortality worldwide. The treatment of HCC is complicated by its variable biological behavior and the frequent coexistence of chronic liver disease, particularly cirrhosis. To date, multiple treatment modalities have been developed according to the stage of the tumor and the hepatic functional reserve, including transarterial treatments such as transarterial chemoembolization, transarterial oily chemoembolization (TOCE), and hepatic arterial infusion chemotherapy (HAIC). We conducted a phase I and II study of the combination therapy with double platinum agents, miriplatin and cisplatin, and confirmed its safety and efficacy. Here, we describe two cases of unresectable HCC who were successfully treated by miriplatin-TOCE/cisplatin-HAIC combination therapy, resulting in complete responses with no significant adverse events. This report will provide that the combination therapy can be the therapeutic option for HCC patients in the advanced stage.

    DOI: 10.12998/wjcc.v5.i6.238

    Web of Science

    PubMed

    researchmap

  • Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial 査読

    Kenya Kamimura, Takeshi Suda, Takeshi Yokoo, Hiroteru Kamimura, Tsutomu Kanefuji, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Satoshi Yamagiwa, Shuji Terai

    BMC CANCER   17 ( 1 )   322   2017年5月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Based on promising results from a Phase I study of hepatic arterial infusion chemotherapy using a combination of miriplatin and cisplatin powder (DDP-H) for unresectable hepatocellular carcinoma (UMIN-CTR000003541), a multicenter, open-label, randomized phase II study was conducted to evaluate the efficacy and safety of the combination therapy versus miriplatin monotherapy.
    Methods: Nineteen patients, five and fourteen Barcelona-Clinic Liver Cancer staging classification A and B cases, respectively, were randomly assigned to receive either miriplatin monotherapy (n = 9) or miriplatin/DDP-H combination therapy (n = 10). DDP-H and/or miriplatin were administered through the hepatic arteries supplying the lobes of the liver containing tumors, and progression free survival was analyzed as a primary end point in addition to other secondary endpoints. The corresponding therapy was repeated unless disease progression or severe adverse events were recorded.
    Results: The monotherapy or combination therapy was performed for 15 or 36 sessions in total, respectively. Although there were no significant differences between the two groups for treatment intervals (p = 0.96) or the dose of miriplatin used in each session (p = 0.99), the progression free survival and overall disease control rate were significantly better in the combination therapy group (91 vs 423 days, p = 0.025; 40.0 vs 77.8%, p = 0.0025, respectively). Consistent with these observations, a trend of a significantly slower increase in des-gamma-carboxyprothrombin was observed, and the number of treatment sessions was nearly significantly larger in the combination therapy group (p &lt; 0.0001, p = 0.057, respectively). Conversely, the median survival time did not show a significant difference (706 days, monotherapy vs 733 days, combination therapy; p = 0.40). A significant decrease in cholinesterase was observed during the course of treatment only in patients receiving combination therapy (r = -0.86, p &lt; 0.0001). A few cases in both arms showed hematological and/or non-hematological toxicities that were categorized as grade 1 (NCI-CTCAE).
    Conclusions: The higher disease control effects with the combination of miriplatin and DDP-H indicate that it is a promising alternative treatment for cases with multiple HCCs, especially for those that can tolerate the treatment without experiencing a reduction in hepatic reserve.

    DOI: 10.1186/s12885-017-3320-7

    Web of Science

    PubMed

    researchmap

  • BCL11B gene heterozygosity causes weight loss accompanied by increased energy consumption, but not defective adipogenesis, in mice 査読

    Jun Inoue, Yusuke Ihara, Daisuke Tsukamoto, Keisuke Yasumoto, Tsutomu Hashidume, Kenya Kamimura, Shigeki Hirano, Makoto Shimizu, Ryo Kominami, Ryuichiro Sato

    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY   81 ( 5 )   922 - 930   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:TAYLOR & FRANCIS LTD  

    BCL11B is a zinc finger-type transcription factor that regulates the development of the white adipose tissue (WAT), skin, central nervous system, and immune system. BCL11B is required for proper adipocyte differentiation, and BCL11B-/- embryos at E19.5 have very low amounts of the subcutaneous WAT. Here, we demonstrated that BCL11B+/- mice have lower body weight than BCL11B+/+ mice, whereas the expression of adipogenic marker genes in the WAT was comparable between BCL11B+/+ and BCL11B+/- mice. Histological analysis indicated that BCL11B+/- mice fed a high-fat diet have much smaller white adipocytes and lipid droplets in the WAT and liver, respectively. In addition, BCL11B+/- mice had increased energy consumption under both standard and high-fat diets. Thus, this study identifies BCL11B as a regulator of energy metabolism, and it is unlikely that BCL11B functions in the WAT contribute to energy metabolism in BCL11B+/- mice.

    DOI: 10.1080/09168451.2016.1274642

    Web of Science

    PubMed

    researchmap

  • Drug-eluting beads in hepatocellular carcinoma 査読

    Hiroyuki Abe, Kenya Kamimura, Shuji Terai

    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY   10 ( 3 )   337 - 338   2017年3月

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:SAGE PUBLICATIONS LTD  

    DOI: 10.1177/1756283X16681710

    Web of Science

    PubMed

    researchmap

  • Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C 査読

    Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Shuji Terai

    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES   14 ( 5 )   403 - 411   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:IVYSPRING INT PUBL  

    Objectives: To determine whether the soluble programmed cell death ligand 1 (sPD-L1) levels inpatients with chronic hepatitis C (CHC) are associated with the clinical features of the disease and the efficacy of treatment, including interferon (IFN)-alpha.
    Methods: We investigated the sPD-L1 levels in the sera of 80 genotype 1b Japanese patients with CHC who underwent 12 weeks of telaprevir (TVR)-or simeprevir (SMV)-based triple therapy followed by 12 weeks of dual therapy with pegylated IFN-alpha plus ribavirin. Serum was also obtained from 22 patients with chronic hepatitis B (CHB) and from 10 healthy donors (HC). The sPD-L1 levels were measured using an ELISA kit. In addition, we examined the PD-L1 expression on the cell surface of immortalized hepatocytes (HPT1) after incubation with cytokines, including IFN-gamma.
    Results: The pretreatment serum sPD-L1 levels were significantly increased in patients with CHC (median 109.3 pg/ml, range 23.1-402.3) compared with patients with CHB (69.2 pg/ml, 15.5-144.8; P &lt; 0.001) and HC (100.3 pg/ml, 40.1-166.6; P = 0.039). No significant differences in the sustained virological response (SVR) rates were found between the TVR-(85.0%, n=40) and SMV-treated (80.0%, n=40) groups, and the pretreatment levels of serum sPD-L1 were not significantly different between patients who achieved SVR (105.0 pg/ml, 23.1-402.3) and non-SVR patients (133.5 pg/ml, 39.9-187.2; P = 0.391). The pretreatment level of sPD-L1 was positively correlated with the alanine aminotransferase and alpha-fetoprotein levels (R-2 = 0.082, P = 0.016, and R-2 = 0.149, P = 0.002, respectively). Although immortalized hepatocytes do not express PD-L1, we confirmed that PD-L1 expression was induced after stimulation with IFN-gamma.
    Conclusions: In this study, we first found that sPD-L1 was increased in patients with CHC. Our results indicate that the level of serum sPD-L1 might be associated with the progression of CHC and the generation of hepatocellular carcinoma.

    DOI: 10.7150/ijms.18784

    Web of Science

    PubMed

    researchmap

  • Tumor markers for early diagnosis for brain metastasis of hepatocellular carcinoma: A case series and literature review for effective loco-regional treatment 査読

    Kenya Kamimura, Yuji Kobayashi, Yoshifumi Takahashi, Hiroyuki Abe, Daisuke Kumaki, Takeshi Yokoo, Hiroteru Kamimura, Norihiro Sakai, Akira Sakamaki, Satoshi Abe, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    CANCER BIOLOGY & THERAPY   18 ( 2 )   79 - 84   2017年

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:TAYLOR & FRANCIS INC  

    Intrahepatic lesions of hepatocellular carcinoma (HCC) have been controlled by significant advances in treatment using loco-regional therapies, including, surgery, ablative therapy, catheter-based chemotherapy, and embolization. Consequently, the number of patients with extrahepatic metastatic lesions has increased. Their prognosis remains poor with approximately &lt;1y of survival from the time of diagnosis. A molecularly targeted drug, sorafenib, have been used to treat extrahepatic lesions and shown the prolonged survival time. However, the therapeutic benefit for the brain metastasis remains unclear, since it causes intratumor bleeding leading to the severe brain damage. No guidelines for the brain metastasis of HCC have been developed to date due to the shortage of the experiences and evidences. Therefore, the development of standard therapy for brain metastasis following the early diagnosis is essential by accumulating the information of clinical courses and evidences. For this purpose, we reviewed cases of HCC brain metastasis reported to date and analyzed additional 8 cases from our hospital, reviewing 592 advanced HCC cases to estimate the possible metastatic lesions in the brain. With careful review of cases and literature, we suggest that the cases with lung metastasis with increase tendency of tumor markers within recent 3-6months have higher risks of brain metastasis. Therefore, they should be carefully followed by imaging modalities. In addition, the loco-regional treatment, including surgical resection and radiation therapy should be performed for better prognosis by preventing re-bleeding from the tumors.

    DOI: 10.1080/15384047.2016.1276134

    Web of Science

    PubMed

    researchmap

  • Two cases of cholangiocellular carcinoma complicated with Trousseau’s syndrome

    Yoko Shinagawa, Kenya Kamimura, Norihiro Sakai, Daisuke Kumaki, Kohei Ogawa, Rie Azumi, Kentaro Tominaga, Akira Sakamaki, Satoshi Ikarashi, Kazunao Hayashi, Takashi Yamamoto, Kenichi Mizuno, Satoshi Yamagiwa, Shuji Terai

    Acta Hepatologica Japonica   58 ( 9 )   528 - 535   2017年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japan Society of Hepatology  

    Trousseau’s syndrome has been reported in 1965 by Armand Trousseau and known as systemic thrombosis complicated with the malignancy. We have experienced two cases of cholangiocellular carcinoma complicated with the Trousseau’s syndrome. The cases were 90 years-old male and 58 years-old female with approximately 40 mm-sized liver tumor diagnosed with cholangiocellular carcinoma by various imaging modalities and histological analysis. The tumors progressed significantly in short period and both cases showed Trousseau’s syndrome which resulted in patients’ death. The patients with malignancy which showed significant progression must be followed up for the thrombosis and if necessary, anti-coagulant therapy should be considered.

    DOI: 10.2957/kanzo.58.528

    Scopus

    researchmap

  • Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease. 査読

    Wakamatsu T, Yamamoto S, Kamimura K, Nakatsue T, Iino N, Iguchi S, Kaneko Y, Goto S, Kazama JJ, Narita I

    CEN case reports   5 ( 2 )   125 - 130   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s13730-015-0209-7

    Web of Science

    PubMed

    researchmap

  • Case of severe alcoholic hepatitis treated with granulocytapheresis 査読

    Yukari Watanabe, Kenya Kamimura, Tomohiro Iwasaki, Hiroyuki Abe, Shunsaku Takahashi, Ken-ichi Mizuno, Manabu Takeuchi, Atsushi Eino, Ichiei Narita, Shuji Terai

    WORLD JOURNAL OF CLINICAL CASES   4 ( 11 )   369 - 374   2016年11月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    Severe alcoholic hepatitis (AH) has a high mortality, and it is associated with encephalopathy, acute renal failure, sepsis, gastrointestinal bleeding, and endotoxemia. The 28-d mortality remains poor (34%-40%), because no effective treatment has been established. Recently, corticosteroids (CS) have been considered effective for significantly improving the prognosis of those with AH, as it prevents the production of pro-inflammatory cytokines. However, CS are not always appropriate as an initial therapeutic option, such as in cases with an infection or resistance to CS. We describe a patient with severe AH complicated by a severe infection caused by the multidrug resistance bacteria (Pseudomonas aeruginosa), and was successfully treated with granulocytapheresis monotherapy without using CS. The experience of this case will provide understanding of the disease and information treating cases without using CS.

    DOI: 10.12998/wjcc.v4.i11.369

    Web of Science

    PubMed

    researchmap

  • Liver-targeted hydrodynamic gene therapy: Recent advances in the technique 査読

    Takeshi Yokoo, Kenya Kamimura, Hiroyuki Abe, Yuji Kobayashi, Tsutomu Kanefuji, Kohei Ogawa, Ryo Goto, Masafumi Oda, Takeshi Suda, Shuji Terai, Masafumi Oda

    WORLD JOURNAL OF GASTROENTEROLOGY   22 ( 40 )   8862 - 8868   2016年10月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    One of the major research focuses in the field of gene therapy is the development of clinically applicable, safe, and effective gene-delivery methods. Since the first case of human gene therapy was performed in 1990, a number of gene-delivery methods have been developed, evaluated for efficacy and safety, and modified for human application. To date, viral-vector-mediated deliveries have shown effective therapeutic results. However, the risk of lethal immune response and carcinogenesis have been reported, and it is still controversial to be applied as a standard therapeutic option. On the other hand, delivery methods for non-viral vector systems have been developed, extensively studied, and utilized in in vivo gene-transfer studies. Compared to viral-vector mediated gene transfer, nonviral systems have less risk of biological reactions. However, the lower gene-transfer efficiency was a critical hurdle for applying them to human gene therapy. Among a number of nonviral vector systems, our studies focus on hydrodynamic gene delivery to utilize physical force to deliver naked DNA into the cells in the living animals. This method achieves a high gene-transfer level by DNA solution injections into the tail vein of rodents, especially in the liver. With the development of genome editing methods, in vivo gene-transfer therapy using this method is currently the focus in this research field. This review explains the method principle, efficiency, safety, and procedural modifications to achieve a high level of reproducibility in large-animal models.

    DOI: 10.3748/wjg.v22.i40.8862

    Web of Science

    PubMed

    researchmap

  • Identification of BCL11B as a regulator of adipogenesis 査読

    Jun Inoue, Yusuke Ihara, Daisuke Tsukamoto, Keisuke Yasumoto, Tsutomu Hashidume, Kenya Kamimura, Yuji Nakai, Shigeki Hirano, Makoto Shimizu, Ryo Kominami, Ryuichiro Sato

    SCIENTIFIC REPORTS   6   32750   2016年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    The differentiation of preadipocytes into adipocytes is controlled by several transcription factors, including peroxisome proliferator-activated receptor gamma(PPAR gamma) and CCAAT/enhancer-binding protein alpha(C/EBP alpha), which are known as master regulators of adipogenesis. BCL11B is a zinc finger-type transcription factor that regulates the development of the skin and central nervous and immune systems. Here, we found that BCL11B was expressed in the white adipose tissue (WAT), particularly the subcutaneous WAT and that BCL11B(-/)-mice had a reduced amount of subcutaneous WAT. During adipogenesis, BCL11B expression transiently increased in 3T3-L1 preadipocytes and mouse embryonic fibroblasts (MEFs). The ability for adipogenesis was reduced in BCL11B knockdown 3T3-L1 cells and BCL11B(-/)-MEFs, whereas the ability for osteoblastogenesis was unaffected in BCL11B(-/)-MEFs. Luciferase reporter gene assays revealed that BCL11B stimulated C/EBP beta activity. Furthermore, the expression of downstream genes of the Wnt/beta-catenin signaling pathway was not suppressed in BCL11B(-/)-MEFs during adipogenesis. Thus, this study identifies BCL11B as a novel regulator of adipogenesis, which works, at least in part, by stimulating C/EBP beta activity and suppressing the Wnt/beta-catenin signaling pathway.

    DOI: 10.1038/srep32750

    Web of Science

    PubMed

    researchmap

  • Effects of Fibrotic Tissue on Liver-targeted Hydrodynamic Gene Delivery 査読

    Yuji Kobayashi, Kenya Kamimura, Hiroyuki Abe, Takeshi Yokoo, Kohei Ogawa, Yoko Shinagawa-Kobayashi, Ryo Goto, Ryosuke Inoue, Masato Ohtsuka, Hiromi Miura, Tsutomu Kanefuji, Takeshi Suda, Masanori Tsuchida, Yutaka Aoyagi, Guisheng Zhang, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY-NUCLEIC ACIDS   5 ( 8 )   e359   2016年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CELL PRESS  

    Hydrodynamic gene delivery is a common method for gene transfer to the liver of small animals, and its clinical applicability in large animals has been demonstrated. Previous studies focused on functional analyses of therapeutic genes in animals with normal livers and little, however, is known regarding its effectiveness and safety in animals with liver fibrosis. Therefore, this study aimed to examine the effects of liver fibrosis on hydrodynamic gene delivery efficiency using a rat liver fibrosis model. We demonstrated for the first time, using pCMV-Luc plasmid, that this procedure is safe and that the amount of fibrotic tissue in the liver decreases gene delivery efficiency, resulting in decrease in luciferase activity depending on the volume of fibrotic tissue in the liver and the number of hepatocytes that are immunohistochemically stained positive for transgene product. We further demonstrate that antifibrotic gene therapy with matrix metalloproteinase-13 gene reduces liver fibrosis and improves efficiency of hydrodynamic gene delivery. These results demonstrate the negative effects of fibrotic tissue on hydrodynamic gene delivery and its recovery by appropriate antifibrotic therapy.

    DOI: 10.1038/mtna.2016.63

    Web of Science

    PubMed

    researchmap

  • Natural regression of fibrosis in chronic hepatitis B 査読

    Shogo Ohkoshi, Haruka Hirono, Kazuhiko Watanabe, Katsuhiko Hasegawa, Kenya Kamimura, Masahiko Yano

    WORLD JOURNAL OF GASTROENTEROLOGY   22 ( 24 )   5459 - 5466   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    The fibrosis of liver cirrhosis was considered to be irreversible before the anti-viral drugs showed that it is reversible when they lead to continuous suppression of viral replication and inflammation. However, several reports previously showed that fibrosis of type B liver cirrhosis was almost completely absorbed after the natural remission of chronic inflammation. This phenomenon might not be limited to exceptional patients, but rather occur commonly, considering the dynamic clinical features of chronic hepatitis B (CHB), where inactive carrier stage normally follows aggravation of hepatitis and progression of fibrosis at the time of HBeAg seroconversion. Thus, fibrosis levels of CHB as a hepatocellular carcinoma (HCC)-surveillance marker, particularly those of the inactive stage, could be underestimated, because some of them might have been (pre) cirrhotic in the past and recovered with the natural regression of fibrosis. We argue that cirrhosis-induced HCC mechanisms, rather than direct action of viral genome, may be more common than generally considered in CHB patients. This may have some impact on reconsidering the surveillance rationale for HCC in CHB, from where advanced HCCs tended to be missed. In addition, a molecular marker to assess the cancer-prone characteristics of the liver will definitely be needed to resolve the issue.

    DOI: 10.3748/wjg.v22.i24.5459

    Web of Science

    PubMed

    researchmap

  • Effective prevention of hand-foot syndrome by the consumption of dried bonito broth 査読

    Kenya Kamimura, Yoko Shinagawa, Kohei Ogawa, Yuji Kobayashi, Hiroyuki Abe, Takeshi Yokoo, Hiroteru Kamimura, Hirokazu Kawai, Takeshi Suda, Satoshi Yamagiwa, Hiroshi Baba, Shuji Terai

    Japanese Journal of Cancer and Chemotherapy   43 ( 4 )   463 - 465   2016年4月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Japanese Journal of Cancer and Chemotherapy Publishers Inc.  

    To examine whether the consumption of dried bonito both is effective for the prevention of hand-foot syndrome (HFS), concentrated bonito broth was administered to 10 patients with HCC who were treated with sorafenib. Among the 10 patients, seven showed an increase in peripheral blood flow, as observed on Doppler ultrasonography. Only one patient showed Grade 1 HFS on day 14 after the initiation of sorafenib (10%)
    this incidence rate of HFS was significantly lower than that obtained in our previous studies and reported data. These results suggest that consumption of dried bonito broth contributes to the prevention of HFS by maintaining peripheral blood flow.

    Scopus

    PubMed

    researchmap

  • Image-guided hydrodynamic gene delivery to the liver: Toward clinical applications 招待 査読

    Kenya Kamimura, Takeshi Suda, Tsutomu Kanefuji

    Gene Therapy and Cell Therapy Through the Liver: Current Aspects and Future Prospects   85 - 92   2016年1月

     詳細を見る

    記述言語:英語   掲載種別:論文集(書籍)内論文   出版者・発行元:Springer Japan  

    Various metabolic and monogenic diseases have genetic defects in the liver and are often caused by lack or overproduction of a critical gene product in its cells. Conventional therapeutic methods are often insuffi cient or unavailable to manage genetic diseases in the liver
    therefore, more effi cient strategies are urgently needed. Gene therapy emerged as novel method of treatment relying on liverdirected transfer of a gene-coding sequence to produce the missing gene products or a nucleic acid sequence to inhibit the production of the gene product in excess. Practically, the success of the nucleic acid-based approaches is dependent on the availability of a method capable of delivering the gene or nucleic acid therapeutics to liver cells. Various methods of gene delivery have been developed, including viral methods and nonviral methods comprising synthetic vectors and physical methods. Hydrodynamic gene delivery is among the most effi cient and the most commonly used method for liver-directed gene delivery. Here we will briefl y summarize the principles and the progress that have been made in hydrodynamic gene delivery toward clinical applications.

    DOI: 10.1007/978-4-431-55666-4_8

    Scopus

    researchmap

  • Effective Prevention of Liver Fibrosis by Liver-targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in a Rat Liver Fibrosis Model 査読

    Hiroyuki Abe, Kenya Kamimura, Yuji Kobayashi, Masato Ohtsuka, Hiromi Miura, Riuko Ohashi, Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Masanori Tsuchida, Yutaka Aoyagi, Guisheng Zhang, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY-NUCLEIC ACIDS   5   e276   2016年1月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Liver fibrosis is the final stage of liver diseases that lead to liver failure and cancer. While various diagnostic methods, including the use of serum marker, have been established, no standard therapy has been developed. The objective of this study was to assess the approach of overexpressing matrix metalloproteinase-13 gene (MMP13) in rat liver to prevent liver fibrosis progression. A rat liver fibrosis model was established by ligating the bile duct, followed by liver-targeted hydrodynamic gene delivery of a MMP13 expression vector, containing a CAG promoter-MMP13-IRES-tdTomato-polyA cassette. After 14 days, the serum level of MMP13 peaked at 71.7 pg/ml in MMP13-treated group, whereas the nontreated group only showed a level of similar to 5 pg/ml (P &lt; 0.001). These levels were sustained for the next 60 days. The statistically lower level of the hyaluronic acids in treated group versus the nontreated group (P &lt; 0.05) reveals the therapeutic effect of MMP13 overexpression. Quantitative analysis of tissue stained with sirius red showed a statistically larger volume of fibrotic tissue in the nontreated group compared to that of MMP13-treated rats (P &lt; 0.05). These results suggest that the liver-targeted hydrodynamic delivery of MMP13 gene could be effective in the prevention of liver fibrosis.

    DOI: 10.1038/mtna.2015.49

    Web of Science

    PubMed

    researchmap

  • The Combination Therapy of Dissolution Using Carbonated Liquid and Endoscopic Procedure for Bezoars: Pragmatical and Clinical Review 査読

    Kohei Ogawa, Kenya Kamimura, Ken-ichi Mizuno, Yoko Shinagawa, Yuji Kobayashi, Hiroyuki Abe, Yukari Watanabe, Shunsaku Takahashi, Kazunao Hayashi, Junji Yokoyama, Manabu Takeuchi, Masaaki Kobayashi, Satoshi Yamagiwa, Yuichi Sato, Shuji Terai

    GASTROENTEROLOGY RESEARCH AND PRACTICE   2016   7456242   2016年

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:HINDAWI LTD  

    Bezoars are relatively rare foreign bodies of gastrointestinal tract and often cause ileus and ulcerative lesions in the stomach and subsequent bleeding and perforation due to their size and stiffness. Therefore, the removal of bezoars is essential and recent development of devices, the endoscopic removal procedure, is often applied. However, due to their stiffness, simple endoscopic removal failed in not a few cases, and surgical removal has also been used. Recently, the efficacy of a combination therapy of endoscopic procedure and dissolution using carbonated liquid has been reported. To develop the safe and effective removal procedure, we carefully reviewed a total of 55 reported cases in this study including our 3 additional cases, successfully treated with dissolution with endoscopic fragmentation. In summary, the data showed the efficiency in the combination therapy, treating the larger size of bezoar and reducing the length of hospital stay. To the best of our knowledge, this is the largest pragmatical and clinical review for the combination therapy of dissolution and endoscopic treatment for bezoars. This review should help physicians to manage bezoars more efficiently.

    DOI: 10.1155/2016/7456242

    Web of Science

    PubMed

    researchmap

  • Diagnosis and Management of Gastrointestinal Foreign Bodies 査読

    Kenya Kamimura, David C. Evans, Ken-ichi Mizuno, Juan E. Sola

    GASTROENTEROLOGY RESEARCH AND PRACTICE   2016   5692650   2016年

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   出版者・発行元:HINDAWI PUBLISHING CORP  

    DOI: 10.1155/2016/5692650

    Web of Science

    PubMed

    researchmap

  • Endoscopic Removal of Ingested Dentures and Dental Instruments: A Retrospective Analysis 査読

    Ken-ichi Mizuno, Kazuya Takahashi, Kentaro Tominaga, Yuki Nishigaki, Hiroki Sato, Satoshi Ikarashi, Kazunao Hayashi, Takashi Yamamoto, Yutaka Honda, Satoru Hashimoto, Kenya Kamimura, Manabu Takeuchi, Junji Yokoyama, Yuichi Sato, Masaaki Kobayashi, Shuji Terai

    GASTROENTEROLOGY RESEARCH AND PRACTICE   2016   3537147   2016年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:HINDAWI PUBLISHING CORP  

    Background. Dentures and dental instruments are frequently encountered ingested foreign bodies. The aim of the present study was to assess the safety and efficacy of endoscopically removing ingested dental objects. Methods. Twenty-nine consecutive patients with 29 dental objects who were treated at the Niigata University Medical and Dental Hospital from August 2009 to December 2015 were retrospectively reviewed. Characteristics of the patients and the ingested dental objects, the clinical features and findings of radiological imaging tests, and outcomes of endoscopic removal were analyzed. Results. Patients' mean age was 62.9 + 21.0 years. The ingested dental objects included 23 dentures (13 crowns, 4 bridges, 4 partial dentures, and 2 other dentures) and 6 dental instruments. Twenty-seven upper gastrointestinal endoscopies and 2 colonoscopies were performed, and their success rates were 92.6% and 100%, respectively. There were 2 cases of removal failure; one case involved an impacted partial denture in the cervical esophagus, and this case required surgical removal. Conclusions. Endoscopic removal of ingested dentures and dental instruments is associated with a favorable success rate and acceptable complications. The immediate intervention and appropriate selection of devices are essential for managing ingested dental objects.

    DOI: 10.1155/2016/3537147

    Web of Science

    PubMed

    researchmap

  • First case of bacteremia caused by Helicobacter cinaedi in a patient with liver cirrhosis: a case report and literature review 査読

    Kenya Kamimura, Daisuke Kumaki, Masashi Arita, Yuji Kobayashi, Ken-ichi Mizuno, Fumiko Kusama, Megumi Kobayashi, Hiroyuki Abe, Yoshifumi Takahashi, Kohei Ogawa, Yoko Shinagawa, Manabu Takeuchi, Yuichi Sato, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    Clinical Journal of Gastroenterology   8 ( 5 )   306 - 317   2015年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer-Verlag Tokyo  

    Patients with liver cirrhosis are known to be immunocompromised hosts due to the dysfunction of the cellular and humoral immune systems, allowing easier bacterial translocation from the intestine to the systemic circulation via the portal vein. Sepsis can often be seen in these patients
    however, approximately 10 % of patients show negative results with the standard culture period (3–4 days) and their pathogens remain undiagnosed. Here we report the first case of a patient with liver cirrhosis diagnosed with bacteremia due to Helicobacter cinaedi after gastrointestinal symptoms and review 62 cases of H. cinaedi infection in patients with other diseases. The patient showed positive results for H. cinaedi after 10 days of culture. Administration of a carbapenem was effective and clinical symptoms recovered 20 days after admission. H. cinaedi is an enterohepatic bacterial species that causes bacteremia in immunocompromised patients. Due to the difficulty of detection, few cases have been reported to date and to the best of our knowledge, this is the first published case of bacteremia due to H. cinaedi infection in a patient with liver cirrhosis. Since bacteremia in patients with liver cirrhosis can result in fatality, we recommend vigilance for H. cinaedi infection, longer periods of blood culture, polymerase chain reaction analysis, and empirical antibiotic therapy to help improve prognosis.

    DOI: 10.1007/s12328-015-0600-0

    Scopus

    PubMed

    researchmap

  • Site-specific impact of a regional hydrodynamic injection: Computed tomography study during hydrodynamic injection targeting the swine liver 査読

    Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Kenya Kamimura, Dexi Liu, Shuji Terai

    Pharmaceutics   7 ( 3 )   334 - 343   2015年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:MDPI AG  

    A hemodynamic study of hydrodynamic gene delivery (HGD) from the tail vein in rodents has inspired a mechanism and an approach to further improve the efficacy of this procedure. However, there is no report on the hemodynamics of a regional HGD, which is an inevitable approach in large animals. Here, we report the hemodynamics of a regional hydrodynamic injection in detail based on 3D volume data and the dynamism of tissue intensity over time by using computed tomography (CT) both during and after a regional hydrodynamic injection that targeted the liver of a pig weighing 15.6 kg. Contrast medium (CM) was injected at a steady speed of 20 mL/s for 7.5 s under the temporal balloon occlusion of the hepatic vein (HV). A retrograde flow formed a wedge-shaped strong enhancement area downstream of the corresponding HV within 2.5 s, which was followed by drainage into another HV beginning from the target area and the portal vein (PV) toward a non-target area of the liver. After the injection, the CM was readily eliminated from the PV outside the target area. These data suggest that an interventional radiology approach is effective in limiting the hydrodynamic impacts in large animals at a target area and that the burden overflowing into the PV is limited. A further investigation that simultaneously evaluates gene delivery efficiency and hemodynamics using CT is needed to establish feasible parameters for a regional HGD in large animals.

    DOI: 10.3390/pharmaceutics7030334

    Scopus

    PubMed

    researchmap

  • Diagnostic imaging of hepatic lymphoma 査読

    Hiroyuki Abe, Kenya Kamimura, Hirokazu Kawai, Hiroteru Kamimura, Koji Domori, Yuji Kobayashi, Minoru Nomoto, Yutaka Aoyagi

    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY   39 ( 4 )   435 - 442   2015年9月

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:ELSEVIER MASSON  

    Hepatic lymphoma is a rare disease with poor prognosis because of delayed diagnosis. The disease comprises primary, metastatic, and intravascular hepatic lymphomas. The pathological characteristics of lymphomas differ contributing to difficulty in early diagnosis. Early diagnosis and appropriate treatment result in improved prognosis; therefore, diagnostic radiology and its development with various contrast agents are critical for improving disease outcomes. Herein, we review hepatic lymphomas and summarize the results of imaging studies in correlation with pathological characteristics. The information provided will help physicians in early diagnosis and thereby improving prognosis. (C) 2014 Published by Elsevier Masson SAS.

    DOI: 10.1016/j.clinre.2014.11.001

    Web of Science

    PubMed

    researchmap

  • Image-guided hydrodynamic gene delivery: Current status and future directions 査読

    Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Yuji Kobayashi, Kohei Ogawa, Yoko Shinagawa, Ryosuke Inoue, Shuji Terai

    Pharmaceutics   7 ( 3 )   213 - 223   2015年8月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   出版者・発行元:MDPI AG  

    Hydrodynamics-based delivery has been used as an experimental tool to express transgene in small animals. This in vivo gene transfer method is useful for functional analysis of genetic elements, therapeutic effect of oligonucleotides, and cancer cells to establish the metastatic cancer animal model for experimental research. Recent progress in the development of image-guided procedure for hydrodynamics-based gene delivery in large animals directly supports the clinical applicability of this technique. This review summarizes the current status and recent progress in the development of hydrodynamicsbased gene delivery and discusses the future directions for its clinical application.

    DOI: 10.3390/pharmaceutics7030213

    Scopus

    PubMed

    researchmap

  • Advances in understanding and treating liver diseases during pregnancy: A review 査読

    Kenya Kamimura, Hiroyuki Abe, Hirokazu Kawai, Hiroteru Kamimura, Yuji Kobayashi, Minoru Nomoto, Yutaka Aoyagi, Shuji Terai

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 17 )   5183 - 5190   2015年5月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    Liver disease in pregnancy is rare but pregnancy-related liver diseases may cause threat to fetal and maternal survival. It includes pre-eclampsia; eclampsia; haemolysis, elevated liver enzymes, and low platelets syndrome; acute fatty liver of pregnancy; hyperemesis gravidarum; and intrahepatic cholestasis of pregnancy. Recent basic researches have shown the various etiologies involved in this disease entity. With these advances, rapid diagnosis is essential for severe cases since the decision of immediate delivery is important for maternal and fetal survival. The other therapeutic options have also been shown in recent reports based on the clinical trials and cooperation and information sharing between hepatologist and gynecologist is important for timely therapeutic intervention. Therefore, correct understandings of diseases and differential diagnosis from the pre-existing and co-incidental liver diseases during the pregnancy will help to achieve better prognosis. Therefore, here we review and summarized recent advances in understanding the etiologies, clinical courses and management of liver disease in pregnancy. This information will contribute to physicians for diagnosis of disease and optimum management of patients.

    DOI: 10.3748/wjg.v21.i17.5183

    Web of Science

    PubMed

    researchmap

  • Rheological Modification of Hydrodynamic Gene Delivery

    Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Akiomi Ushida, Tomiichi Hasegawa, Kenya Kamimura, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY   23 ( 350594 )   S140 - S141   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging 査読

    Tsutomu Kanefuji, Toru Takano, Takeshi Suda, Kouhei Akazawa, Takeshi Yokoo, Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Hidefumi Aoyama, Minoru Nomoto, Shuji Terai

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 15 )   4583 - 4591   2015年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBLISHING GROUP INC  

    AIM: To establish a prognostic formula that distinguishes non-hypervascular hepatic nodules (NHNs) with higher aggressiveness from less hazardous one.
    METHODS: Seventy-three NHNs were detected in gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging (Gd-EOB-DTPA-MRI) study and confirmed to change 2 mm or more in size and/or to gain hypervascularity. All images were interpreted independently by an experienced, board-certified abdominal radiologist and hepatologist; both knew that the patients were at risk for hepatocellular carcinoma development but were blinded to the clinical information. A formula predicting NHN destiny was developed using a generalized estimating equation model with thirteen explanatory variables: age, gender, background liver diseases, Child-Pugh class, NHN diameter, T1-weighted imaging/T2-weighted imaging detectability, fat deposition, lower signal intensity in arterial phase, lower signal intensity in equilibrium phase, alpha-fetoprotein, des-gamma-carboxy prothrombin, alpha-fetoprotein-L3, and coexistence of classical hepatocellular carcinoma. The accuracy of the formula was validated in bootstrap samples that were created by resampling of 1000 iterations.
    RESULTS: During a median follow-up period of 504 d, 73 NHNs with a median diameter of 9 mm (interquartile range: 8-12 mm) grew or shrank by 68.5% (fifty nodules) or 20.5% (fifteen nodules), respectively, whereas hypervascularity developed in 38.4% (twenty eight nodules). In the fifteen shrank nodules, twelve nodules disappeared, while 11.0% (eight nodules) were stable in size but acquired vascularity. A generalized estimating equation analysis selected five explanatories from the thirteen variables as significant factors to predict NHN progression. The estimated regression coefficients were 0.36 for age, 6.51 for lower signal intensity in arterial phase, 8.70 or 6.03 for positivity of hepatitis B virus or hepatitis C virus, 9.37 for des-gamma- carboxy prothrombin, and -4.05 for fat deposition. A formula incorporating the five coefficients revealed sensitivity, specificity, and accuracy of 88.0%, 86.7%, and 87.7% in the formulating cohort, whereas these of 87.2% +/- 5.7%, 83.8% +/- 13.6%, and 87.3% +/- 4.5% in the bootstrap samples.
    CONCLUSION: These data suggest that the formula helps Gd-EOB-DTPA-MRI detect a trend toward hepatocyte transformation by predicting NHN destiny.

    DOI: 10.3748/wjg.v21.i15.4583

    Web of Science

    PubMed

    researchmap

  • Collagenous gastritis: Review. 査読

    Kamimura K, Kobayashi M, Sato Y, Aoyagi Y, Terai S

    World journal of gastrointestinal endoscopy   7   265 - 273   2015年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   出版者・発行元:3  

    DOI: 10.4253/wjge.v7.i3.265

    PubMed

    researchmap

  • Late Onset Post-Transfusion Hepatitis E Developing during Chemotherapy for Acute Promyelocytic Leukemia 査読

    Kyoko Fuse, Yuichi Matsuyama, Masato Moriyama, Shukuko Miyakoshi, Yasuhiko Shibasaki, Jun Takizawa, Tatsuo Furukawa, Ichiro Fuse, Hiro Matsumura, Shigeharu Uchida, Yoshifumi Takahashi, Kenya Kamimura, Hiroyuki Abe, Takeshi Suda, Yutaka Aoyagi, Hirohito Sone, Masayoshi Masuko

    INTERNAL MEDICINE   54 ( 6 )   657 - 661   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a leukemia patient who developed hepatitis E seven months after undergoing a transfusion with contaminated blood products. The latency period in this case was significantly longer than that of typical hepatitis E. Recently, chronic infection with hepatitis E virus (HEV) genotype 3 has been reported in immunocompromised patients. There is a possibility that our patient was unable to eliminate the virus due to immunosuppression following chemotherapy and the administration of steroids. The prevalence of HEV in healthy Japanese individuals is relatively high and constitutes a critical source of infection via transfusion. Hepatitis E is an important post-transfusion infection, and immunocompromised patients may exhibit a long latency period before developing the disease.

    DOI: 10.2169/internalmedicine.54.2332

    Web of Science

    PubMed

    researchmap

  • Successful management of severe intrahepatic cholestasis of pregnancy: report of a first Japanese case 査読

    Kenya Kamimura, Hiroyuki Abe, Naomi Kamimura, Masayuki Yamaguchi, Maiko Mamizu, Kanna Ogi, Yoshifumi Takahashi, Ken-ichi Mizuno, Hiroteru Kamimura, Yuji Kobayashi, Manabu Takeuchi, Kunihiko Yoshida, Kyoko Yamada, Takayuki Enomoto, Koichi Takakuwa, Minoru Nomoto, Miki Obata, Yoshinori Katsuragi, Yukio Mishima, Ryo Kominami, Tomoteru Kamimura, Yutaka Aoyagi

    BMC GASTROENTEROLOGY   14   160   2014年9月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: Intrahepatic cholestasis of pregnancy (ICP) is a cholestasis condition caused by elevated levels of serum bile acids that mainly occurs in the third trimester of pregnancy. Maternal symptoms include pruritus; elevation of transaminases, biliary enzymes, and bilirubin levels; and abnormal liver function tests. Fetal symptoms include spontaneous preterm labor, fetal distress, and intrauterine death. It is more prevalent in the Caucasians and is rarely found in Asian countries, including Japan. The etiology of ICP has been reported as involving various factors such as, environmental factors, hormone balance, and genetic components. The genetic factors include single-nucleotide polymorphisms (SNPs) in the genes of canalicular transporters, including ABCB4 and ABCB11. It has also been reported that the combination of these SNPs induces severe cholestasis and liver dysfunction.
    Case presentation: Here, we report for the first time a 24-year Japanese case of severe ICP diagnosed by typical symptoms, serum biochemical analysis, and treated with the administration of ursodeoxycholic acid which improved cholestasis and liver injury and prevented fetal death. The sequence analysis showed SNPs reported their association with ICP in the ABCB11 (rs2287622, V444A) and ABCB4 (rs1202283, N168N) loci.
    Conclusion: The risk of ICP has been reported to be population-specific, and it is rare in the Japanese population. Our case was successfully treated with ursodeoxycholic acid and the genetic sequence analysis has supported the diagnosis. Because genetic variation in ABCB4 and ABCB11 has also been reported in the Japanese population, we need to be aware of potential ICP cases in pregnant Japanese women although further studies are necessary.

    DOI: 10.1186/1471-230X-14-160

    Web of Science

    PubMed

    researchmap

  • Safety Assessment of Liver-Targeted Hydrodynamic Gene Delivery in Dogs 査読

    Kenya Kamimura, Tsutomu Kanefuji, Takeshi Yokoo, Hiroyuki Abe, Takeshi Suda, Yuji Kobayashi, Guisheng Zhang, Yutaka Aoyagi, Dexi Liu

    PLOS ONE   9 ( 9 )   e107203   2014年9月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:PUBLIC LIBRARY SCIENCE  

    Evidence in support of safety of a gene delivery procedure is essential toward gene therapy. Previous studies using the hydrodynamics-based procedure primarily focus on gene delivery efficiency or gene function analysis in mice. The current study focuses on an assessment of the safety of computer-controlled and liver-targeted hydrodynamic gene delivery in dogs as the first step toward hydrodynamic gene therapy in clinic. We demonstrate that the impacts of the hydrodynamic procedure were limited in the injected region and the influences were transient. Histological examination and the hepatic microcirculation measurement using reflectance spectrophotometry reveal that the liver-specific impact of the procedure involves a transient expansion of the liver sinusoids. No systemic damage or toxicity was observed. Physiological parameters, including electrocardiogram, heart rate, blood pressure, oxygen saturation, and body temperature, remained in normal ranges during and after hydrodynamic injection. Body weight was also examined to assess the long-term effects of the procedure in animals who underwent 3 hydrodynamic injections in 6 weeks with 2-week time interval in between. Serum biochemistry analysis showed a transient increase in liver enzymes and a few cytokines upon injection. These results demonstrate that image-guided, liver-specific hydrodynamic gene delivery is safe.

    DOI: 10.1371/journal.pone.0107203

    Web of Science

    PubMed

    researchmap

  • Value of shear wave velocity measurements for the risk assessment of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease 査読

    Masaaki Takamura, Tsutomu Kanefuji, Takeshi Suda, Takeshi Yokoo, Hiroteru Kamimura, Atsunori Tsuchiya, Kenya Kamimura, Yasushi Tamura, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa, Minoru Nomoto, Yutaka Aoyagi

    HEPATOLOGY INTERNATIONAL   8 ( 2 )   240 - 249   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    To evaluate the value of measuring shear wave velocity evoked by acoustic radiation force impulse (VTTQ) for the risk assessment of hepatocellular carcinoma (HCC) development in patients with nonalcoholic fatty liver disease (NAFLD).
    VTTQ was measured three times in each of the four liver segments in 163 NAFLD patients, including 14 HCC cases; the results were statistically evaluated.
    The VTTQ was 3.04 +/- A 0.17 m/s (median +/- A median absolute deviation) and 1.27 +/- A 0.25 m/s in patients with and without HCC, respectively, and was significantly higher in HCC cases (p &lt; 0.001). When the patients were classified as F0-F4 based on VTTQ cutoff values, VTTQ was significantly higher in the left lobe than in the right lobe for F0 (p &lt; 0.0001) and for F1 and F2 combined (p &lt; 0.0001), but not significantly higher for F3 and F4 combined (p = 0.070). The robust coefficient of variation was significantly higher in the left than in the right (p = 0.018) and significantly increased as VTTQ increased (p = 0.0002). Multivariate analysis showed that total bilirubin concentration {p = 0.014, 38.9 (2.08-727) [odds ratio (95 % confidence interval)]} and VTTQ [p = 0.006, 113 (3.91-3245)] were the only independent explanatory factors for HCC presence among the seven variables identified by univariate analysis. The area under the receiver-operating characteristic curve in the differentiation of HCC from non-HCC was 0.943 for VTTQ and was comparable to that for other noninvasive markers such as Fib-4 (0.964) or higher than that in BARD (0.838).
    These results suggest that fibrosis occurs heterogeneously throughout the liver and that VTTQ measurements are useful in HCC risk evaluation in a NAFLD cohort.

    DOI: 10.1007/s12072-014-9517-9

    Web of Science

    PubMed

    researchmap

  • Granulocytapheresis for the Treatment of Severe Alcoholic Hepatitis: A Case Series and Literature Review 査読

    Kenya Kamimura, Michitaka Imai, Akira Sakamaki, Shigeki Mori, Masaaki Kobayashi, Ken-ichi Mizuno, Manabu Takeuchi, Takeshi Suda, Minoru Nomoto, Yutaka Aoyagi

    DIGESTIVE DISEASES AND SCIENCES   59 ( 2 )   482 - 488   2014年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   出版者・発行元:SPRINGER  

    Severe alcoholic hepatitis has a high mortality rate due to limited therapeutic methods. Although corticosteroids have been used to control the inflammatory response, the outcomes vary and no standardized therapy has been established. Novel therapeutic approaches, such as anti-TNF-alpha, pentoxifilline, and others have been tested clinically on the basis of their cytokinemic pathophysiology with limited success. However, treatment of leukocytosis that causes cytokinemia and hepatic inflammation in patients via granulocytapheresis and leukocytapheresis showed promising results in a number of reports. Here, we report two cases of severe alcoholic hepatitis treated with granulocytapheresis. The liver function and inflammation recovered after the therapy. A review of 35 cases treated with granulocytapheresis and leukocytapheresis demonstrated their efficacy in treating alcoholic hepatitis by controlling leukocytosis as well as cytokines such as IL-8. Multidisciplinary treatment for severe alcoholic hepatitis should be considered case by case on the basis of the complexity and severity of the condition.

    DOI: 10.1007/s10620-013-2871-y

    Web of Science

    PubMed

    researchmap

  • Hemodynamics of a hydrodynamic injection 査読

    Tsutomu Kanefuji, Takeshi Yokoo, Takeshi Suda, Hiroyuki Abe, Kenya Kamimura, Dexi Liu

    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT   1   14029   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:CELL PRESS  

    The hemodynamics during a hydrodynamic injection were evaluated using cone beam computed tomography (CBCT) and fluoroscopic imaging. The impacts of hydrodynamic (5 seconds) and slow (60 seconds) injections into the tail veins of mice were compared using 9% body weight of a phase-contrast medium. Hydrodynamically injected solution traveled to the heart and drew back to the hepatic veins (HV), which led to liver expansion and a trace amount of spillover into the portal vein (PV). The liver volumes peaked at 165.6 +/- 13.3% and 165.5 +/- 11.9% of the original liver volumes in the hydrodynamic and slow injections, respectively. Judging by the intensity of the CBCT images at the PV, HV, right atrium, liver parenchyma (LP), and the inferior vena cava (IVC) distal to the HV conjunction, the slow injection resulted in the higher intensity at PV than at LP. In contrast, a significantly higher intensity was observed in LP after hydrodynamic injection in comparison with that of PV, suggesting that the liver took up the iodine from the blood flow. These results suggest that the enlargement speed of the liver, rather than the expanded volume, primarily determines the efficiency of hydrodynamic delivery to the liver.

    DOI: 10.1038/mtm.2014.29

    Web of Science

    researchmap

  • Alcoholic Liver Disease Complicated by Deep Bleeding into the Muscles or Retroperitoneum: Report of Three Cases and a Review of the Literature 査読

    Masaaki Takamura, Jun Watanabe, Akira Sakamaki, Yutaka Honda, Kenya Kamimura, Atsunori Tsuchiya, Satoshi Yamagiwa, Takeshi Suda, Yasunobu Matsuda, Yutaka Aoyagi

    INTERNAL MEDICINE   53 ( 16 )   1763 - 1768   2014年

     詳細を見る

    記述言語:英語   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    We herein report three cases of alcoholic cirrhosis complicated by deep bleeding. In two of the three cases, intramuscular or retroperitoneal hematomas developed spontaneously. In contrast, in the remaining case, an intramuscular hematoma developed after trauma. In the former two patients, the intramuscular hematomas recurred at other sites during hospitalization. All three patients received conservative therapy, and one patient with a retroperitoneal hematoma underwent transcatheter arterial embolization. All of the patients eventually died of liver failure. The occurrence of severe alcoholic liver disease with deep bleeding has recently been reported with increasing frequency, and clinicians should bear this condition in mind as a life-threatening complication of alcoholic liver disease.

    DOI: 10.2169/internalmedicine.53.2123

    Web of Science

    PubMed

    researchmap

  • Early Diagnosis of Hepatic Intravascular Lymphoma: A Case Report and Literature Review 査読

    Hiroyuki Abe, Kenya Kamimura, Maiko Mamizu, Yasuhiko Shibazaki, Takanobu Ishiguro, Shin-ichi Katada, Yu-ki Nishiyama, Yoshifumi Takahashi, Yu-ya Hatano, Ken-ichi Mizuno, Yukari Watanabe, Aiko Nagashima, Jun Takizawa, Manabu Takeuchi, Hirokazu Kawai, Minoru Nomoto, Hirohito Sone, Masatoyo Nishizawa, Yutaka Aoyagi

    INTERNAL MEDICINE   53 ( 6 )   587 - 593   2014年

     詳細を見る

    担当区分:責任著者   記述言語:英語   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    Hepatic intravascular large B-cell lymphoma (IVL) is a rare disease entity that involves invasion into various organs. Due to the aggressive behavior and poor prognosis of the disease and the difficulty in making an early diagnosis, some cases are diagnosed at autopsy. Early suspicion and the use of imaging studies and liver biopsies are key for diagnosing IVL; however, no reports have described the results of imaging studies due to the limited number of cases. We herein report the results of imaging studies of hepatic IVL, including the findings PET-CT, dynamic-CT, EOB-MRI and CEUS. These results may help physicians to make an early diagnosis and improve the prognosis.

    DOI: 10.2169/internalmedicine.53.1812

    Web of Science

    PubMed

    researchmap

  • Parameters Affecting Image-guided, Hydrodynamic Gene Delivery to Swine Liver 査読

    Kenya Kamimura, Takeshi Suda, Guisheng Zhang, Yutaka Aoyagi, Dexi Liu

    MOLECULAR THERAPY-NUCLEIC ACIDS   2   e128   2013年10月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Development of a safe and effective method for gene delivery to hepatocytes is a critical step toward gene therapy for liver diseases. Here, we assessed the parameters for gene delivery to the livers of large animals (pigs, 40-65 kg) using an image-guided hydrodynamics-based procedure that involves image-guided catheter insertion into the lobular hepatic vein and hydrodynamic injection of reporter plasmids using a computer-controlled injector. We demonstrated that injection parameters (relative position of the catheter in the hepatic vasculature, intravascular pressure upon injection, and injection volume) are directly related to the safety and efficiency of the procedure. By optimizing these parameters, we explored for the first time, the advantage of the procedure for sequential injections to multiple lobes in human-sized pigs. The optimized procedure resulted in sustained expression of the human alpha-1 antitrypsin gene in livers for more than 2 months after gene delivery. In addition, repeated hydrodynamic gene delivery was safely conducted and no adverse events were seen in the entire period of the study. Our results support the clinical applicability of the image-guided hydrodynamic gene delivery method for the treatment of liver diseases.

    DOI: 10.1038/mtna.2013.52

    Web of Science

    PubMed

    researchmap

  • Development of IgG4-related disease in a patient diagnosed with idiopathic membranous nephropathy 査読

    Yoko Wada, Takako Saeki, Kazuhiro Yoshita, Rivka Ayalon, Kenya Kamimura, Masaaki Nakano, Ichiei Narita

    Clinical Kidney Journal   6 ( 5 )   486 - 490   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:5  

    We report a case of IgG4-related disease (IgG4-RD) diagnosed after 3 years of follow-up for idiopathic membranous nephropathy (MN). MN has been considered as glomerular lesion of IgG4-related kidney diseases in recent years and was diagnosed simultaneously with or after a diagnosis of IgG4-RD in previously reported cases. In the present case, IgG4-RD developed 3 years after the diagnosis of idiopathic MN, indicating a possible relationship between idiopathic MN and IgG4-RD through common underlying mechanisms of development. © 2013 © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please email: journals.permissions@oup.com.

    DOI: 10.1093/ckj/sft062

    Scopus

    PubMed

    researchmap

  • FDG-PETおよび肝生検にて診断しえた脊髄血管内悪性リンパ腫の71歳女性例

    石黒 敬信, 堅田 慎一, 二宮 格, 上村 顕也, 西澤 正豊

    臨床神経学   53 ( 10 )   855 - 855   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本神経学会  

    researchmap

  • A case of esophageal intramural pseudodiverticulosis

    Akira Sakamaki, Masaaki Kobayashi, Michitaka Imai, Kenichi Mizuno, Kenya Kamimura, Manabu Takeuchi, Rintaro Narisawa, Yutaka Aoyagi

    Gastroenterological Endoscopy   55 ( 10 )   3368 - 3374   2013年10月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A 63-year-old man presented at our hospital with the complaint of continuous dysphagia. He was a chronic smoker and also consumed excessive amounts of alcohol. A barium esophagogram showed multiple outpouchings in the entire esophagus. Gastrointestinal endoscopy revealed multiple ostia and a stenotic lesion at the lower thoracic esophagus. Candida infection was detected in white patches around the ostia. We made the diagnosis of esophageal intramural pseudodiverticulosis, prohibited the consumption of alcohol and performed endoscopic dilatation. Thereafter his symptoms showed a tendency to improve. A case report of esophageal intramural pseudodiverticulosis with typical endoscopic and radiographic images and candidiasis is presented accompanied by a review of the literature.

    Scopus

    researchmap

  • Novel electric power-driven hydrodynamic injection system for gene delivery: Safety and efficacy of human factor IX delivery in rats 査読

    T. Yokoo, K. Kamimura, T. Suda, T. Kanefuji, M. Oda, G. Zhang, D. Liu, Y. Aoyagi

    Gene Therapy   20 ( 8 )   816 - 823   2013年8月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The development of a safe and reproducible gene delivery system is an essential step toward the clinical application of the hydrodynamic gene delivery (HGD) method. For this purpose, we have developed a novel electric power-driven injection system called the HydroJector-EM, which can replicate various time-pressure curves preloaded into the computer program before injection. The assessment of the reproducibility and safety of gene delivery system in vitro and in vivo demonstrated the precise replication of intravascular time-pressure curves and the reproducibility of gene delivery efficiency. The highest level of luciferase expression (272 pg luciferase per mg of proteins) was achieved safely using the time-pressure curve, which reaches 30 mm Hg in 10 s among various curves tested. Using this curve, the sustained expression of a therapeutic level of human factor IX protein (&gt
    500 ng ml-1) was maintained for 2 months after the HGD of the pBS-HCRHP-FIXIA plasmid. Other than a transient increase in liver enzymes that recovered in a few days, no adverse events were seen in rats. These results confirm the effectiveness of the HydroJector-EM for reproducible gene delivery and demonstrate that long-term therapeutic gene expression can be achieved by automatic computer-controlled hydrodynamic injection that can be performed by anyone. © 2013 Macmillan Publishers Limited.

    DOI: 10.1038/gt.2013.2

    Scopus

    PubMed

    researchmap

  • Active treatments are a rational approach for hepatocellular carcinoma in elderly patients 査読

    Takeshi Suda, Aiko Nagashima, Shyunsaku Takahashi, Tsutomu Kanefuji, Kenya Kamimura, Yasushi Tamura, Masaaki Takamura, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa, Minoru Nomoto, Yutaka Aoyagi

    WORLD JOURNAL OF GASTROENTEROLOGY   19 ( 24 )   3831 - 3840   2013年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BAISHIDENG PUBL GRP CO LTD  

    AIM: To determine whether an active intervention is beneficial for the survival of elderly patients with hepatocellular carcinoma (HCC).
    METHODS: The survival of 740 patients who received various treatments for HCC between 1983 and 2011 was compared among different age groups using Cox regression analysis. Therapeutic options were principally selected according to the clinical practice guidelines for HCC from the Japanese Society of Hepatology. The treatment most likely to achieve regional control capability was chosen, as far as possible, in the following order: resection, radiofrequency ablation, percutaneous ethanol injection, transcatheter arterial chemoembolization, transarterial oily chemoembolization, hepatic arterial infusion chemotherapy, systemic chemotherapy including molecular targeting, or best supportive care. with a clinical goal of striking the best balance between functional hepatic reserve and the volume of the targeted area, irrespective of their age. The percent survival to life expectancy was calculated based on a Japanese national population survey.
    RESULTS: The median ages of the subjects during each 5-year period from 1986 were 61, 64, 67, 68 and 71 years and increased significantly with time (P &lt; 0.0001). The Child-Pugh score was comparable among younger (59 years of age or younger), middle-aged (60-79 years of age), and older (80 years of age or older) groups (P = 0.34), whereas the tumor-node- metastasis stage tended to be more advanced in the younger group (P = 0.060). Advanced disease was significantly more frequent in the younger group compared with the middle-aged group (P = 0.010), whereas there was no difference between the middleaged and elderly groups (P = 0.75). The median survival times were 2593, 2011, 1643, 1278 and 1195 d for 49 years of age or younger, 50-59 years of age, 60-69 years of age, 70-79 years of age, or 80 years of age or older age groups, respectively, whereas the median percent survival to life expectancy were 13.9%, 21.9%, 24.7%, 25.7% and 37.6% for each group, respectively. The impact of age on actual survival time was significant (P = 0.020) with a hazard ratio of 1.021, suggesting that a 10-year-older patient has a 1.23-fold higher risk for death, and the overall survival was the worst in the oldest group. On the other hand, when the survival benefit was evaluated on the basis of percent survival to life expectancy, age was again found to be a significant explanatory factor (P = 0.022); however, the oldest group showed the best survival among the five different age groups. The youngest group revealed the worst outcomes in this analysis, and the hazard ratio of the oldest against the youngest was 0.35 for death. The survival trends did not differ substantially between the survival time and percent survival to life expectancy, when survival was compared overall or among various therapeutic interventions.
    CONCLUSION: These results suggest that a therapeutic approach for HCC should not be restricted due to patient age. (C) 2013 Baishideng. All rights reserved.

    DOI: 10.3748/wjg.v19.i24.3831

    Web of Science

    PubMed

    researchmap

  • 肝炎から肝硬変・肝癌まで 肝癌の早期発見 腫瘍マーカー

    田村康, 上村顕也, 五十嵐正人, 川合弘一, 須田剛士, 青柳豊

    月刊臨床と研究   90 ( 2 )   200 - 203   2013年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:大道学館出版部  

    CiNii Article

    CiNii Books

    J-GLOBAL

    researchmap

  • A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma 査読

    Akihiko Osaki, Takeshi Suda, Kenya Kamimura, Atsunori Tsuchiya, Yasushi Tamura, Masaaki Takamura, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa, Yutaka Aoyagi

    CANCER MEDICINE   2 ( 1 )   86 - 98   2013年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Cisplatin (CDDP) is an anticancer agent that is commonly used in hepatic arterial infusion (HAI) chemotherapy for hepatocellular carcinoma (HCC). This study aimed to clarify the safe and effective dose of CDDP in HAI for HCC. The hypervascular area was measured in 42 HCCs before and after HAI with CDDP. Serum platinum concentration was quantified in the peripheral and/or middle hepatic veins by atomic absorption spectrometry. The relation between the HCC response and CDDP dose was statistically analyzed. The multiple HCC nodules in an individual case generally demonstrated the same response to CDDP. The free-platinum concentration stayed relatively constant in the hepatic vein during HAI followed by a rapid decline, while total-platinum gradually increased then slowly disappeared over several days. After CDDP-HAI, 15 HCCs shrunk and 27 HCCs grew. The reduction rate in the shrunken nodules was tended to be correlated with CDDP dose after standardization with the target liver volume. On the other hand, the growth rate of the enlarged HCCs was significantly correlated with CDDP dose after normalization with creatinine clearance. These data support a recommendation of CDDP-HAI infusion where the amount of CDDP (mg) administered is less than patient creatinine clearance (mL/min/1.73 m(2)) upon an assumption of HCC doubling time of 90 days, and the targeted liver is smaller than 200 times the CDDP dose (mg). A further analysis is required to define appropriate injection speeds.

    DOI: 10.1002/cam4.55

    Web of Science

    PubMed

    researchmap

  • Immunohistochemical character of hepatic angiomyolipoma: For its management 査読

    Yuka Kobayashi, Kenya Kamimura, Minoru Nomoto, Soichi Sugitani, Yutaka Aoyagi

    Case Reports in Medicine   2013   298143   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Hindawi Limited  

    Hepatic angiomyolipoma (AML) is notoriously difficult to diagnose without an invasive surgery even with the recent development of the various imaging modalities. Additionally, recent reports showed its malignant behavior after the surgery
    it is important to diagnose the character of each tumor including the possible malignant potential and determine the postoperative management for each case. For this purpose, we have reviewed reports and focused on the immunohistochemical staining with p53 and ki67 of the tumors showing the representative case of 60-year-old female. The imaging study of her tumor showed the character similar to the hepatocellular carcinoma, and she underwent the hepatectomy. The resected tumor stained positive for HMB-45 that is a marker of the AML, and 30-50% of the tumor cells were positively stained with Ki67 that is a mitotic marker. Also, the atypical epithelioid cells displayed p53 immunoreactivity. These results suggest the malignant potential of our tumor based on the previous reports
    therefore the careful followup for this case is necessary for a long period whether it shows metastasis, sizing up, and so forth. © 2013 Yuka Kobayashi et al.

    DOI: 10.1155/2013/298143

    Scopus

    PubMed

    researchmap

  • Immunoglobulin G4-Related Disease with Several Inflammatory Foci 査読

    Akira Sakamaki, Kenya Kamimura, Kazuhiko Shioji, Junko Sakurada, Takeshi Nakatsue, Yoko Wada, Michitaka Imai, Ken-ichi Mizuno, Takashi Yamamoto, Manabu Takeuchi, Yuichi Sato, Masaaki Kobayashi, Makoto Naito, Ichiei Narita, Yutaka Aoyagi

    INTERNAL MEDICINE   52 ( 4 )   457 - 462   2013年

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    We herein report the case of a 62-year-old Japanese man who presented with jaundice, dry eyes and abdominal discomfort. Imaging studies revealed swelling of the periorbital tissue, parotid and submandibular glands, pulmonary hilar lymph nodes, pancreas, bile ducts, gall bladder walls, bilateral kidneys, arterial walls and prostate. A significant increase in the serum level IgG4 was seen, and the patient was diagnosed with IgG4-related disease after undergoing a biopsy of the pancreas and prostate. We herein report a case of IgG4-related disease with multiple ten organ involvement at the onset of the disease that was successfully treated with prednisolone (PSL) therapy.

    DOI: 10.2169/internalmedicine.52.9239

    Web of Science

    PubMed

    researchmap

  • Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma 査読

    Kenya Kamimura, Takeshi Suda, Yasushi Tamura, Masaaki Takamura, Takeshi Yokoo, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa, Minoru Nomoto, Yutaka Aoyagi

    BMC GASTROENTEROLOGY   12   127   2012年9月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Background: There is no standard therapeutic procedure for the hepatocellular carcinoma (HCC) in patients with poor hepatic reserve function. With the approval of newly developed chemotherapeutic agent of miriplatin, we have firstly conducted the phase I study of CDDP powder (DDP-H) and miriplatin combination therapy and reported its safety and efficacy for treating unresectable HCC in such cases. To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for the combination of transarterial oily chemoembolization (TOCE) and transarterial chemotherapy (TAC) using miriplatin and DDP-H for treating unresectable hepatocellular carcinoma (HCC).
    Methods: Transarterial chemotherapy using DDP-H was performed through the proper hepatic artery targeting the HCC nodules by increasing the dose of DDP-H (35-65 mg/m(2)) followed by targeting the HCC nodules by transarterial oily chemoembolization with miriplatin.
    Results: A total of nine patients were enrolled in this study and no DLT was observed with any dose of DDP-H in all cases in whom 80 mg (median, 18-120) miriplatin was administered. An anti-tumour efficacy rating for partial response was obtained in one patient, while a total of four patients (among eight evaluated) showed stable disease response, leading to 62.5% of disease control rate. The pharmacokinetic results showed no further increase in plasma platinum concentration following miriplatin administration.
    Conclusion: Our results suggest that a combination of DDP-H and miriplatin can be safely administered up to their respective MTD for treating HCC.

    DOI: 10.1186/1471-230X-12-127

    Web of Science

    PubMed

    researchmap

  • Formula to Predict Platelet Count after Partial Splenic Arterial Embolization in Patients with Hypersplenism 査読

    Akihiko Osaki, Takeshi Suda, Nobuo Waguri, Toru Ishikawa, Takeshi Yokoo, Kenya Kamimura, Yasushi Tamura, Masaaki Takamura, Masato Igarashi, Hirokazu Kawai, Satoshi Yamagiwa, Yutaka Aoyagi

    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY   23 ( 7 )   900 - 907   2012年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ELSEVIER SCIENCE INC  

    Purpose: To establish a formula to guide appropriate embolization volume for postprocedural platelet gain following partial splenic arterial embolization (PSE) for hypersplenism.
    Materials and Methods: The hepatic volume (Vh) and splenic volume (Vsp) were measured by using 2-mm-thick computed tomography images before and after PSE in 20 patients with various chronic liver diseases. A formula was derived from the relationship between the platelet count increase ratio (dPlt%) and the organ volumes, which was then evaluated in another cohort.
    Results: After an embolization of a median of 72.1% of the spleen (interquartile range, 38.2%-93.8%), the dPlt% was 67.7% +/- 40.0 and significantly correlated with the increasing ratio of Vh to Vsp (P = .019, rho = 0.52). Because the difference in Vh/Vsp ratio after PSE was significantly correlated with the spleen embolization ratio (eVsp%; P = .0003, rho = 0.72), the estimated dPlt% could be derived from the Vh/Vsp ratio before PSE and the eVsp%. The estimated dPlt% was significantly correlated with the actual dPlt% (P = .0003, rho = 0.72). When the formula was evaluated in another cohort of 14 cases, another strict correlation was observed (P &lt; .0001, rho = 0.92).
    Conclusions: These data suggest that platelet count after PSE can be predicted before the procedure by using the Vh/Vsp ratio and the anticipated spleen embolization volume. The use of such a prediction can prevent too much or too little embolization, thereby leading to an improvement in the risk/return trade-off in PSE.

    DOI: 10.1016/j.jvir.2012.03.008

    Web of Science

    PubMed

    researchmap

  • Efficient palliative involved-field radiotherapy on highly progressive diffuse large B-cell primary gastric lymphoma with liver cirrhosis 査読

    Junji Kohisa, Kenya Kamimura, Akito Iwanaga, Kazuhiko Shioji, Hirokazu Kawai, Takeshi Suda, Kenji Suzuki, Junko Sakurada, Makoto Naito, Yutaka Aoyagi

    Clinical Journal of Gastroenterology   5 ( 2 )   164 - 169   2012年4月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We report the case of a 73-year-old woman having diffuse large B-cell primary gastric lymphoma with a cirrhotic liver caused by hepatitis C virus infection. She visited our hospital with symptoms of nausea and vomiting, which appeared to be caused by stenosis due to the tumor. Metastatic tumors were seen in the gastric and jugular lymph nodes. The clinical stage was IVB with a high risk of poor prognosis according to the international index. Because of poor hepatic reserve function, standard chemotherapy could not be administered. To maintain her quality of life, palliative involved-field radiotherapy was performed. The symptoms and tumor markers significantly improved, and computed tomography and endoscopy indicated the disappearance of the primary gastric tumor. Two months after radiotherapy and her return home, she died of pneumonia. Autopsy showed neither lymphoma cells nor stenosis of gastric lesion. The significant antitumor effect on primary tumor in our case suggests that the involved-field radiotherapy, although palliative, can be a therapeutic option for primary gastric lymphoma patients with various complications. © Springer 2012.

    DOI: 10.1007/s12328-012-0292-7

    Scopus

    researchmap

  • Hepatic angiomyolipoma: diagnostic findings and management. 査読

    Kamimura K, Nomoto M, Aoyagi Y

    International journal of hepatology   2012   410781   2012年

     詳細を見る

    担当区分:筆頭著者, 責任著者  

    DOI: 10.1155/2012/410781

    PubMed

    researchmap

  • 非B非C型肝癌の現状と問題点 Cryptogenic肝癌と他の非B非C型肝癌の臨床病理学的比較

    川合弘一, 須田剛士, 上村顕也, 田村康, 五十嵐正人, 野本実, 岡田正彦, 青柳豊

    月刊消化器内科   53 ( 4 )   440 - 446   2011年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:科学評論社  

    CiNii Article

    CiNii Books

    J-GLOBAL

    researchmap

  • 肝動注化学療法,TACEに抵抗性であった多発肝細胞癌に対し,ミリプラチン動注が有効であった1例

    阿部聡司, 五十嵐正人, 上村顕也, 土屋淳紀, 矢野雅彦, 田村康, 高村昌昭, 川合弘一, 山際訓, 須田剛, 野本実, 青柳豊

    癌の臨床   56 ( 4 )   337 - 342   2011年1月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Multicentric occurrence of hepatocellular carcinoma with nonalcoholic steatohepatitis 査読

    Hirokazu Kawai, Minoru Nomoto, Takeshi Suda, Kenya Kamimura, Atsunori Tsuchiya, Yasushi Tamura, Masahiko Yano, Masaaki Takamura, Masato Igarashi, Toshifumi Wakai, Satoshi Yamagiwa, Yasunobu Matsuda, Shogo Ohkoshi, Isao Kurosaki, Yoshio Shirai, Masahiko Okada, Yutaka Aoyagi

    World Journal of Hepatology   3 ( 1 )   15 - 23   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:1  

    Aim: To reveal the manner of hepatocellular carcinoma (HCC) development in patients with nonalcoholic steatohepatitis (NASH) focusing on multicentric occurrence (MO) of HCC. Methods: We compared clinicopathological characteristics between patients with and without MO of HCC arising from NASH background. The clinical features were implicated with reference to the literature available. Results: MO of HCC was identified with histological proof in 4 out of 12 patients with NASH-related HCC (2 males and 2 females). One patient had synchronous MO
    an advanced HCC, two well-differentiated HCCs and a dysplastic nodule, followed by the development of metachronous MO of HCC. The other three patients had multiple advanced HCCs accompanied by a well-differentiated HCC or a dysplastic nodule. Of these three patients, one had synchronous MO, one had metachronous MO and the other had both synchronous and metachronous MO. There were no obvious differences between the patients with or without MO in terms of liver function tests, tumor markers and anatomical extent of HCC. On the other hand, all four patients with MO of HCC were older than 70 years old and had the comorbidities of obesity, type 2 diabetes mellitus (T2DM), hypertension and cirrhosis. Although these conditions were not limited to MO of HCC, all the conditions were met in only one of eight patients without MO of HCC. Thus, concurrence of these conditions may be a predisposing situation to synchronous MO of HCC. In particular, old age, T2DM and cirrhosis were suggested to be prerequisite for MO because these factors were depicted in common among two other cases with MO of HCC under NASH in the literature. Conclusion: The putative predisposing factors and necessary preconditions for synchronous MO of HCC in NASH were suggested in this study. Further investigations are required to clarify the accurate prevalence and predictors of MO to establish better strategies for treatment and prevention leading to the prognostic improvement in NASH. © 2011 Baishideng.

    DOI: 10.4254/wjh.v3.i1.15

    Scopus

    PubMed

    researchmap

  • Advances in gene delivery systems 査読

    Kenya Kamimura, Takeshi Suda, Guisheng Zhang, Dexi Liu

    Pharmaceutical Medicine   25 ( 5 )   293 - 306   2011年

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   出版者・発行元:Springer International Publishing  

    The transfer of genes into cells, both in vitro and in vivo, is critical for studying gene function and conducting gene therapy. Methods that utilize viral and nonviral vectors, as well as physical approaches, have been explored. Viral vector-mediated gene transfer employs replication-deficient viruses such as retrovirus, adenovirus, adeno-associated virus and herpes simplex virus. A major advantage of viral vectors is their high gene delivery efficiency. The nonviral vectors developed so far include cationic liposomes, cationic polymers, synthetic peptides and naturally occurring compounds. These nonviral vectors appear to be highly effective in gene delivery to cultured cells in vitro but are significantly less effective in vivo. Physical methods utilize mechanical pressure, electric shock or hydrodynamic force to transiently permeate the cell membrane to transfer DNA into target cells. They are simpler than viral- and nonviral-based systems and highly effective for localized gene delivery. The past decade has seen significant efforts to establish the most desirable method for safe, effective and target-specific gene delivery, and good progress has been made. The objectives of this review are to (i) explain the rationale for the design of viral, nonviral and physical methods for gene delivery
    (ii) provide a summary on recent advances in gene transfer technology
    (iii) discuss advantages and disadvantages of each of the most commonly used gene delivery methods
    and (iv) provide future perspectives. © 2011 Adis Data Information BV. All rights reserved.

    DOI: 10.2165/11594020-000000000-00000

    Scopus

    PubMed

    researchmap

  • 肝胆膵薬物治療学の進歩―この30年―肝臓分野:VIII.肝癌治療薬 ドキソルビシン(アドリアマイシン),エピルビシン(ファルモルビシン)

    須田剛士, 上村顕也, 田村康, 五十嵐正人, 川合弘一, 青柳豊

    肝胆膵   61 ( 6 )   1120 - 1124   2010年12月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Intracellular Gene Transfer in Rats by Tail Vein Injection of Plasmid DNA 査読

    Tian Zhou, Kenya Kamimura, Guisheng Zhang, Dexi Liu

    AAPS JOURNAL   12 ( 4 )   692 - 698   2010年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    In this study, we examined the effect of various factors on gene delivery efficiency of tail vein injection of plasmid DNA into rats. We measured the level of reporter gene expression in the internal organs including the lung, heart, spleen, kidney, and liver as function of injection volume, injection time, and DNA dose. Persistency of reporter gene expression in transfected animals was also examined. We demonstrated that plasmid delivery to rats by the tail vein is effective as long as the volume of injected DNA solution is adjusted to 7-8% of body weight with an injection time of less than 10 s. With the exception of a short-term increase in serum concentration of alanine aminotransferase and transient irregularity in cardiac function during and soon after the injection, the procedure is well tolerated. Lac Z staining of the liver from transfected animals showed approximately 5-10% positive cells. Persistency test for transgene expression in animals using plasmid carrying cDNA of human alpha 1 antitrypsin gene driven by chicken beta actin gene promoter with CMVenhancers showed peak level of transgene product 1 day after the injection followed by a gradual decline with time. Peak level was regained by a second injection performed on day 38 after the first injection. These results show that tail vein injection is an effective means for introducing plasmid DNA into liver cells in rats. We believe that this procedure will be extremely useful for gene function studies in the context of whole animal in rats.

    DOI: 10.1208/s12248-010-9231-z

    Web of Science

    PubMed

    researchmap

  • 肝細胞癌以外の肝腫瘍 肝類上皮血管内皮腫

    上村顕也, 須田剛士, 青柳豊

    日本臨床   225 - 228   2010年10月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Malignant potential of hepatic angiomyolipoma: Case report and literature review 査読

    Kenya Kamimura, Akihiko Oosaki, Satoshi Sugahara, Shigeki Mori, Tetsuya Moroda, Osamu Satoh, Takashi Morita, Kakuhei Kimura, Takashi Kamura, Minoru Nomoto, Yutaka Aoyagi

    Clinical Journal of Gastroenterology   3 ( 2 )   104 - 110   2010年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatic angiomyolipoma (AML) is known as a rare benign tumor with invasive growth. In the past, some of these tumors were misdiagnosed as hepatocellular carcinomas, because of the similar pattern on imaging studies. Recently, correct diagnoses have been increasing, with the development of HMB-45 immunohistochemical staining, and it appears that the majority of these tumors behave as benign tumors. However, there are not a few cases which have resulted in fatal courses because of recurrence and metastasis of the tumor. The clinical features and signs of the malignant potential of this tumor are unknown
    thus, the management and treatment of the tumor are still controversial. Here in this article, we report a case of hepatic AML which showed a size increase of 175% in 1 year, and portal vein thrombosis detected by angiography. During a follow up of 3 years after a curative hepatic lobectomy, no metastasis or recurrence was seen. Review of the literature suggests that portal vein thrombosis could be one of the markers of the malignant potential and transformation of this tumor. Therefore, in this paper, we recommend surgical treatment of hepatic AML in which there is a strong suspicion of portal vein thrombosis. © Springer 2010.

    DOI: 10.1007/s12328-010-0136-2

    Scopus

    researchmap

  • Image-guided, Intravascular Hydrodynamic Gene Delivery to Skeletal Muscle in Pigs 査読

    Kenya Kamimura, Guisheng Zhang, Dexi Liu

    MOLECULAR THERAPY   18 ( 1 )   93 - 100   2010年1月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Development of an effective, safe, and convenient method for gene delivery to muscle is a critical step toward gene therapy for muscle-associated diseases. Toward this end, we have explored the possibility of combining the image-guided catheter insertion technique with the principle of hydrodynamic delivery to achieve muscle-specific gene transfer in pigs. We demonstrate that gene transfer efficiency of the procedure is directly related to flow rate, injection pressure, and injection volume. The optimal gene delivery was achieved at a flow rate of 15 ml/second with injection pressure of 300 psi and injection volume equal to 1.5% of body weight. Under such a condition, hydrodynamic injection of saline containing pCMV-Luc (100 mu g/ml) resulted in luciferase activity of 10(6) to 10(7) relative light units (RLU)/mg of proteins extracted from the targeted muscle 5 days after hydrodynamic gene delivery. Result from immunohistochemical analysis revealed 70-90% transfection efficiency of muscle groups in the hindlimb and persistent reporter gene expression for 2 months in transfected cells. With an exception of transient edema and elevation of creatine phosphokinase, no permanent tissue damage was observed. These results suggest that the image-guided, intravenous hydrodynamic delivery is an effective and safe method for gene delivery to skeletal muscle.

    DOI: 10.1038/mt.2009.206

    Web of Science

    PubMed

    researchmap

  • collagenous colitisの現況と新知見 胃・十二指腸におけるcollagenous colitis類似病変の特徴

    小林正明, 佐藤祐一, 上村顕也, 成澤林太郎, 関根厚雄, 青柳豊, 味岡洋一, 渡辺英伸

    胃と腸   44 ( 13 )   2019 - 2028   2009年12月

     詳細を見る

    記述言語:日本語  

    DOI: 10.11477/mf.1403101821

    J-GLOBAL

    researchmap

  • Progress toward liver-based gene therapy 査読

    Takeshi Suda, Kenya Kamimura, Tomoyuki Kubota, Yasushi Tamura, Masato Igarashi, Hirokazu Kawai, Yutaka Aoyagi, Dexi Liu

    HEPATOLOGY RESEARCH   39 ( 4 )   325 - 340   2009年4月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    The liver is involved in the synthesis of serum proteins, regulation of metabolism and maintenance of homeostasis and provides a variety of opportunities for gene therapy. The enriched vasculature and blood circulation, fenestrated endothelium, abundant receptors on the plasma membranes of the liver cells, and effective transcription and translation machineries in the hepatocytes are some unique features that have been explored for delivery, and functional analysis, of genetic sequences in the liver. Both viral and non-viral methods have been developed for effective gene delivery and liver-based gene therapy. This review describes the fundamentals of gene delivery, and the preclinical and clinical progress that has been made toward gene therapy using the liver as a target.

    DOI: 10.1111/j.1872-034X.2008.00479.x

    Web of Science

    CiNii Article

    researchmap

  • Image-guided, Lobe-specific Hydrodynamic Gene Delivery to Swine Liver 査読

    Kenya Kamimura, Takeshi Suda, Wei Xu, Guisheng Zhang, Dexi Liu

    MOLECULAR THERAPY   17 ( 3 )   491 - 499   2009年3月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Image-guided, lobe-specific hydrodynamic gene delivery to liver was assessed in pigs. The procedure involved image-guided insertion of a balloon catheter to the hepatic vein of the selected lobe from the jugular vein and hydrodynamic injection of plasmid DNA using a newly developed computer-controlled injection device. We demonstrated that the impact of the procedure was regional with minimal effects on neighboring lobes. Level of gene expression resulted from the procedure was 10(7) relative light units (RLU)/mg in the targeted lobes and 10(2)-10(5) RLU/mg in the nontargeted lobes 4 hours after hydrodynamic injection of pCMV-Luc plasmids. Occlusion of blood flow in the inferior vena cava (IVC) or IVC plus portal vein (PV) was effective in elevating hydrodynamic pressure in the targeted vasculature but did not enhance gene delivery efficiency. Physiological examination on pigs with IVC occlusion revealed transient decreases of blood pressure and respiration rate. Removal of occlusion from IVC resulted in a rapid and transient increase in heart rate. Occlusion of the PV and hepatic vein showed no effect on physiological and cardiac activities. No major changes in serum composition were observed. These results suggest that (i) image-guided, lobe-specific hydrodynamic procedure is effective for regional gene delivery to liver, (ii) blockade in IVC should be avoided for hydrodynamic gene delivery to the liver, and (iii) clinical application of hydrodynamic gene delivery to liver is feasible.

    DOI: 10.1038/mt.2008.294

    Web of Science

    PubMed

    researchmap

  • gamma-Ray-Induced Mouse Thymic Lymphomas: Bcl11b Inactivation and Prelymphoma Cells 査読

    Ryo Kominami, Hiroyuki Ohi, Kenya Kamimura, Masaki Maruyama, Takashi Yamamoto, Ken-ichi Takaku, Shin-ichi Morita, Rieka Go, Yukio Mishima

    RADIATION HEALTH RISK SCIENCES   232 - +   2009年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)   出版者・発行元:SPRINGER  

    Bcl11b+/- heterozygous mice and Bcl11b+/-p53+/- doubly heterozygous mice showed more susceptibility to gamma-ray-induced thymic lymphomas than Bcl11b wild-type mice and p53+/- mice, respectively. Most of the thymic lymphomas developed in irradiated Bcl11b+/-p53+/- mice retained the Bcl11b wild-type allele, indicating that Bcl11b is a haploinsufficient tumor suppressor gene. Of interest is the high retention of the wild-type Bcl11b allele in those radiation-induced tumors, and this leads to the implication that the main contribution of irradiation in the Bcl11b+/-p53+/- mice is not to tumor initiation, by inducing allelic losses, but to the promotion of thymic lymphoma development. Although the reason for this unexpected high retention is unclear, an explanation might be the apoptosis given by loss of Bcl11b in the Jurkat T-cell line, because apoptosis appears to contradict the predicted property of tumor suppressors. Our chapter also shows the presence of clonally growing large thymocytes in atrophic thymuses at 40 days after irradiation. Those cells are probably prelymphoma cells because of the genetic alteration detected. However, the cell number was low, and therefore abrogation of the hindrance in cell proliferation through additional genetic and/or epigenetic changes may be a prerequisite for lymphoma development.

    Web of Science

    researchmap

  • Physical Approaches for Nucleic Acid Delivery to Liver 査読

    Kenya Kamimura, Dexi Liu

    AAPS Journal   10 ( 4 )   589 - 595   2008年12月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   出版者・発行元:SPRINGER  

    The liver is a key organ for numerous metabolic pathways and involves many inherited diseases that, although being different in their pathology, are often caused by lack or overproduction of a critical gene product in the diseased cells. In principle, a straightforward method to fix such problem is to introduce into these cells with a gene-coding sequence to provide the missing gene product or with the nucleic acid sequence to inhibit production of the excessive gene product. Practically, however, success of nucleic acid-based pharmaceutics is dependent on the availability of a method capable of delivering nucleic acid sequence in the form of DNA or RNA to liver cells. In this review, we will summarize the progress toward the development of physical methods for nucleic acid delivery to the liver. Emphasis is placed on the mechanism of action, pros, and cons of each method developed so far. We hope the information provided will encourage new endeavor to improve the current methodologies or develop new strategies that will lead to safe and effective delivery of nucleic acids to the liver.

    DOI: 10.1208/s12248-008-9067-y

    Web of Science

    PubMed

    researchmap

  • 腹膜播種と著明な脈管内発育傾向を呈した肝類上皮血管内皮腫の1例

    上村 顕也, 山本 幹, 須田 剛士, 高橋 達, 野本 実, 櫻田 淳子, 青柳 豊

    肝臓 = ACTA HEPATOLOGICA JAPONICA   49 ( 1 )   14 - 21   2008年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:社団法人 日本肝臓学会  

    症例は54歳男性.1997年に近医で画像検査上,多発性肝腫瘤と肝右葉の萎縮,変形を指摘されたが腫瘍生検の同意が得られなかったことから厳重経過観察されていた. しかし2002年7月下旬頃より黄疸,腹部膨満が出現したため精査加療目的に当科へ入院した.当院での腹腔鏡検査を含めた精査の結果,肝類上皮血管内皮腫が肝動脈,門脈,胆管を閉塞し腹膜播種から腹水貯留を生じていた.黄疸が著明で化学療法は困難で徐々に肝不全が悪化し第137病日死亡退院された. 剖検の結果,腫瘍細胞は第VIII因子,CD34陽性で肝類上皮血管内皮腫と診断し,肺転移,癌性腹膜炎を伴っていた.肝類上皮血管内皮腫は非常に稀な疾患であるが,治療困難で早期診断のため肝腫瘍の鑑別として検討すべき腫瘍と考え報告する.

    DOI: 10.2957/kanzo.49.14

    CiNii Article

    CiNii Books

    researchmap

  • Survival of Three Nonocclusive Mesenteric Ischemia Patients following Early Diagnosis by Multidetector Row Computed Tomography and Prostaglandin E1 Treatment 査読

    Kenya Kamimura, Akihiko Oosaki, Satoshi Sugahara, Shigeki Mori

    INTERNAL MEDICINE   47 ( 22 )   2001 - 2006   2008年

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:JAPAN SOC INTERNAL MEDICINE  

    Nonocclusive mesenteric ischemia (NOMI) is an acute mesenteric circulatory disorder which is characterized by spasm and narrowing of the arterial branches. In contrast to occlusive disease, early diagnosis of NOMI is difficult because of its mild symptoms, thus resulting in a high mortality rate. In this study, we report three cases who survived NOMI because of early diagnosis by multidetector row computed tomography and immediate treatment with prostaglandin E1, which is known to improve blood flow by relaxing vascular smooth muscle. We conclude that early diagnosis and treatment of NOMI with prostaglandin E1 considerably improves the prognosis of this disease.

    DOI: 10.2169/internalmedicine.47.1213

    Web of Science

    CiNii Article

    researchmap

  • Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages. 査読 国際誌

    K Kamimura, Y Mishima, M Obata, T Endo, Y Aoyagi, R Kominami

    Oncogene   26 ( 40 )   5840 - 50   2007年8月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Bcl11b/Rit1 is involved in T-cell development and undergoes chromosomal rearrangements in human T-cell leukemias. Thymocytes of Bcl11b(-/-) newborn mice exhibit apoptosis at a certain developmental stage when thymocytes re-enter into the cell-cycle. Here, we show that Bcl11b-knockdown T-cell lines, when exposed to growth stimuli, exhibited apoptosis at the S phase with concomitant decreases in a cell-cycle inhibitor, p27 and an antiapoptotic protein, Bcl-xL, owing to transcriptional repression. This repression was a likely consequence of the impairment of Sirt1, a nicotinamide adenine dinucleotide-dependent deacetylase associating with Bcl11b. Activation of the apoptotic process cleaved the mediator protein, Claspin, and inhibited phosphorylation of cell-cycle checkpoint kinase 1 (Chk1) that plays a central role in sensing and responding to incomplete replication. Bcl11b(-/-) thymocytes also failed to phosphorylate Chk1 when UV irradiated. These results implicate Bcl11b in the remedy for DNA replication stress and maintenance of genomic integrity.

    PubMed

    researchmap

  • Multi-step lymphomagenesis deduced from DNA changes in thymic lymphomas and atrophic thymuses at various times after gamma-irradiation 査読

    H. Ohi, Y. Mishima, K. Kamimura, M. Maruyama, K. Sasai, R. Kominami

    ONCOGENE   26 ( 36 )   5280 - 5289   2007年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:NATURE PUBLISHING GROUP  

    Whole-body gamma-irradiation to mice causes thymic atrophy where a population of precancerous cells with mutation can be found. Thus, clonal growth and DNA changes at Bcl11b, Ikaros, Pten, Notch1 and Myc were examined in not only thymic lymphomas but also in atrophic thymuses at various times after irradiation. Clonal expansion was detected from the distinct patterns of rearrangements at the TCR beta receptor locus in a fraction of atrophic thymuses at as early as 30 days after irradiation. This expansion may be in part owing to the rearranged TCR beta signaling because the transfer of bone marrow cells with the rearrangement and the wild-type locus into severe-combined immunodeficiency mice showed preferential growth of the rearranged thymocytes in atrophic thymus. Loss of heterozygosity (LOH) at Bcl11b and trisomy of Myc were found at high frequencies in both lymphomas and atrophic thymuses, and in contrast, LOH at Ikaros and Pten were rare in atrophic thymuses but prevalent in lymphomas. Notch1 activation was detected in lymphomas and in atrophic thymuses only at a late stage. Similar patterns of DNA changes were found in atrophic thymuses induced in Bcl11b(+/-) mice. These results suggest the order of genetic changes during lymphomagenesis, Bcl11b and Myc being at the early stage; whereas Ikaros, Pten and Notch1 at the late stage.

    DOI: 10.1038/sj.onc.1210325

    Web of Science

    PubMed

    researchmap

  • Haploinsufficiency of Bcl11b for suppression of lymphomagenesis and thymocyte development 査読

    Kenya Kamimura, Hiroyuki Ohi, Tomoyuki Kubota, Kiyoshi Okazuka, Yoshihiro Yoshikai, Yu-ichi Wakabayashi, Yutaka Aoyagi, Yukio Mishima, Ryo Kominami

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   355 ( 2 )   538 - 542   2007年4月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Recurrent chromosomal rearrangements at BCL11B are found in human hematopoietic malignancies mostly of T-cell origin. However, it is unclear how this disruption contributes to oncogenesis, because the majority of leukemias express BCL11B from an undisrupted allele. Here, we show that Bcl11b(+/-)p53(+/-) mice exhibited greater susceptibility to lymphomas than Bcl11b(+/+)p53(+/-) mice but most lymphomas retained and expressed the wild-type Bcl11b allele. This strongly suggests that Bcl11b is haplo insufficient for suppression of thymic lymphoma development in mice of the p53(+/-) background, a situation in which functional loss of only one allele confers a selective advantage for tumor growth. The haploinsufficiency is further supported by that Bcl11b(+/-) mouse embryos were impaired in thymocyte development and survival. These results indicate relevance of BCL11B aberration to human leukemogenesis. (c) 2007 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2007.02.003

    Web of Science

    PubMed

    researchmap

  • Collagenous gastritis: Endoscopic and pathologic evaluation of the nodularity of gastric mucosa 査読

    Kenya Kamimura, Masaaki Kobayashi, Rintaro Narisawa, Hidenobu Watanabe, Yuichi Sato, Terasu Honma, Atsuo Sekine, Yutaka Aoyagi

    DIGESTIVE DISEASES AND SCIENCES   52 ( 4 )   995 - 1000   2007年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:SPRINGER  

    DOI: 10.1007/s10620-006-9278-y

    Web of Science

    PubMed

    researchmap

  • 血管肉腫全身転移の1例

    上村顕也, 高橋達, 山本幹, 山際訓, 本間照, 野本実, 江部佑輔, 青柳豊

    日本消化器病学会雑誌   101 ( 2 )   183 - 187   2004年2月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.11405/nisshoshi.101.183

    Scopus

    PubMed

    CiNii Article

    researchmap

  • 胆管細胞癌を合併した自己免疫性肝炎の1剖検例

    上村 顕也, 高橋 達, 山本 幹, 佐藤 明人, 市田 隆文, 野本 実, 青柳 豊

    肝臓 = ACTA HEPATOLOGICA JAPONICA   45 ( 6 )   313 - 319   2004年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:社団法人 日本肝臓学会  

    DOI: 10.2957/kanzo.45.313

    Scopus

    researchmap

  • 腸管狭窄のため内視鏡診断が困難であった直腸低分化充実型腺癌の1例

    保屋野 真, 小林 正明, 上村 顕也, 横山 純二, 本間 照, 青柳 豊, 飯合 恒夫, 岡本 春彦, 畠山 勝義, 塩路 和彦, 味岡 洋一

    ENDOSCOPIC FORUM for digestive disease   19 ( 2 )   225,234 - 229,234   2003年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 顆粒球除去療法を施工した重症型アルコール性肝炎の1例

    上村 顕也, 小林 正明, 森 茂紀, 柳沢 善計

    肝臓   43 ( 7 )   316 - 321   2002年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:The Japan Society of Hepatology  

    症例は59歳, 女性. 大酒家. 約半年前より飲酒量が増加, 全身倦怠感, 黄疸, 下腿の浮腫, 体重増加を主訴として当院へ入院となった. 入院時現症では意識は清明であったが著明な肝腫大, 黄疸, 浮腫, 腹水徴候を認めた. 検査成績では多核白血球優位の白血球増加, 総ビリルビンの上昇, プロトロンビン時間の低下を認め重症型アルコール性肝炎と診断した. IL-6及び好中球の増加, 活性化作用を持つと考えられているIL-8が著明に上昇し, 顆粒球エラスターゼも高値を呈した. 腸管滅菌, 抗生剤投与に加えて白血球による直接的肝障害に対して顆粒球除去療法を, 高サイトカイン血症による重症化のネットワークを断つ目的で血漿交換, 血液濾過透析, ウリナスタチンの投与等を中心に治療し明らかな改善傾向を認めた. 全身状態の悪化とともに肝不全が再増悪したが, 病態の中心である白血球に対する治療が有効であり今後の治療法の検討も含め示唆に富む症例であった.

    DOI: 10.2957/kanzo.43.316

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2003017657

  • 硬化型肝細胞癌の初期画像所見を確認しえた1例

    上村顕也, 小林正明, 森茂紀, 柳沢善計, 小杉伸一, 大橋泰博, 木村格平, 野本実, 加村毅

    消化器画像   4 ( 4 )   473 - 478   2002年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医学書院  

    HBVキャリアーの50歳男.2000年の検診時に腹部エコーで指摘された肝S5の1cmの腫瘍性病変が,2001年の検診で6cm大に増大していたため精査加療目的で入院となった.腫瘍は,エコーで辺縁がlow,内部が比較的high echoicに描出され,ダイナミックCTでは早期相で辺縁が濃染,後期相にかけて中心へ向かい濃染されていく所見を呈した.肝外悪性病変は認められず,画像所見から胆管細胞癌を疑い肝右葉切除を施行した.病理組織学的所見より硬化型肝細胞癌と診断された.術後約半年経過現在,腫瘍マーカーの上昇や腫瘍の再発所見を認めていない

    DOI: 10.11477/mf.1427900437

    J-GLOBAL

    researchmap

▶ 全件表示

書籍等出版物

  • 地域発患者の診かた : 救急の技で一般外来診療は進化する

    遠藤, 直人, 上村, 顕也, 井口, 清太郎

    クリニコ出版  2022年4月  ( ISBN:9784910396194

     詳細を見る

    総ページ数:303p   記述言語:日本語

    CiNii Books

    researchmap

  • The Management of Constipation: Current Status and Future Prospects

    ( 担当: 共著 ,  範囲: Constipation)

    Intech Open  2019年 

     詳細を見る

  • Nucleic Acid-Based Therapy: Development of a Nonviral-Based Delivery Approach

    ( 担当: 共著 ,  範囲: Gene Therapy)

    Intech Open  2019年 

     詳細を見る

  • Gene Therapy and Cell Therapy Through the Liver, Chapter 8, Image-Guided Hydrodynamic Gene Delivery to the Liver: Toward Clinical Applications

    上村 顕也( 担当: 単著)

    Springer  2016年1月 

     詳細を見る

  • Advances and Challenges in the Delivery of Oligonucleotide-based Therapies, 2014 Ch 8, Hydrodynamic Gene Delivery

    上村 顕也( 担当: 共編者(共編著者))

    Future Science  2015年12月 

     詳細を見る

  • 肝血管腫の画像診断 上村顕也、青栁豊

    上村 顕也( 担当: 共著)

    医薬ジャーナル  2015年2月 

     詳細を見る

  • A Special Issue on “Diagnosis and Management of Benign Liver Tumors”, Int J Hepatology

    上村 顕也( 担当: 編集 ,  範囲: Chief Guest Editor)

    2013年 

     詳細を見る

  • Advanced Textbook on Gene Transfer, Gene Therapy and Genetic Pharmacology

    上村 顕也

    2013年 

     詳細を見る

  • 肝類上皮血管内皮腫. 新領域別症候群シリーズ

    上村 顕也( 担当: 共著 ,  範囲: 肝胆道症候群 (第2版) 肝臓編(下))

    日本臨床  2010年 

     詳細を見る

▶ 全件表示

MISC

  • 『高齢者(75歳以上)の非アルコール性脂肪性肝疾患の現状と課題』非アルコール性脂肪性肝炎を背景とした高齢者肝硬変に対する非侵襲的スコアリングシステムの有用性の検討

    坂牧 僚, 酒井 規裕, 阿部 寛幸, 横尾 健, 上村 顕也, 寺井 崇二

    日本高齢消化器病学会誌   25 ( 1 )   74 - 74   2022年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本高齢消化器病学会  

    researchmap

  • 【肝臓と他臓器相関】脂肪性肝疾患における自律神経系を介した消化管ホルモンの関与

    大脇 崇史, 上村 顕也, 永山 逸夫, 高 昌良, 名古屋 拓郎, 井上 良介, 薛 徹, 寺井 崇二

    消化器・肝臓内科   11 ( 6 )   709 - 713   2022年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • ハイドロダイナミック法の遺伝子治療への応用に向けて

    上村 顕也

    BIO Clinica   37 ( 6 )   563 - 566   2022年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)北隆館  

    遺伝子治療は、送達すべき遺伝子を生物学的に安全、効率的かつ再現性をもって生体内の臓器、組織選択的に送達する技術及びそれを可能とする方法論、医療機器の開発が必須である。我々は、ウイルスベクターや化学物質を使用せずに、水圧で遺伝子・薬物・細胞を臓器・組織内へとデリバリーする方法であるハイドロダイナミック法(Hydrodynamics-based Gene Delivery、以下HGD)に注目し、遺伝子導入の基礎研究を行なっている。小動物での遺伝子治療効果、ブタなどの大動物の肝臓・筋肉への臓器・組織特異的な遺伝子導入法の前臨床研究をおこなっており、その内容の一部についてご紹介申し上げる。(著者抄録)

    researchmap

  • 脂肪性肝疾患における自律神経系経路を介した脂質代謝制御の解明と治療薬スクリーニング

    上村 顕也, 大脇 崇史, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A254 - A254   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Relative Dose Intensityに基づく高齢者レンバチニブ投与における全生存期間の検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A302 - A302   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患の小児・成人移行期医療の課題-全人的ケアの確立を目指して 成人外来へ受診する可能性をもつ小児脂肪肝の特徴

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   63 ( Suppl.1 )   A169 - A169   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 老化と消化器がんの病態・診療 Relative Dose Intensityに注目した高齢者レンバチニブ治療の安全性と有効性

    横尾 健, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A186 - A186   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝線維化研究の進展と臨床応用 肝線維化関連遺伝子発現変化にもとづく抗線維化作用を有するリパーパシングドラッグの探索

    酒井 規裕, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A138 - A138   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 脂肪肝炎:今後の展開 自律神経経路が制御する多臓器連関の解析と脂肪肝炎制御への展開

    上村 顕也, 大脇 崇史, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A60 - A60   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝移植適応疾患の病態解明と診療展開 肝障害に伴う臓器連関による血中セロトニン濃度変化と病態の検討 肝不全の病態変化を推測するマーカーの樹立へ

    薛 徹, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A219 - A219   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 脂肪肝炎:今後の展開 自律神経経路が制御する多臓器連関の解析と脂肪肝炎制御への展開

    上村 顕也, 大脇 崇史, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A60 - A60   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝線維化研究の進展と臨床応用 肝線維化関連遺伝子発現変化にもとづく抗線維化作用を有するリパーパシングドラッグの探索

    酒井 規裕, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A138 - A138   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 老化と消化器がんの病態・診療 Relative Dose Intensityに注目した高齢者レンバチニブ治療の安全性と有効性

    横尾 健, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A186 - A186   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝移植適応疾患の病態解明と診療展開 肝障害に伴う臓器連関による血中セロトニン濃度変化と病態の検討 肝不全の病態変化を推測するマーカーの樹立へ

    薛 徹, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   119 ( 臨増総会 )   A219 - A219   2022年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • アルコール性肝硬変におけるB型肝炎ウイルス感染の発癌と予後に対する関与についての検討

    坂牧 僚, 小山 究太郎, 森田 真一, 阿部 寛幸, 上村 顕也, 高村 昌昭, 寺井 崇二

    アルコールと医学生物学   40   47 - 49   2021年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:梵天書房  

    researchmap

  • 【肝不全・肝硬変に対する再生療法-最先端の今】基礎的知見の進歩 自律神経経路を介した臓器連関と肝再生

    上村 顕也, 井上 良介, 名古屋 拓郎, 高 昌良, 大脇 崇史, 寺井 崇二

    臨床消化器内科   36 ( 13 )   1623 - 1628   2021年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

    <文献概要>生体臓器は,外界からのさまざまな刺激や病態に対し,臓器連関により恒常性を維持している.この臓器間を繋ぐ要諦の一つが自律神経経路である.これまで肝障害や肝疾患では,さまざまな細胞や液性因子,腸内細菌に焦点を当てた臓器連関の報告が中心であった.今回,自律神経経路を介した臓器連関が肝障害時の肝再生や,脂肪性肝疾患の病態に関与することが明らかとなった.このメカニズムの解明が,難治性疾患の新規治療法の開発にも結び付くと考える.

    researchmap

  • 原発性胆汁性胆管炎患者の予後を最もよく予想する治療反応性判定Criteriaについて

    木村 成宏, 高村 昌昭, 武田 信峻, 荒生 祥尚, 高綱 将史, 渡邉 雄介, 竹内 卓, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増大会 )   A698 - A698   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 有症化した症候性巨大肝嚢胞に対して、ミノサイクリン硬化療法が著効した一例

    木南 佳也, 小川 和也, 石井 壮一, 遠藤 沙織, 石川 夏生, 阿部 寛幸, 佐藤 裕樹, 坂牧 僚, 上村 顕也, 寺井 崇二

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   69回・91回   93 - 93   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • 自律神経経路を介した臓器連関と肝疾患

    上村 顕也, 大脇 崇史, 高 昌良, 永山 逸夫, 名古屋 拓郎, 井上 良介, 上野 将紀, 寺井 崇二

    日本自律神経学会総会プログラム・抄録集   74回   87 - 87   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本自律神経学会  

    researchmap

  • 有症化した症候性巨大肝嚢胞に対して、ミノサイクリン硬化療法が著効した一例

    木南 佳也, 小川 和也, 石井 壮一, 遠藤 沙織, 石川 夏生, 阿部 寛幸, 佐藤 裕樹, 坂牧 僚, 上村 顕也, 寺井 崇二

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   69回・91回   93 - 93   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • 原発性胆汁性胆管炎患者の予後を最もよく予想する治療反応性判定Criteriaについて

    木村 成宏, 高村 昌昭, 武田 信峻, 荒生 祥尚, 高綱 将史, 渡邉 雄介, 竹内 卓, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増大会 )   A698 - A698   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 急性肝障害からの回復の予測バイオマーカーとしての血中セロトニン測定の意義

    薛 徹, 上村 顕也, 大脇 崇史, 荒生 祥尚, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   62 ( Suppl.2 )   A536 - A536   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 【膵癌研究最前線】膵臓選択的ハイドロダイナミック遺伝子導入法

    柴田 理, 上村 顕也, 田中 裕登, 小川 光平, 阿部 寛幸, 五十嵐 聡, 横尾 健, 寺井 崇二

    消化器・肝臓内科   10 ( 3 )   342 - 346   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 潜在性肝性脳症は水素型SIBOに関連し、その治療にはリファキシミンが有効である

    坂牧 僚, 横山 邦彦, 高橋 一也, 成瀬 匠, 冨永 顕太郎, 佐藤 裕樹, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   27 ( 3 )   176 - 176   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • BRTO中に出血を来し、NBCAによるEISを併用し治療を完遂した十二指腸静脈瘤の1例

    前田 悠一郎, 荒生 祥尚, 小島 雄一, 川田 雄三, 渡邉 雄介, 薛 徹, 阿部 寛幸, 坂牧 僚, 上村 博輝, 横尾 健, 土屋 淳紀, 上村 顕也, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   27 ( 3 )   134 - 134   2021年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • ヨード造影剤で増悪したDuhring疱疹状皮膚炎の1例

    筒井 由夏, 長谷川 瑛人, 内田 梢太, 平山 香菜, 武居 慎吾, 石渡 彩乃, 佐藤 亜美, 加畑 雄大, 林 良太, 藤川 大基, 阿部 理一郎, 坂牧 僚, 上村 顕也, 冨樫 きょう子

    日本皮膚科学会雑誌   131 ( 8 )   1883 - 1883   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本皮膚科学会  

    researchmap

  • 被包化膵壊死への真菌感染による敗血症性ショックをきたした一例

    山田 麻理奈[大越], 上村 顕也, 石川 夏生, 小関 洋平, 田中 裕登, 水澤 健, 佐藤 裕樹, 五十嵐 聡, 林 和直, 坂牧 僚, 横山 純二, 寺井 崇二

    ENDOSCOPIC FORUM for digestive disease   37 ( 1 )   30 - 30   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 高齢者消化器がん化学療法〜高齢者のがん治療を安全・効果的に遂行するための取り組み 高齢肝細胞癌症例における分子標的治療薬の生存期間延長効果と予測因子の検討

    横尾 健, 酒井 規裕, 渡邉 雄介, 荒生 祥尚, 木村 成宏, 阿部 寛幸, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    日本高齢消化器病学会誌   24 ( 1 )   115 - 115   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(NPO)日本高齢消化器病学会  

    researchmap

  • point shear wave elastographyを利用した肝線維化のheterogeneityの検証

    横尾 健, 杉田 萌乃, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    超音波医学   48 ( Suppl. )   S713 - S713   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

  • 肝癌に対する局所療法としての放射線療法の安全性と有効性の検証

    山田 麻理奈, 上村 顕也, 柴田 理, 森田 真一, 寺井 崇二

    肝臓   62 ( Suppl.1 )   A338 - A338   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 多発肝転移、リンパ節転移を伴う直腸原発神経内分泌腫瘍に対して集学的治療が有効であった一例 当院での症例群の検討と共に

    小川 和也, 阿部 寛幸, 上村 顕也, 寺井 崇二

    肝臓   62 ( Suppl.1 )   A266 - A266   2021年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝発癌抑制を目指したB型肝炎の最新治療 肝細胞癌におけるYAPとHBx蛋白の臨床的有用性の検討

    小田 知友美, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増総会 )   A73 - A73   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 【小児期発症慢性肝疾患における移行期医療の現状と課題-小児と成人のダイアログ-】NAFLD Pediatric fatty liver disease(PeFLD)における概説と成人との比較(肝組織学的検討を含めて) 小児と成人の相違

    上村 博輝, 山崎 文紗子, 佐藤 毅昂, 薛 徹, 土屋 淳紀, 上村 顕也, 高村 昌昭, 寺井 崇二, 長崎 啓祐, 斎藤 昭彦, 梅津 哉

    肝胆膵   82 ( 3 )   425 - 440   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 消化器疾患と神経系の臓器相関 脂肪性肝疾患における自律神経系ネットワークを介したセロトニンの関与

    大脇 崇史, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増総会 )   A144 - A144   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 胆膵疾患研究の最前線〜from bench to bedside, from bedside to bench〜 膵臓選択的ハイドロダイナミック遺伝子導入法による新規膵癌モデル動物の確立

    柴田 理, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   118 ( 臨増総会 )   A232 - A232   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • アルコール性肝硬変におけるALD/NAFLD Index低値例の臨床的特徴

    坂牧 僚, 横山 邦彦, 森田 真一, 上村 顕也, 高村 昌昭, 寺井 崇二

    アルコールと医学生物学   39   96 - 97   2020年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)響文社  

    researchmap

  • 進行肝細胞癌に対する集学的治療:エビデンスとコンセンサス 肝癌に対する放射線治療の安全性と有用性の検討

    上村 顕也, 大越 麻理奈, 寺井 崇二

    肝臓   61 ( Suppl.3 )   A811 - A811   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 脂肪性肝疾患:治療のターゲットとゴール 脂肪性疾患の病態進行と自律神経ネットワークを介する臓器連関の関与

    上村 顕也, 大脇 崇史, 寺井 崇二

    肝臓   61 ( Suppl.3 )   A758 - A758   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • MC4R遺伝子及びMaid遺伝子両欠損マウスを用いた新規脂肪肝モデルマウスの検討

    森田 真一, 坂牧 僚, 永山 逸夫, 大越 麻理奈, 小山 究太郎, 田中 裕登, 大脇 崇史, 小田 知友美, 柴田 理, 木村 淳史, 阿部 寛幸, 上村 顕也, 寺井 崇二

    肝臓   61 ( Suppl.3 )   A876 - A876   2020年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝性脳症〜わが国における現状と課題〜 潜在性肝性脳症患者における呼気中水素・メタン分析の有用性の検討

    坂牧 僚, 横山 邦彦, 小山 究太郎, 森田 真一, 阿部 寛幸, 上村 顕也, 高村 昌昭, 横山 純二, 寺井 崇二

    日本門脈圧亢進症学会雑誌   26 ( 3 )   76 - 76   2020年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 肝臓を基軸とした臓器連関 肝臓を基軸とし自律神経系経路を介する多臓器連関の肝病態への関与の解明

    上村 顕也, 大脇 崇史, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A613 - A613   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 脂肪性肝疾患における自律神経系ネットワークを介したセロトニンの関与

    大脇 崇史, 上村 顕也, 高 昌良, 名古屋 拓郎, 永山 逸夫, 大越 麻理奈, 薛 徹, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A670 - A670   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • mALBI score/gradeからみたNASH薬物治療に対する肝予備能への影響

    高村 昌昭, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A691 - A691   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 健診受検者における年齢層別NAFLDの解析と高齢者の意識変化

    横尾 健, 佐藤 公俊, 丹羽 佑輔, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A671 - A671   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • mALBI score/gradeからみたNASH薬物治療に対する肝予備能への影響

    高村 昌昭, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A691 - A691   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 2D-Shear Wave ElastographyとTransient Elastographyの乖離症例の特徴

    杉田 萌乃, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A695 - A695   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 2D-Shear Wave ElastographyとTransient Elastographyの乖離症例の特徴

    杉田 萌乃, 横尾 健, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A695 - A695   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 健診受検者における年齢層別NAFLDの解析と高齢者の意識変化

    横尾 健, 佐藤 公俊, 丹羽 佑輔, 荒生 祥尚, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   61 ( Suppl.2 )   A671 - A671   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝癌分子標的薬治療時の鰹だし併用による肝予備能維持効果

    小関 洋平, 上村 顕也, 坂牧 僚, 大越 麻理奈, 田中 裕登, 寺井 崇二

    日本消化器病学会雑誌   117 ( 臨増総会 )   A296 - A296   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝癌治療に対する内科外科のすみわけと連携における放射線治療の役割

    上村 顕也, 柴田 理, 大越 麻理奈, 寺井 崇二

    日本消化器病学会雑誌   117 ( 臨増総会 )   A292 - A292   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 非アルコール性脂肪性肝疾患(NAFLD)の病態進行における自律神経を介した臓器間ネットワークの関与

    高 昌良, 上村 顕也, 名古屋 拓郎, 酒井 規裕, 坂牧 僚, 横尾 健, 寺井 崇二

    日本門脈圧亢進症学会雑誌   26 ( 2 )   143 - 146   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    【目的】非アルコール性脂肪性肝疾患(non-alcoholic fatty liver disease、NAFLD)は肝不全の一病態として重要な治療対象である。これまでに我々は肝障害時の肝再生に自律神経を介した消化管ホルモンの活性化の重要性を明らかにした。本研究では、NAFLDモデルマウスを対象として、その病態への神経ネットワークの関与および治療対象としての可能性を検討することを目的とした。【方法】NAFLDモデルマウスとして、コリン欠乏・メチオニン減量(CDAA)食給餌モデルと高脂肪食(HFD)給餌モデルを対象として、肝臓からの求心性内臓神経、迷走神経肝臓枝の遮断を行い、消化管ホルモン、腸内細菌叢への影響を評価した。【成績】CDAA食給餌モデルで彼からのグレリン分泌の活性化を認めたが、神経遮断により抑制され、NAFLDの進行抑制効果を認めた。また、両モデルで神経遮断により腸内細菌叢の構成が変化した。【結語】神経ネットワークへの介入が消化管ホルモン、腸内細菌叢に影響を与え、NAFLDの進行を抑制することが明らかとなった。(著者抄録)

    researchmap

  • 臨床応用に向けた肝癌の病態解明 放射線照射によるDNA損傷時のHHMの役割

    丹羽 佑輔, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   117 ( 臨増総会 )   A161 - A161   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 消化器疾患における共生微生物叢研究の新たな知見 NAFLDの病態における自律神経ネットワークを介した腸内細菌叢の関与

    高 昌良, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   117 ( 臨増総会 )   A78 - A78   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 臓器間ネットワークと肝疾患 自律神経経路を介する肝-脳-消化管軸の非アルコール性脂肪肝炎の病態への関与

    上村 顕也, 大脇 崇史, 寺井 崇二

    肝臓   61 ( Suppl.1 )   A182 - A182   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝発癌進展研究の最前線 肝発癌,治療抵抗性にかかわるHHM遺伝子のDNA損傷応答メカニズムの解析

    上村 顕也, 丹羽 佑輔, 寺井 崇二

    肝臓   61 ( Suppl.1 )   A44 - A44   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝疾患における移行期医療 小児NAFLD患者の背景疾患と移行医療への課題

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   61 ( Suppl.1 )   A142 - A142   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝癌に対する局所療法としての放射線療法の安全性と有効性の検証

    大越 麻理奈, 上村 顕也, 柴田 修, 森田 慎一, 坂牧 僚, 田中 裕登, 小関 洋平, 寺井 崇二

    日本内科学会雑誌   109 ( Suppl. )   155 - 155   2020年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • ハイドロダイナミック遺伝子導入法による肝線維化・肝癌に対する遺伝子治療研究

    上村顕也, 横尾健, 阿部寛幸, 三浦浩美, 大塚正人, 尾田雅文, 仁科博史, 寺井崇二

    肝細胞研究会プログラム・抄録集   27th   2020年

     詳細を見る

  • ハイドロダイナミクス法によるマウス肝臓でのCRISPRゲノム編集の最適条件の探索

    今福樹来, 黒崎亜希, 岡田千沙, 亀山洋子, 上村顕也, LIU Dexi, 三浦浩美, 大塚正人

    日本分子生物学会年会プログラム・要旨集(Web)   43rd   2020年

     詳細を見る

  • 有腹水肝硬変症例に対するtolvaptan投与前後のM2BPGiの経時的変化とその臨床的意義

    高村 昌昭, 坂牧 僚, 寺井 崇二, 上村 博輝, 土屋 淳紀, 薛 徹, 上村 顕也, 横尾 健

    肝臓   60 ( Suppl.3 )   A936 - A936   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • NASHの病態への臓器間ネットワークの関与

    高 昌良, 上村 顕也, 名古屋 拓郎, 井上 良介, 酒井 規裕, 丹羽 祐輔, 坂牧 僚, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増大会 )   A846 - A846   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝癌の局所制御及び集学的治療法としての放射線治療の検討

    上村 顕也, 柴田 理, 寺井 崇二

    肝臓   60 ( Suppl.3 )   A875 - A875   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • IgG4関連硬化性胆管炎の一例

    中村 涼太, 田中 裕登, 大越 麻里奈, 小関 洋平, 水澤 健, 五十嵐 聡, 林 和直, 佐藤 裕樹, 坂牧 僚, 上村 顕也, 横山 純二, 寺井 崇二

    日本消化器病学会甲信越支部例会抄録集   65回   81 - 81   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • 肝硬度測定を用いたICG検査の代替の試み

    熊谷 優, 横尾 健, 佐藤 毅昂, 茂木 聡子, 川田 雄三, 薛 徹, 水野 研一, 木村 成宏, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増大会 )   A849 - A849   2019年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • マウス肝線維化進展予防薬の探索及びレトロゾールによる線維化進展予防効果の検証

    酒井 規裕, 上村 顕也, 名古屋 拓郎, 丹羽 佑輔, 高 昌良, 薛 徹, 横尾 健, 坂牧 僚, 榎本 初音, 立木 秀尚, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A680 - A680   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • アルコール性肝硬変の予後における、るいそうおよび肥満の影響

    坂牧 僚, 横山 邦彦, 上村 顕也, 高村 昌昭, 寺井 崇二

    肥満研究   25 ( Suppl. )   304 - 304   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肥満学会  

    researchmap

  • 肝癌に対する分子標的治療中のヒスチジンによる肝予備能維持効果と副作用予防

    上村 顕也, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A674 - A674   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • NASHモデルマウスにおける自律神経系を介したグレリンの関与

    名古屋 拓郎, 上村 顕也, 井上 良介, 酒井 規裕, 後藤 諒, 高 昌良, 丹羽 佑輔, 坂牧 僚, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A682 - A682   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝臓病理の臨床への貢献と次世代への飛躍を目指して 小児NAFLD患者の臨床スコアの動態とSerial Biopsyによる知見

    上村 博輝, 上村 顕也, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A607 - A607   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 高齢者におけるFIB-4 indexの特徴

    横尾 健, 薛 徹, 上村 博輝, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   60 ( Suppl.2 )   A696 - A696   2019年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝硬変を背景とした門脈血栓に対する治療戦略の検討

    茂木聡子, 横尾健, 熊谷優, 薛徹, 坂牧僚, 上村博輝, 上村顕也, 土屋淳紀, 高村昌昭, 寺井崇二

    日本門脈圧亢進症学会雑誌   25 ( 3 )   71 - 71   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    J-GLOBAL

    researchmap

  • 非ウイルス性肝硬変時代の門亢症〜ウイルス性との共通点・相違点を中心に〜 原発性胆汁性胆管炎における食道・胃静脈瘤の検討

    薛 徹, 横山 純二, 高綱 将史, 荒生 祥尚, 上村 輝博, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本門脈圧亢進症学会雑誌   25 ( 3 )   110 - 110   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 門亢症に伴う慢性肝不全の臓器関連〜脳・腎・腸〜 NASHの病態進行との自律神経を介した臓器間ネットワークの関与

    高 昌良, 上村 顕也, 名古屋 拓郎, 大脇 崇史, 井上 良介, 酒井 規裕, 丹羽 祐輔, 坂牧 僚, 横尾 健, 寺井 崇二

    日本門脈圧亢進症学会雑誌   25 ( 3 )   77 - 77   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 非ウイルス性肝硬変時代の門亢症〜ウイルス性との共通点・相違点を中心に〜 原発性胆汁性胆管炎における食道・胃静脈瘤の検討

    薛 徹, 横山 純二, 高綱 将史, 荒生 祥尚, 上村 輝博, 坂牧 僚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本門脈圧亢進症学会雑誌   25 ( 3 )   110 - 110   2019年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • FDG-PETが重粒子線治療の効果判定に有用であった、若年者切除不能肝内胆管癌の1例

    渡邉 緑, 柴田 理, 上村 顕也, 安住 里映, 渋谷 圭, 大野 達也, 寺井 崇二

    日本消化器病学会甲信越支部例会抄録集   64回   34 - 34   2019年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • 当院における小腸カルチノイド7例の臨床的検討

    冨永 顕太郎, 川田 雄三, 本田 穣, 上村 顕也, 横山 純二, 寺井 崇二, 田島 陽介, 中野 雅人, 島田 能史, 亀山 仁史, 若井 俊文, アネコフ・アレクセイ, 味岡 洋一, 阿部 達也, 梅津 哉, 岩渕 三哉

    日本大腸肛門病学会雑誌   72 ( 5 )   348 - 348   2019年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本大腸肛門病学会  

    researchmap

  • 当院における高齢発症原発性胆汁性胆管炎患者の予後予測マーカーについて

    高村 昌昭, 木村 成宏, 薛 徹, 上村 博輝, 坂牧 僚, 横尾 健, 土屋 淳紀, 上村 顕也, 松田 康伸, 寺井 崇二

    肝臓   60 ( Suppl.1 )   A407 - A407   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • メダカを用いた食品・医薬品の機能性評価基盤の構築 メダカモデルを用いた薬物スクリーニングと医学研究応用

    寺井 崇二, 上村 顕也

    日本栄養・食糧学会大会講演要旨集   73回   174 - 174   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本栄養・食糧学会  

    researchmap

  • NASH/NAFLDの病態解明に向けた基礎的検討 NASH/NAFLDの病態における自律神経を介した消化管ホルモンの関与

    上村 顕也, 名古屋 拓郎, 寺井 崇二

    肝臓   60 ( Suppl.1 )   A146 - A146   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝癌診療ガイドライン2017を再検証する 肝癌に対する放射線治療の検討

    上村 顕也, 柴田 理, 寺井 崇二

    肝臓   60 ( Suppl.1 )   A132 - A132   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 免疫チェックポイント阻害薬による免疫関連有害事象と考えられる肝障害を呈した2例

    坂牧 僚, 上村 顕也, 寺井 崇二

    肝臓   60 ( Suppl.1 )   A488 - A488   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝癌に対する分子標的薬の有害事象の発症予測

    上村 顕也, 寺井 崇二

    肝臓   60 ( Suppl.1 )   A487 - A487   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当院における高齢発症原発性胆汁性胆管炎患者の予後予測マーカーについて

    高村 昌昭, 木村 成宏, 薛 徹, 上村 博輝, 坂牧 僚, 横尾 健, 土屋 淳紀, 上村 顕也, 松田 康伸, 寺井 崇二

    肝臓   60 ( Suppl.1 )   A407 - A407   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当院における肝癌に対する放射線治療の検討

    柴田 理, 上村 顕也, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 高村 昌昭, 丸山 克也, 太田 篤, 海津 元樹, 青山 英史, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A456 - A456   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 高齢肝癌症例におけるソラフェニブの効果と有用性

    横尾 健, 森田 真一, 木村 成宏, 薛 徹, 坂牧 僚, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A413 - A413   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 高齢肝癌症例におけるソラフェニブの効果と有用性

    横尾 健, 森田 真一, 木村 成宏, 薛 徹, 坂牧 僚, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A413 - A413   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • メタボリックシンドロームとしての脂肪肝 SGLT2阻害薬によるNASH進展抑制効果の検証 メダカNASHモデルを用いて

    上村 顕也, 後藤 諒, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A142 - A142   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝線維化研究の展開と臨床応用 マウス肝線維化進展予防薬の探索及びレトロゾールによる線維化進展予防効果の検証

    酒井 規裕, 上村 顕也, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A214 - A214   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当院における肝癌に対する放射線治療の検討

    柴田 理, 上村 顕也, 木村 成宏, 薛 徹, 横尾 健, 坂牧 僚, 上村 博輝, 土屋 淳紀, 高村 昌昭, 丸山 克也, 太田 篤, 海津 元樹, 青山 英史, 寺井 崇二

    日本消化器病学会雑誌   116 ( 臨増総会 )   A456 - A456   2019年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 放射線照射によるDNA損傷時のHHMの機能解析

    丹羽佑輔, 上村顕也, 小川光平, 高昌良, 酒井規裕, 名古屋拓郎, 坂牧僚, 横尾健, 高見太郎, 山本直樹, 坂井田功, 寺井崇二

    肝細胞研究会プログラム・抄録集   26th   2019年

     詳細を見る

  • 当院における小腸カルチノイド7例の臨床的検討

    冨永顕太郎, 川田雄三, 本田穣, 上村顕也, 横山純二, 寺井崇二, 田島陽介, 中野雅人, 島田能史, 亀山仁史, 若井俊文, アネコフ アレクセイ, 味岡洋一, 阿部達也, 梅津哉, 岩渕三哉

    日本大腸肛門病学会雑誌(Web)   72 ( 5 )   2019年

     詳細を見る

  • ダブルバルーン内視鏡で診断に至った消化管重複症の成人例

    丹羽佑輔, 上村顕也, 小林隆昌, 高橋一也, 冨永顕太郎, 河久順志, 阿部聡司, 川合弘一, 横山純二, 杉野英明, 梅津哉, 寺井崇二

    Endoscopic Forum for Digestive Disease   35 ( 1 )   44 - 44   2019年

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    J-GLOBAL

    researchmap

  • 当院における肝癌に対する分子標的薬治療の安全性と有効性の検討

    森田真一, 上村顕也, 坂牧僚, 柴田理, 水澤健, 佐藤裕樹, 寺井崇二

    日本内科学会雑誌   108 ( Suppl. )   259 - 259   2019年

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    J-GLOBAL

    researchmap

  • 手足症候群に対するヒスチジンの効果

    上村 顕也, 品川 陽子, 後藤 諒, 横尾 健, 坂牧 僚, 上村 博輝, 阿部 聡司, 寺井 崇二

    The Liver Cancer Journal   10 ( Suppl.2 )   25 - 26   2018年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)メディカルレビュー社  

    researchmap

  • C型肝炎SVR後に退縮した多発性限局性脂肪肝の1例

    酒井規裕, 上村顕也, 冨永顕太郎, 坂牧僚, 水野研一, 寺井崇二

    肝臓   59 ( Supplement 3 )   A983 - A983   2018年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • Pembrolizumabによる二次性硬化性胆管炎が疑われた一例

    小川光平, 上村顕也, 阿部聡司, 高昌良, 冨永顕太郎, 河久順志, 五十嵐聡, 林和直, 坂牧僚, 水野研一, 横山純二, 寺井崇二

    肝臓   59 ( Supplement 3 )   A990 - A990   2018年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • 肝疾患と臓器相関 肝疾患における自律神経による臓器間ネットワークの関与

    上村 顕也, 名古屋 拓郎, 寺井 崇二

    肝臓   59 ( Suppl.3 )   A862 - A862   2018年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • ダブルバルーン内視鏡で診断に至った消化管重複症の成人例

    丹羽 佑輔, 上村 顕也, 小林 隆昌, 高橋 一也, 冨永 顕太郎, 河久 順志, 阿部 聡司, 川合 弘一, 横山 純二, 杉野 英明, 梅津 哉, 寺井 崇二

    日本消化器病学会甲信越支部例会・日本消化器内視鏡学会甲信越支部例会抄録集   63回・85回   59 - 59   2018年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    researchmap

  • Classification of Heterogeneous Hepatocellular Carcinoma Using Four Hepatic Progenitor Cell Markers and Three Serum Tumor Markers

    Atsunori Tsuchiya, Satoshi Seino, Yuichi Kojima, Naruhiro Kimura, Toru Setsu, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Kenya Kamimura, Masaaki Takamura, Shuji Terai

    HEPATOLOGY   68   545A - 546A   2018年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • NASHモデルマウスにおける自律神経系を介した消化管ホルモンの関与

    名古屋 拓郎, 上村 顕也, 井上 良介, 酒井 規裕, 後藤 諒, 高 昌良, 丹羽 佑輔, 坂牧 僚, 中村 由香, 上野 将紀, 寺井 崇二

    日本消化器病学会雑誌   115 ( 臨増大会 )   A732 - A732   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • フレイルとサルコペニアについて 進行消化器癌における体組成と予後との関連

    川合 弘一, 小林 隆昌, 中野 応央樹, 五十嵐 聡, 河久 順志, 阿部 聡司, 上村 博輝, 坂牧 僚, 林 和直, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    新潟医学会雑誌   132 ( 10 )   350 - 352   2018年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    近年、様々な疾患で体組成が病態や予後と関連していることが報告されている。我々の検討で、経動脈的治療を行った進行肝細胞癌症例のうち、骨格筋の6ヵ月間変化率が-4.6%未満の症例は予後不良であることが明らかとなった。また低皮下脂肪量も予後不良因子の一つであることを見出した。膵癌非切除例においては、内臓脂肪量が1ヵ月間で大きく減少した群で予後不良だった。進行消化器癌においては体組成、特にその変化率と予後が密接に関連していることが示唆された。(著者抄録)

    researchmap

    その他リンク: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2018&ichushi_jid=J00990&link_issn=&doc_id=20200305060005&doc_link_id=%2Fdg3nigta%2F2018%2F013210%2F005%2F0350-0352%26dl%3D0&url=http%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdg3nigta%2F2018%2F013210%2F005%2F0350-0352%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  • 消化管疾患と肝疾患の関連-消化管・肝臓間の相互の影響- 自律神経線維による肝,脳,腸の臓器間ネットワークを介した肝切除後の肝再生メカニズムの検討

    上村 顕也, 寺井 崇二

    肝臓   59 ( Suppl.2 )   A609 - A609   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • マウス肝線維化進展予防薬の探索及び効果の検証

    酒井 規裕, 上村 顕也, 後藤 諒, 小川 光平, 坂牧 僚, 阿部 聡司, 榎本 初音, 立木 秀尚, 寺井 崇二

    肝臓   59 ( Suppl.2 )   A723 - A723   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 左肺上葉切除2ヵ月後に発症した胃間膜軸性捻転の1例

    荒生 祥尚, 池見 雅俊, 高木 将之, 清野 智, 阿部 寛幸, 小柳 英人, 岩城 孝和, 親松 学, 佐藤 賢治, 上村 顕也, 寺井 崇二

    ENDOSCOPIC FORUM for digestive disease   34 ( 1 )   25 - 30   2018年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    肺葉切除後に胃間膜軸性捻転を来し、内視鏡的整復が困難であった1例を報告する。症例は80歳代、男性。以前より滑脱型の食道裂孔ヘルニアを指摘されていた。左肺腺癌に対して左肺上葉切除を施行された2ヵ月後に左胸腹痛を自覚し、造影CTで食道裂孔ヘルニアの悪化と周囲に腹水出現を認めたため入院した。保存的治療で症状は改善したが、食事再開に伴い再度症状が悪化した。造影CTでは胃が短軸性に捻転している所見を認めた。内視鏡的整復を試みたが困難であり、外科的にヘルニア修復および胃壁固定術を施行し、以後、再発なく軽快している。特発性胃軸捻転症は内視鏡的整復成功例が散見されるが、二次性胃軸捻転症では癒着などのため困難なことが多い。本症例も肺葉切除後の二次性胃軸捻転症として、内視鏡的整復術を施行するも困難であった。(著者抄録)

    J-GLOBAL

    researchmap

  • 臨床応用可能な肝臓選択的核酸医薬送達法の確立

    上村顕也, 横尾健, 寺井崇二

    Bio Clinica   33 ( 1 )   34‐38   2018年1月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • レンバチニブが著効した,肝細胞癌,多発肺転移の1例

    柴田理, 上村顕也, 酒井規裕, 森田真一, 水澤健, 佐藤裕樹, 坂牧僚, 寺井崇二

    日本消化器病学会甲信越支部例会抄録集   63rd   85 - 85   2018年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-甲信越支部  

    J-GLOBAL

    researchmap

  • 遺伝子治療の現況と新規遺伝子治療法開発に向けた基礎及び臨床研究

    上村顕也

    新潟県医師会報   ( 813 )   2‐8   2017年12月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Intraductal Papillary Neoplasm of the Bile Duct: A Rare Liver Tumor Complicated by Malignancy

    Kentaro Tominaga, Kenya Kamimura, Akira Sakamaki, Shuji Terai

    HEPATOLOGY   66 ( 5 )   1695 - 1697   2017年11月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY  

    DOI: 10.1002/hep.29266

    Web of Science

    researchmap

  • Long-term Gene Expression and Effective Prevention of Liver Fibrosis by Liver-Specific Delivery of Oligonucleotide Therapeutics

    Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Yuji Kobayashi, Norihiro Sakai, Takuro Nagoya, Ryo Goto, Akira Sakamaki, Satoshi Abe, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   66   368A - 369A   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Human Homologue of Maid contributes to DNA damage response pathway in HCC.

    Kohei Ogawa, Kenya Kamimura, Ryo Goto, Ryosuke Inoue, Yoko Shinagawa, Yuji Kobayashi, Hiroyuki Abe, Satoshi Abe, Akira Sakamaki, Takeshi Yokoo, Hirokazu Kawai, Satoshi Yamagiwa, Taro Takami, Naoki Yamamoto, Isao Sakaida, Shuji Terai

    HEPATOLOGY   66   373A - 373A   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Live image and mechanistic analysis of Mesenchymal stem cells (MSCs) and induced bone marrow derived macrophages (id-BMMs) combination therapy for liver cirrhosis in mice 査読

    Yusuke Watanabe, Atsunori Tsuchiya, Satoshi Seino, Syunzou Ikarashi, Suguru Takeuchi, Takayuki Watanabe, Kenya Kamimura, Masaaki Takamura, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   66   76A - 76A   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Usefulness of follicular helper T cell subset frequencies in the diagnosis of autoimmune hepatitis 査読

    Naruhiro Kimura, Satoshi Yamagiwa, Ryoko Horigome, Hiroteru Kamimura, Kenya Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Shuji Terai

    HEPATOLOGY   66   687A - 688A   2017年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • 肝外転移を伴う肝細胞癌の予後予測因子の検討

    竹内 卓, 高村 昌昭, 阿部 聡司, 坂牧 僚, 上村 顕也, 土屋 淳紀, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   58 ( Suppl.2 )   A608 - A608   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • NAFLDにおけるイベント発生の前方視的検討

    川合 弘一, 松田 康伸, 阿部 聡司, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 石川 達, 山際 訓, 杉谷 想一, 渡辺 雅史, 寺井 崇二

    日本消化器病学会雑誌   114 ( 臨増大会 )   A769 - A769   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • HHMの肝発癌における分子生物学的メカニズムの解明

    小川 光平, 上村 顕也, 後藤 諒, 井上 良介, 品川 陽子, 酒井 規裕, 名古屋 拓郎, 小林 雄司, 阿部 寛幸, 阿部 聡司, 坂牧 僚, 横尾 健, 川合 弘一, 山際 訓, 高見 太郎, 山本 直樹, 坂井田 功, 寺井 崇二

    日本消化器病学会雑誌   114 ( 臨増大会 )   A732 - A732   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Serial liver biopsiesで確定診断に至った自己免疫性急性肝不全の一例

    上村 博輝, 山際 訓, 中島 尚, 菅野 智之, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 野本 実, 梅津 哉, 岩崎 友洋, 小方 則夫, 寺井 崇二

    肝臓   58 ( 6 )   373 - 374   2017年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性肝疾患のそう痒症に対するナルフラフィン塩酸塩の長期的効果と安全性の検証

    上村 顕也, 横尾 健, 上村 博輝, 坂牧 僚, 阿部 聡司, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   58 ( Suppl.1 )   A462 - A462   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝動脈化学塞栓療法/肝動注化学療法にて治療した肝細胞癌患者におけるL3SMI6ヵ月間変化率による予後解析

    小林 隆昌, 川合 弘一, 中野 応央樹, 阿部 聡司, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 寺井 崇二

    肝臓   58 ( Suppl.1 )   A342 - A342   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝前駆細胞マーカー陽性肝細胞癌の臨床的特徴とAFP-L3分画を用いた拾い上げの可能性の検討

    清野 智, 土屋 淳紀, 小島 雄一, 渡邉 雄介, 阿部 聡司, 坂牧 僚, 上村 顕也, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   58 ( Suppl.1 )   A268 - A268   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • HHMはDNA損傷ストレスに対する応答機構を介して肝発癌抑制に寄与する

    小川 光平, 上村 顕也, 後藤 諒, 井上 良介, 品川 陽子, 阿部 寛幸, 阿部 聡司, 坂牧 僚, 横尾 健, 川合 弘一, 山際 訓, 高見 太郎, 山本 直樹, 坂井田 功, 寺井 崇二

    肝臓   58 ( Suppl.1 )   A448 - A448   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 高齢肝細胞癌患者における予後と治療アルゴリズム有用性について

    高村 昌昭, 川合 弘一, 寺井 崇二, 阿部 聡司, 坂牧 僚, 土屋 淳紀, 上村 顕也, 山際 訓

    日本消化器病学会雑誌   114 ( 臨増総会 )   A389 - A389   2017年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma 査読

    Kenya Kamimura, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Toru Ishikawa, Takeshi Suda, Satoshi Yamagiwa, Shuji Terai

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   31   361 - 361   2016年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • IFN関連精神症状と診断された既往があり、DAA治療中にも精神症状を呈したC型慢性肝炎の1例

    坂牧 僚, 上村 顕也, 酒井 規裕, 冨永 顕太郎, 阿部 聡司, 水野 研一, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   57 ( Suppl.3 )   A772 - A772   2016年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Combination therapy with mesenchymal stem cells and macrophages from bone marrow shows favorable outcome in mouse CCl4-induced liver cirrhosis model

    Yusuke Watanabe, Atsunori Tsuchiya, Yuichi Kojima, Satoshi Seino, Kenya Kamimura, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   64   841A - 841A   2016年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Development of Image-guided, Liver Lobe-specific Hydrodynamic Gene Delivery Method for Gene Therapy in Liver Diseases

    Kenya Kamimura, Takeshi Yokoo, Hiroyuki Abe, Yuji Kobayashi, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   64   271A - 271A   2016年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Frequency of CCR7(-)PD-1(+) follicular helper T cell subset as a possible diagnostic marker of autoimmune hepatitis

    Satoshi Yamagiwa, Naruhiro Kimura, Ryoko Horigome, Tomoyuki Sugano, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Hirokazu Kawai, Shuji Terai

    HEPATOLOGY   64   822A - 822A   2016年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Platinum-based transhepatic arterial chemotherapy using a combination of miriplatin and CDDP powder in patients with hepatocellular carcinoma 査読

    Kohei Ogawa, Kenya Kamimura, Takeshi Suda, Takeshi Yokoo, Akira Sakamaki, Satoshi Abe, Hiroteru Kamimura, Atsunori Tsuchiya, Masaaki Takamura, Hirokazu Kawai, Nobuo Waguri, Toru Ishikawa, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   64   652A - 652A   2016年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • Significance of hepatic progenitor cell marker-positive hepatocellular carcinoma and its possible prediction by AFP-L3 査読

    Atsunori Tsuchiya, Yuichi Kojima, Satoshi Seino, Yusuke Watanabe, Kenya Kamimura, Masaaki Takamura, Hirokazu Kawai, Satoshi Yamagiwa, Shuji Terai

    HEPATOLOGY   64   669A - 670A   2016年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:WILEY  

    Web of Science

    researchmap

  • 進行肝細胞癌に対するアイエーコールとミリプラの併用肝動注療法の意義 多施設共同研究による第II相試験

    上村 顕也, 横尾 健, 坂牧 僚, 阿部 聡司, 上村 博輝, 兼藤 努, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 須田 剛士, 和栗 暢生, 石川 達, 寺井 崇二

    肝臓   57 ( Suppl.2 )   A560 - A560   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 内臓脂肪と皮下脂肪のCT断面積によるTACE・TAIにて治療された肝細胞癌患者の予後解析

    小林 隆昌, 川合 弘一, 中野 応央樹, 阿部 聡司, 坂牧 僚, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 寺井 崇二

    肥満研究   22 ( Suppl. )   203 - 203   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肥満学会  

    researchmap

  • 新規サルコペニアマーカー骨格筋量年間変化率は肝動脈化学塞栓療法/肝動注化学療法にて治療された肝細胞癌患者の予後予測に有用である

    小林 隆昌, 川合 弘一, 荒生 祥尚, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 寺井 崇二

    肝臓   57 ( Suppl.2 )   A607 - A607   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝幹前駆細胞マーカー陽性肝細胞癌の臨床的意義とAFP-L3での陽性患者予測

    土屋 淳紀, 小島 雄一, 上村 顕也, 高村 昌昭, 熊木 大輔, 平野 正明, 青野 高志, 酒井 剛, 川合 弘一, 山際 訓, 若井 俊文, 寺井 崇二

    肝臓   57 ( Suppl.2 )   A589 - A589   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • NASHの病態進展における肝ミトコンドリアDNAコピー数と酸化ヌクレオチド・DNA除去機構の検討

    川合 弘一, 荒生 祥尚, 小林 隆昌, 中野 応央樹, 上村 顕也, 寺井 崇二

    肥満研究   22 ( Suppl. )   188 - 188   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肥満学会  

    researchmap

  • 自然経過で縮小した多臓器(肝、肺、腎)炎症性偽腫瘍の1例

    五十嵐 俊三, 土屋 淳紀, 中野 応央樹, もたい 陽介, 山本 幹, 横山 純二, 横尾 健, 上村 顕也, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   57 ( 6 )   287 - 294   2016年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    症例は関節リウマチの診断で外来加療中の76歳女性。当科受診2ヵ月前から全身倦怠感、1ヵ月前から軽度右季肋部痛を自覚していた。近医を受診し、腹部超音波検査で肝右葉に35mm大の腫瘤を指摘された。造影CTでは肝右葉から右腎に及ぶ造影効果の乏しい腫瘤に加え、両側腎、左肺に腫瘤を認めた。悪性腫瘍を疑い、肝生検目的で当科に入院した。腹部超音波検査では約2週間で肝腫瘤が16mmに縮小していたが、診断目的で経皮的肝針生検を施行した。検体内には軽度炎症細胞浸潤を伴う高度線維化領域を認めたが、腫瘍性病変は指摘できなかった。組織像に加え画像検査で肝、腎、肺いずれの病変も縮小したことから、炎症性偽腫瘍と診断し経過観察の方針とした。本疾患はあらゆる臓器を原発とする可能性があり、しばしば悪性腫瘍との鑑別が困難で切除に至る症例もある。多発症例も報告されているが、検索し得た限りでは3臓器にわたる多発症例はなく貴重な症例と考え報告する。(著者抄録)

    DOI: 10.2957/kanzo.57.287

    Scopus

    researchmap

  • 新潟県地域保健・健康増進事業のデータから見るC型肝炎の傾向と対策

    土屋 淳紀, 横尾 健, 上村 顕也, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   57 ( Suppl.1 )   A426 - A426   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 鰹だしの末梢血流増加作用を利用した手足症候群の予防効果の検証

    上村 顕也, 品川 陽子, 小川 光平, 小林 雄司, 阿部 寛幸, 横尾 健, 上村 博輝, 川合 弘一, 須田 剛士, 山際 訓, 馬場 洋, 寺井 崇二

    癌と化学療法   43 ( 4 )   463 - 465   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    鰹だしの末梢血流増加作用を利用した手足症候群(HFS)の予防効果について検討した。ソラフェニブ(SFN)内服開始のために入院した肝細胞癌症例10例を対象とした。濃厚鰹だしを飲用せず、SFNを内服した対照群3例では、足底血管のtime averaged mean blood flow velocity(TAMEAN)の平均値はSFN内服開始1週後に前値に比較して低下を認め、2例にGrade 1、2のHFSを認めた。濃厚鰹だしを飲用した10例中7例でTAMEAN値が内服開始前後(1週)で上昇を認め、2例では33.5%の低下を認め、1例では著変を認めなかった。各症例における濃厚鰹だし飲用前後の血流変化は、飲用群で対照群に比較して有意に血流増加を認めた。血流増加を認めた症例ではサーモグラフィを施行すると手足末梢温が維持、改善していた。血流低下を認めたうちの1例のみでGrade 1のHFSを内服開始14日目に発症した(発症率10%)。経過中、濃厚鰹だしによる副作用を認めなかった。

    researchmap

  • ソラフェニブによる手足症候群に対する"濃厚鰹だし"の予防効果

    上村 顕也, 品川 陽子, 小川 光平, 阿部 寛幸, 小林 雄司, 横尾 健, 坂牧 僚, 阿部 聡司, 上村 博輝, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   57 ( Suppl.1 )   A218 - A218   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 当院における自己免疫性肝炎の診断、予後について

    木村 成宏, 山際 訓, 菅野 智之, 倉岡 直亮, 本田 博樹, 上村 顕也, 土屋 淳紀, 高村 昌昭, 寺井 崇二

    肝臓   57 ( Suppl.1 )   A171 - A171   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • ラジオ波焼灼術を施行した肝細胞癌患者に対するNomogramを用いた生命予後予測モデルの開発と術前ICG-PDR測定の臨床的意義

    安住 基, 須田 剛士, 横尾 健, 上村 博輝, 土屋 淳紀, 上村 顕也, 高村 昌昭, 川合 弘一, 松田 康伸, 山際 訓, 寺井 崇二

    肝臓   57 ( Suppl.1 )   A158 - A158   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 臓器特異的ハイドロダイナミック遺伝子導入法による肝疾患の遺伝子治療

    上村 顕也, 横尾 健, 阿部 寛幸, 小林 雄司, 大塚 正人, 三浦 浩美, 小川 光平, 品川 陽子, 井上 良介, 山際 訓, 寺井 崇二

    日本消化器病学会雑誌   113 ( 臨増総会 )   A301 - A301   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 【腎機能を悪化させない日常診療】 肝疾患における腎機能のみかたと対策

    上村 博輝, 山際 訓, 高村 昌昭, 横尾 健, 土屋 淳紀, 上村 顕也, 川合 弘一, 寺井 崇二

    成人病と生活習慣病   46 ( 3 )   370 - 375   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)東京医学社  

    肝臓は蛋白質の合成・代謝と物質の解毒・排泄などの重要な役割を担っている。また、門脈を介してすべての消化器(消化管、胆道、膵臓)と網内系臓器である脾臓と連携しているため肝臓の機能低下は多くの臓器に影響を与える。抗ウイルス療法の進歩によりC型肝炎患者の肝硬変への進展が抑えられることが予想されるが、いまだ肝硬変、肝細胞癌患者の治療対象者数は多い。そのため肝細胞癌早期発見のための造影MRI使用やプラチナ製剤による抗癌剤治療の選択に腎予備能を考慮しなければいけない機会が多い。本企画の意図に則り、肝疾患診療で遭遇する慢性肝炎に合併する腎疾患、肝硬変が進行した場合の腎病態、トルバプタン承認後の難治性腹水に対しての最新の利尿薬治療について解説する。(著者抄録)

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2016225651

  • 肝組織老化の機序と肝疾患の病態との関連 (特集 肝臓とアンチエイジング)

    上村 顕也, 寺井 崇二

    Anti-aging medicine   11 ( 6 )   804 - 808   2015年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:メディカルレビュー社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2016059592

  • 最近経験した胃石症の3例 成因および内視鏡的処置法の検討

    小川 光平, 水野 研一, 品川 陽子, 林 和直, 上村 顕也, 阿部 寛幸, 竹内 学, 小林 正明, 小林 英之, 津野 吉裕, 寺井 崇二

    ENDOSCOPIC FORUM for digestive disease   31 ( 2 )   172 - 172   2015年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)癌と化学療法社  

    researchmap

  • 先天性AT‐III欠損症が疑われる上腸間膜静脈・門脈血栓症の1例

    品川陽子, 上村顕也, 小川光平, 水野研一, 竹内学, 阿部寛幸, 高橋祥史, 小林雄司, 野本実, 寺井崇二, 河久順志, 渡辺順, 森山雅人

    新潟医学会雑誌   129 ( 10 )   630 - 630   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    J-GLOBAL

    researchmap

  • B-RTOの止血効果に対するリスク因子解析

    渡邉 雄介, 盛田 景介, 林 和直, 兼藤 努, 上村 博輝, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 須田 剛士, 鈴木 健司, 野本 実, 寺井 崇二

    新潟医学会雑誌   129 ( 10 )   628 - 628   2015年10月

  • 当科における門脈圧亢進症を伴った骨髄増殖性疾患症例の予後に関する検討

    清野 智, 川合 弘一, 横尾 健, 佐藤 裕樹, 本田 穣, 兼藤 努, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 須田 剛士, 野本 実, 寺井 崇二, 増子 正義, 田中 研介, 柳 雅彦, 佐藤 直子, 矢野 敏雄

    新潟医学会雑誌   129 ( 10 )   631 - 632   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2016166716

  • 効率的なDrug-eluting beadsの調整法

    横尾 健, 兼藤 努, 須田 剛士, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 野本 実, 寺井 崇二

    新潟医学会雑誌   129 ( 10 )   628 - 628   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2016166710

  • 4 プラチナ系抗腫瘍剤の動注療法が効果的であった肝細胞癌の4例 : 血清APM2濃度の治療効果予測マーカーとしての有用性(Ⅰ.一般演題, 第39回リバーカンファレンス)

    小川 光平, 上村 顕也, 品川 陽子, 阿部 寛幸, 高橋 祥史, 小林 雄司, 熊木 大輔, 水野 研一, 竹内 学, 須田 剛士, 青柳 豊, 寺井 崇二, 和栗 暢生, 石川 達

    新潟医学会雑誌   129 ( 10 )   615 - 615   2015年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2016166678

  • Drug-eluting beadsの調整法の検討

    横尾 健, 兼藤 努, 須田 剛士, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A903 - A903   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝臓特異的ハイドロダイナミック法を用いたMatrix metalloproteinase13による肝線維化の遺伝子治療

    小林 雄司, 上村 顕也, 阿部 寛幸, 大塚 正人, 横尾 健, 三浦 浩美, 兼藤 努, 須田 剛士, 青柳 豊, Dexi L., 寺井 崇二

    肝臓   56 ( Suppl.2 )   A776 - A776   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • B型慢性肝炎における核酸アナログ投与後の発癌因子とキャリアにおける水平感染リスクの評価

    上村 博輝, 山際 訓, 高村 昌昭, 横尾 健, 兼藤 努, 上村 顕也, 土屋 淳紀, 川合 弘一, 須田 剛士, 野本 実, 寺井 崇二, 小方 則夫, 大越 章吾, 渡辺 順, 高木 律男

    肝臓   56 ( Suppl.2 )   A763 - A763   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝細胞癌の予後に影響する栄養学因子

    兼藤 努, 須田 剛士, 横尾 健, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A872 - A872   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 慢性腎臓病合併肝細胞癌の予後解析

    木村 成宏, 川合 弘一, 上村 博輝, 兼藤 努, 土屋 淳紀, 上村 顕也, 高村 昌昭, 山際 訓, 須田 剛士, 野本 実, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A870 - A870   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当科における門脈圧亢進症を伴った骨髄増殖性疾患症例の臨床的特徴と予後に関する検討

    清野 智, 川合 弘一, 横尾 健, 兼藤 努, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 須田 剛士, 野本 実, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A863 - A863   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 当科と関連施設に於けるC型慢性肝炎に対するIFN治療後発癌の現状

    薛 徹, 山際 訓, 横尾 健, 上村 博輝, 兼藤 努, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 須田 剛士, 石川 達, 阿部 聡司, 吉田 俊明, 寺井 崇二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A860 - A860   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • ハイドロダイナミック細胞内遺伝子送達システムの開発

    上村 顕也, 阿部 寛幸, 小林 雄司, 兼藤 努, 横尾 健, 須田 剛士, 上村 博輝, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 寺井 崇二

    肝臓   56 ( Suppl.2 )   A776 - A776   2015年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 難治性胸・腹水の治療法とその適応 肝細胞癌合併難治性胸腹水症例に対する治療戦略と有効性

    上村 博輝, 山際 訓, 高橋 俊作, 横尾 健, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 寺井 崇二

    日本門脈圧亢進症学会雑誌   21 ( 3 )   86 - 86   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本門脈圧亢進症学会  

    researchmap

  • 薬剤師が知っておくべき臓器別画像解析の基礎知識 肝臓分野 肝膿瘍の画像診断

    上村 博輝, 山際 訓, 横尾 健, 土屋 淳紀, 上村 顕也, 高村 昌昭, 川合 弘一, 青柳 豊, 寺井 崇二

    医薬ジャーナル   51 ( 8 )   1847 - 1852   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)医薬ジャーナル社  

    肝・胆道感染症は適切な治療が選択できない場合、敗血症へと進展しやすい緊急性の高い疾患である。肝膿瘍は「肝内に細菌、真菌、原虫などが侵入・増殖し、肝組織が融解・壊死を起こして形成された膿瘍」と定義される。総胆管結石などに対する内視鏡的治療が進歩し、胆管炎に伴う肝膿瘍の発生頻度は減少しているが、肝細胞癌に対するラジオ波治療後に肝膿瘍を併発する症例もあり、特徴的画像所見や鑑別ポイントの把握は依然として重要である。(著者抄録)

    researchmap

  • AFP, PIVKA-Ⅱ : 臨床編 (今月の特集 検査と臨床のコラボで理解する腫瘍マーカー)

    青柳 豊, 上村 顕也, 田村 康

    臨床検査   59 ( 7 )   610 - 616   2015年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学書院  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015243795

  • Impact of Injection Volume on Hydrodynamic Delivery To the Liver in Mice

    Tsutomu Kanefuji, Takeshi Yokoo, Takeshi Suda, Kunihiko Sawada, Yoshinori Arai, Hiroyuki Abe, Kenya Kamimura, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY   23   S144 - S144   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Image-Guided, Liver-Targeted Hydrodynamic Gene Delivery in Dogs - Preclinical Assessment of Effectiveness and Safety of the Procedure

    Kenya Kamimura, Hiroyuki Abe, Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Yuji Kobayashi, Guisheng Zhang, Masafumi Oda, Yutaka Aoyagi, Shuji Terai, Dexi Liu

    MOLECULAR THERAPY   23   S106 - S107   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • 9 嚥下障害を契機に発見された前立腺癌縦隔転移の1例(Ⅰ.一般演題, 第55回下越内科集談会)

    品川 陽子, 小川 光平, 水野 研一, 上村 顕也, 竹内 学, 林 和直, 山本 幹, 本田 穣, 橋本 哲, 横山 純二, 佐藤 祐一, 小林 正明, 野本 実, 梅津 哉

    新潟医学会雑誌   129 ( 5 )   291 - 291   2015年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • Effect of Fibrotic Tissue on Liver-Targeted Hydrodynamic Gene Delivery 査読

    Yuji Kobayashi, Kenya Kamimura, Hiroyuki Abe, Masato Ohtsuka, Hiromi Miura, Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Guisheng Zhang, Masanori Tsuchida, Yutaka Aoyagi, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY   23   S141 - S141   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    DOI: 10.1016/S1525-0016(16)33964-8

    Web of Science

    researchmap

  • Effective Prevention of Liver Fibrosis by Liver-Targeted Hydrodynamic Gene Delivery of Matrix Metalloproteinase-13 in Rat Liver Fibrosis Model 査読

    Hiroyuki Abe, Kenya Kamimura, Yuji Kobayashi, Masato Ohtsuka, Hiromi Miura, Riuko Ohashi, Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Masanori Tsuchida, Yutaka Aoyagi, Guisheng Zhang, Dexi Liu, Shuji Terai

    MOLECULAR THERAPY   23   S234 - S234   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    DOI: 10.1016/S1525-0016(16)34197-1

    Web of Science

    researchmap

  • Virtual Touch Quantificationによる肝硬度測定における伝搬速度の測定部位ならびに測定ポイント数の検討

    横尾 健, 兼藤 努, 須田 剛士, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 野本 実, 寺井 崇二

    肝臓   56 ( Suppl.1 )   A429 - A429   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 薬剤師が知っておくべき臓器別画像解析の基礎知識(52)9.肝臓分野(4)肝血管腫の画像診断

    上村 顕也, 青栁 豊

    医薬ジャーナル   51 ( 4 )   5 - 8   2015年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:医薬ジャーナル社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015209399

  • Shear Wave(SW)とVirtual Touch Tissue Quantification(VTTQ)の相関性に基づいたせん断弾性波速度(SWV)方式肝硬度測定における適正測定回数の検討

    兼藤 努, 須田 剛士, 川合 弘一, 横尾 健, 上村 博輝, 上村 顕也, 土屋 淳紀, 高村 昌昭, 山際 訓, 野本 実

    日本消化器病学会雑誌   112 ( 臨増総会 )   A417 - A417   2015年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 鰹だしの末梢血流増加作用は手足症候群の予防に寄与する

    上村 顕也, 土屋 淳紀, 高村 昌昭, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 寺井 崇二

    日本内科学会雑誌   104 ( Suppl. )   245 - 245   2015年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本内科学会  

    researchmap

  • ハイドロダイナミック遺伝子導入法によるラット肝硬変モデルの遺伝子治療

    阿部 寛幸, 上村 顕也, 大塚 正人, 横尾 健, 三浦 浩美, 兼藤 努, 須田 剛士, 青柳 豊

    日本消化器病学会雑誌   111 ( 臨増大会 )   A912 - A912   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    J-GLOBAL

    researchmap

  • 新WHO分類に基づく混合型肝癌再分類でのAFP-L3、臨床経過の違いの考察

    土屋 淳紀, 小島 雄一, 安住 基, 横尾 健, 山本 幹, 上村 博輝, 兼藤 努, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    日本消化器病学会雑誌   111 ( 臨増大会 )   A930 - A930   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 臨床にフィードバックできる基礎研究を目指して 癌関連遺伝子Bel11bの肝腫瘍における発現解析研究

    阿部 寛幸, 上村 顕也, 熊木 大輔, 上村 博輝, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 三嶋 行雄, 木南 凌, 廣瀬 雄己, 大橋 拓, 若井 俊文

    新潟医学会雑誌   128 ( 9 )   477 - 477   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093996

  • 当科における非B非C型肝細胞癌の臨床的特徴

    川合 弘一, 上村 顕也, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    肝臓   55 ( Suppl.2 )   A633 - A633   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 慢性腎臓病合併肝細胞癌の予後解析

    木村 成宏, 川合 弘一, 上村 博輝, 兼藤 努, 土屋 淳紀, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    肝臓   55 ( Suppl.2 )   A616 - A616   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝細胞癌に対するミリプラとアイエーコール肝動注の併用効果に関する検討

    上村 顕也, 須田 剛士, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊, 和栗 暢生, 石川 達

    肝臓   55 ( Suppl.2 )   A612 - A612   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 音響放射圧を用いた肝内せん断弾性波速度測定による非アルコール性脂肪肝疾患の肝細胞癌発癌リスク評価

    高村 昌昭, 須田 剛士, 兼藤 努, 横尾 健, 上村 博輝, 土屋 淳紀, 上村 顕也, 田村 康, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   480 - 480   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015094002

  • 肝細胞癌に対するミリプラとアイエーコール肝動注の併用効果に関する検討

    上村 顕也, 須田 剛士, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊, 和栗 暢生, 石川 達

    新潟医学会雑誌   128 ( 9 )   472 - 472   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093988

  • 肝硬度測定のピットフォール

    須田 剛士, 廣瀬 奏恵, 高村 昌昭, 杉本 愛, 兼藤 努, 横尾 健, 上村 博輝, 土屋 淳紀, 上村 顕也, 田村 康, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 高橋 昌, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   479 - 480   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015094001

  • 身近に潜むE型肝炎

    横尾 健, 高橋 祥史, 上村 顕也, 五十嵐 正人, 須田 剛士, 安住 基, 山本 幹, 土屋 淳紀, 青柳 豊, 石川 晶子, 田崎 正行, 中川 由紀, 齋藤 和英, 布施 香子, 増子 正義, 山崎 和秀

    新潟医学会雑誌   128 ( 9 )   478 - 479   2014年9月

  • 当科で経験したCombined HCC/CCCに関して新しいWHO分類、HCC with progenitor featureも含めて

    小島 雄一, 土屋 淳紀, 安住 基, 横尾 健, 山本 幹, 上村 博輝, 兼藤 努, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 若井 俊文

    新潟医学会雑誌   128 ( 9 )   475 - 476   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093995

  • 当科における肝炎・肝癌治療の現状

    上村 博輝, 上村 顕也, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   472 - 473   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093989

  • 14 切除後8か月で両葉多発病変・門脈腫瘍塞栓で再発した径18mm単発肝細胞癌の1例(Ⅰ.一般演題, 第38回リバーカンファレンス)

    熊木 大輔, 上村 顕也, 高橋 祥史, 小林 雄司, 阿部 寛幸, 水野 研一, 竹内 学, 野本 実, 青柳 豊, 谷 優佑, 味岡 洋一, 梅津 哉

    新潟医学会雑誌   128 ( 9 )   474 - 474   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093991

  • 27 Helicobactor. cinaediによる敗血症を合併したB型肝硬変の1例(Ⅰ.一般演題, 第38回リバーカンファレンス)

    有田 将史, 小林 雄司, 熊木 大輔, 上村 顕也, 水野 研一, 竹内 学, 野本 実, 青柳 豊

    新潟医学会雑誌   128 ( 9 )   477 - 478   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093997

  • 11 当院で経験した肝細胞癌脳転移症例の検討(Ⅰ.一般演題, 第38回リバーカンファレンス)

    小林 雄司, 上村 顕也, 高橋 祥史, 阿部 寛幸, 熊木 大輔, 水野 研一, 竹内 学, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 八木 琢也, 小林 真, 加藤 俊幸

    新潟医学会雑誌   128 ( 9 )   473 - 473   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015093990

  • 切除後8ヵ月で両葉多発病変・門脈腫瘍塞栓で再発した径18mm単発肝細胞癌の1例 当院における最近10年間の径30mm以下の肝細胞癌切除165例の検討を合わせて

    熊木 大輔, 上村 顕也, 高橋 祥史, 小林 雄司, 阿部 寛幸, 水野 研一, 竹内 学, 野本 実, 青柳 豊, 谷 優佑, 味岡 洋一, 梅津 哉

    日本消化器病学会雑誌   111 ( 臨増大会 )   A939 - A939   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 13 壊疽性膿皮症を伴った潰瘍性大腸炎の1例(一般演題, 第54回下越内科集談会)

    水戸 正人, 熊木 大輔, 横山 純二, 本田 穣, 鈴木 健司, 小林 雄司, 水野 研一, 上村 顕也, 竹内 学, 野本 実, 青柳 豊, 下村 尚子, 藤川 大基, 貴舩 夏子

    新潟医学会雑誌   128 ( 6 )   281 - 282   2014年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2015006260

  • 腫瘍マーカー (特集 消化器がん検診の現状とこれから) -- (その他)

    川合 弘一, 田村 康, 上村 顕也

    成人病と生活習慣病 : 日本成人病(生活習慣病)学会準機関誌   44 ( 6 )   728 - 733   2014年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:東京医学社  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014262443

  • Hemodynamics of a Hydrodynamic Injection in Mice

    Tsutomu Kanefuji, Takeshi Yokoo, Hiroyuki Abe, Kenya Kamimura, Takeshi Suda, Yutaka Aoyagi, Dexi Liu

    MOLECULAR THERAPY   22   S97 - S98   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Parameters for Optimal Hydrodynamic Gene Delivery to Pig Liver Using an Image-Guided and Lobe-Specific Procedure

    Kenya Kamimura, Hiroyuki Abe, Takeshi Yokoo, Tsutomu Kanefuji, Takeshi Suda, Guisheng Zhang, Yutaka Aoyagi, Dexi Liu

    MOLECULAR THERAPY   22   S98 - S98   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Overexpression of Matrix Metalloproteinase-13 Gene by the Method of Hydrodynamic Gene Delivery Prevents Liver Fibrosis in Rats 査読

    Hiroyuki Abe, Kenya Kamimura, Takeshi Yokoo, Masato Ohtsuka, Hiromi Miura, Tsutomu Kanefuji, Takeshi Suda, Dexi Liu, Yutaka Aoyagi

    MOLECULAR THERAPY   22   S133 - S133   2014年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • ソラフェニブの手足症候群に対する、濃厚鰹だしの有効性の検証

    上村 顕也, 須田 剛士, 上村 博輝, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊

    肝臓   55 ( Suppl.1 )   A394 - A394   2014年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • エネルギー代謝状態によるNAFLDの病態選別と治療候補分子の動態評価

    須田 剛士, 横尾 健, 兼藤 努, 上村 博輝, 上村 顕也, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊

    日本消化器病学会雑誌   111 ( 臨増総会 )   A333 - A333   2014年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 食道壁内偽憩室症の1例

    坂牧 僚, 小林 正明, 今井 径卓, 水野 研一, 上村 顕也, 竹内 学, 成澤 林太郎, 青柳 豊

    Gastroenterological Endoscopy   55 ( 10 )   3368 - 3374   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    症例は63歳男性。長期のアルコール多飲・喫煙歴がある。嚥下困難を主訴に当院を紹介受診した。食道造影では、食道全体に多発する突出像を認めた。上部消化管内視鏡検査では、多発するピンホール状陥凹の周囲に白色調の付着物質を認め、生検組織でカンジダ感染が検出された。食道壁内偽憩室症と診断し、節酒指導および狭窄に対する内視鏡的拡張術を行い、症状は改善傾向にある。食道カンジダ感染を伴い、典型的な内視鏡像、食道造影像を呈した食道壁内偽憩室症の1例を経験したので、文献的考察を加えて報告する。(著者抄録)

    DOI: 10.11280/gee.55.3368

    CiNii Article

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014026052

  • 多彩な画像所見を呈し肝生検で確診した血管内リンパ腫の1例

    眞水 麻以子, 西山 佑樹, 畠野 雄也, 阿部 寛幸, 上村 顕也, 高橋 祥史, 水野 研一, 竹内 学, 川合 弘一, 野本 実, 青柳 豊, 柴崎 康彦, 瀧澤 淳, 曽根 博仁, 石黒 敬信, 堅田 慎一, 西澤 正豊, 高野 徹

    新潟医学会雑誌   127 ( 10 )   581 - 582   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014161062

  • 遅延性に輸血後E型肝炎を発症した急性前骨髄球性白血病の1例

    高橋 祥史, 上村 顕也, 阿部 寛幸, 水野 研一, 竹内 学, 須田 剛士, 野本 実, 青柳 豊, 布施 香子, 森山 雅人, 増子 正義, 曽根 博仁

    新潟医学会雑誌   127 ( 10 )   568 - 568   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014161035

  • 44 音響放射圧を用いた肝内せん断弾性波速度測定による肝細胞癌発癌リスク評価(Ⅰ.一般演題, 第37回リバーカンファレンス)

    高村 昌昭, 須田 剛士, 兼藤 努, 吉川 成一, 上村 顕也, 田村 康, 五十嵐 正人, 川合 弘一, 山際 訓, 野本 実, 青柳 豊, 松田 康伸

    新潟医学会雑誌   127 ( 10 )   580 - 580   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 39 全生存期間からみたTACEとchemolipiodolizationの比較検討(Ⅰ.一般演題, 第37回リバーカンファレンス)

    兼藤 努, 吉川 成一, 上村 顕也, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 野本 実, 青柳 豊, 松田 康伸, 和栗 暢生

    新潟医学会雑誌   127 ( 10 )   578 - 579   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 40 APM2は肝細胞癌に対するシスプラチンの効果予測マーカー候補である(Ⅰ.一般演題, 第37回リバーカンファレンス)

    上村 顕也, 吉川 成一, 兼藤 努, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 松田 康伸, 野本 実, 青柳 豊

    新潟医学会雑誌   127 ( 10 )   579 - 579   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 35 原発巣の自然退縮後に, リンパ節転移再発を認めた肝細胞癌の1例(Ⅰ.一般演題, 第37回リバーカンファレンス)

    高橋 一也, 高村 昌昭, 早川 雅人, 兼藤 努, 橋本 哲, 上村 顕也, 田村 康, 塩路 和彦, 五十嵐 正人, 川合 弘一, 山際 訓, 佐藤 祐一, 須田 剛士, 青柳 豊

    新潟医学会雑誌   127 ( 10 )   577 - 578   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014161054

  • 20 顕性黄疸にて発症しABCB11遺伝子変異により診断しえた妊娠性肝内胆汁うっ滞症の1例(Ⅰ.一般演題, 第37回リバーカンファレンス)

    阿部 寛幸, 上村 顕也, 眞水 麻以子, 高橋 祥史, 水野 研一, 竹内 学, 野本 実, 青柳 豊, 上村 直美, 小木 幹奈, 吉田 邦彦, 山田 京子, 山口 雅幸, 榎本 隆之, 高桑 好一, 三嶋 行雄, 木南 凌

    新潟医学会雑誌   127 ( 10 )   573 - 573   2013年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014161047

  • 輸血によるE型肝炎ウイルス(HEV)感染症例の一考察

    松山雄一, 古俣妙, 瀬下敏, 今田恒芳, 布施一郎, 布施香子, 森山雅人, 増子正義, 高橋祥史, 上村顕也, 須田剛士

    血液事業   36 ( 2 )   438   2013年8月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 多彩な画像所見を呈し肝生検で診断しえた血管内リンパ腫の1例

    岩瀬 麻以子, 阿部 寛幸, 上村 顕也, 高橋 祥史, 水野 研一, 竹内 学, 川合 弘一, 野本 実, 青柳 豊, 畠野 雄也, 石黒 敬信, 堅田 慎一, 西澤 正豊, 岡塚 貴世志, 瀧澤 淳, 曽根 博仁, 高野 徹

    新潟医学会雑誌   127 ( 7 )   389 - 390   2013年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2014076255

  • 深部出血を合併した肝硬変症例における生存例と死亡例の比較検討

    高村 昌昭, 渡邊 順, 坂牧 僚, 本田 穣, 兼藤 努, 吉川 成一, 上村 顕也, 田村 康, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 松田 康伸, 野本 実, 青柳 豊

    肝臓   54 ( Suppl.1 )   A328 - A328   2013年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 0315 ハイドロダイナミック遺伝子治療を対象とした肝臓モデルの構築(OS08-2 バイオエンジニアリング(1)医療と福祉を支えるバイオエンジニアリング,オーガナイズドセッション 8:「バイオエンジニアリング(1)医療と福祉を支えるバイオエンジニアリング」)

    李 升国, 尾田 雅文, 田邊 裕治, 横尾 健, 上村 顕也, 須田 剛士

    講演論文集   2013 ( 50 )   31501 - 31502   2013年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本機械学会  

    CiNii Article

    CiNii Books

    researchmap

  • 45 顆粒球除去療法を施行した重症型アルコール性肝炎の1例(I.一般演題, 第36回リバーカンファレンス)

    今井 径卓, 坂牧 僚, 水野 研一, 上村 顕也, 竹内 学, 須田 剛士, 野本 実, 青柳 豊, 土田 陽平, 細島 康宏, 田邊 繁世, 風間 順一郎, 吉岡 大雄, 梅津 哉

    新潟医学会雑誌   126 ( 11 )   644 - 644   2012年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2013193690

  • B215 ハイドロダイナミック遺伝子治療装置の制御パラメータ導出法に関する研究(B2-3 医療機器1)

    李 升国, 大塚 紀彰, 尾田 雅文, 田邊 裕治, 横尾 健, 上村 顕也, 須田 剛士

    バイオフロンティア講演会講演論文集   2012 ( 23 )   155 - 156   2012年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本機械学会  

    CiNii Article

    CiNii Books

    researchmap

  • 13 特異な上部消化管病変を合併した潰瘍性大腸炎の1例(I.一般演題, 第95回新潟消化器病研究会)

    坂牧 僚, 横山 純二, 今井 径卓, 水野 研一, 山本 幹, 上村 顕也, 竹内 学, 佐藤 祐一, 青柳 豊, 河内 裕介, 本田 穣, 橋本 哲, 塩路 和彦, 小林 正明, 成澤 林太郎

    新潟医学会雑誌   126 ( 10 )   564 - 564   2012年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2013154077

  • 肝細胞癌に対する肝動注療法における安全で効果的なシスプラチン量の設定(A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma)

    須田 剛士, 大崎 暁彦, 上村 顕也, 兼藤 努, 土屋 淳紀, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 青柳 豊

    日本癌学会総会記事   71回   353 - 354   2012年8月

     詳細を見る

    記述言語:英語   出版者・発行元:日本癌学会  

    researchmap

  • Long Term Transgene Expression in Rat Liver Using a Novel Electromotor-Driven Hydrodynamic Gene Injector

    Takeshi Yokoo, Kenya Kamimura, Takeshi Suda, Tsutomu Kanefuji, Masahfumi Oda, Guisheng Zhang, Dexi Liu, Yutaka Aoyagi

    MOLECULAR THERAPY   20   S240 - S240   2012年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • Image-Guided, Lobe-Specific Hydrodynamic Gene Delivery to Baboon Liver

    Kenya Kamimura, Takeshi Suda, Tsutomu Kanefuji, Guisheng Zhang, Yutaka Aoyagi, Dexi Liu

    MOLECULAR THERAPY   20   S37 - S37   2012年5月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:NATURE PUBLISHING GROUP  

    Web of Science

    researchmap

  • 1214 肝疾患遺伝子治療用インジェクターの制御パラメータ導出手法に関する実験的研究(OS08-3 バイオエンジニアリング(1)医療と福祉を支えるバイオエンジニアリング,オーガナイズドセッション 8:「バイオエンジニアリング(1)医療と福祉を支えるバイオエンジニアリング」)

    大塚 紀彰, 尾田 雅文, 原 利昭, 須田 剛士, 上村 顕也, 横尾 健

    講演論文集   2012 ( 49 )   121401 - 121402   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:一般社団法人日本機械学会  

    CiNii Article

    CiNii Books

    researchmap

  • 当科で経験した肝硬変に深部出血を合併した3例

    渡邉 順, 高村 昌昭, 松尾 祐治, 野澤 優次郎, 橋本 哲, 佐藤 祐一, 坂牧 僚, 本田 譲, 上村 顕也, 土屋 淳紀, 須田 剛士, 青柳 豊

    日本消化器病学会雑誌   109 ( 臨増総会 )   A326 - A326   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 肝細胞癌に対するミリプラチン使用経験とその治療効果についての検討

    田村 康, 土屋 淳紀, 上村 顕也, 矢野 雅彦, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 須田 剛士, 大越 章吾, 野本 実, 青柳 豊

    日本消化器病学会雑誌   108 ( 臨増大会 )   A945 - A945   2011年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 5 部分的膵動脈塞栓術後の血小板数予測の試み(I.一般演題,第63回新潟画像医学研究会)

    大崎 暁彦, 須田 剛士, 石川 達, 和栗 暢生, 川合 弘一, 土屋 淳紀, 上村 顕也, 矢野 雅彦, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 松田 康伸, 大越 章吾, 野本 実, 青柳 豊

    新潟医学会雑誌   125 ( 6 )   339 - 340   2011年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • Gd-EOB-DTPA造影MRIの肝細胞相で低信号を示した慢性肝疾患における乏血性結節の経過 長期経過観察を含めた検討

    高野 徹, 山崎 元彦, 佐藤 章子, 青山 英史, 土屋 淳紀, 上村 顕也, 矢野 雅彦, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 野本 実, 青柳 豊, 加村 毅, 山本 哲史

    新潟医学会雑誌   125 ( 6 )   339 - 339   2011年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books

    researchmap

  • 非アルコール性脂肪肝炎(NASH)における肝内せん断弾性波速度(SWV)の4次元的測定

    須田 剛士, 上村 顕也, 土屋 淳紀, 矢野 雅彦, 田村 康, 高村 昌昭, 五十嵐 正人, 山際 訓, 野本 実, 青柳 豊, 長崎 啓祐, 菊池 透, 川合 弘一, 原田 浩一, 窪田 智之, 石川 達, 上村 朝輝

    新潟医学会雑誌   125 ( 6 )   340 - 340   2011年6月

  • Gd-EOB-DTPA造影MRIで乏血性かつ肝細胞造影相で低信号を示す病変の自然経過

    須田 剛士, 高野 徹, 土屋 淳紀, 上村 顕也, 矢野 雅彦, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 青柳 豊

    肝臓   52 ( Suppl.1 )   A224 - A224   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 切除不能進行肝細胞癌に対するミリプラ/アイエーコール併用肝動注療法(第I相試験)

    上村 顕也, 須田 剛士, 土屋 淳紀, 矢野 雅彦, 田村 康, 高村 昌昭, 五十嵐 正人, 川合 弘一, 山際 訓, 大越 章吾, 野本 実, 青柳 豊

    肝臓   52 ( Suppl.1 )   A344 - A344   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 6 ソナゾイド^<(R)>造影超音波内視鏡 (EUS) を施行した早期胆嚢癌の1例(SessionII 『症例』,第10回新潟胆膵研究会)

    河久 順志, 塩路 和彦, 岩永 明人, 上村 顕也, 冨樫 忠之, 川合 弘一, 鈴木 健司, 成澤 林太郎, 青柳 豊, 黒崎 功

    新潟医学会雑誌   125 ( 4 )   224 - 224   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    CiNii Article

    CiNii Books